



US009334466B2

(12) **United States Patent**
Aehle et al.

(10) **Patent No.:** **US 9,334,466 B2**
(45) **Date of Patent:** **May 10, 2016**

(54) **ALPHA-AMYLASE VARIANTS**

(71) Applicant: **Danisco US Inc.**, Palo Alto, CA (US)

(72) Inventors: **Wolfgang Aehle**, Zwingenberg (DE);
Neelam S. Amin, Burlingame, CA (US)

(73) Assignee: **Danisco US Inc.**, Palo Alto, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/975,048**

(22) Filed: **Aug. 23, 2013**

(65) **Prior Publication Data**

US 2014/0057324 A1 Feb. 27, 2014

Related U.S. Application Data

(62) Division of application No. 12/601,759, filed as application No. PCT/US2008/006787 on May 29, 2008, now Pat. No. 8,546,121.

(60) Provisional application No. 60/924,745, filed on May 30, 2007.

(51) **Int. Cl.**

C11D 3/386 (2006.01)

C12N 9/28 (2006.01)

C12P 21/02 (2006.01)

A21D 8/04 (2006.01)

(52) **U.S. Cl.**

CPC **C11D 3/38618** (2013.01); **A21D 8/042** (2013.01); **C11D 3/386** (2013.01); **C12N 9/2417** (2013.01); **C12P 21/02** (2013.01); **Y02P 20/52** (2015.11)

(58) **Field of Classification Search**

CPC **C12N 9/2414**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,261,828	B1	7/2001	Lund	
6,528,298	B1	3/2003	Svendsen et al.	
6,887,986	B1	5/2005	Svendsen et al.	
7,153,818	B2 *	12/2006	Breves et al.	510/226
2002/0155574	A1	10/2002	Thisted et al.	
2003/0064908	A1	4/2003	Bisgard-Frantzen et al.	
2003/0211958	A1 *	11/2003	Svendsen et al.	510/226

FOREIGN PATENT DOCUMENTS

WO	WO-96/23873	8/1996
WO	WO-99/19467	4/1999
WO	WO-01/66712	9/2001
WO	WO-02/24732	3/2002
WO	WO-2006/002643	1/2006
WO	WO-2006/031554	3/2006
WO	WO-2006/037484	4/2006
WO	WO-2007/079938	7/2007

OTHER PUBLICATIONS

Yuki et al, 2014 NCBI Acc#GAE36589. Alignment with SEQ ID No. 1_A186G.*

Svendsen et al, 2003 SEQ ID No. 26 from 20030211958. Alignment with SEQ ID No. 1_A186G.*

Breves et al, 2004 SEQ ID No. 2 from 20040102349. Alignment with SEQ ID No. 1_A186G.*

Estell et al, from U.S. Appl. No. 14/472,149, SEQ ID No. 2 and 12. Alignment with SEQ ID No. 1_A186G.*

Tsukamoto et al, Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic *Bacillus* sp. #707 and structural similarity to liquefying type alpha-amylases. *Biochem Biophys Res Commun.* Feb. 29, 1988;151(1):25-31.*

GenBank Database Acc#P19571 from Tsukamoto et al, *Biochem Biophys Res Commun.* Feb. 29, 1988;151(1):25-31. Alignment with SID1A186.*

Tsukamoto et al GenBank Acc#P19571 from *Biochem Biophys Res Commun.* Feb. 29, 1988;151(1):25-31. Alignment with SID1A186.*

Kanai et al, *Biochemical and Crystallographic Analyses of Maltohexaose-Producing Amylase from Alkalophilic Bacillus* sp. 707. *Biochemistry* 2004, 43, 14047-14056.*

GenBank Accession No. CAL48155; Bessler, C, et al., "Alpha amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha amylase variants.", Sep. 22, 2006, *Bacillus* sp.; Accessed at www.ncbi.nlm.nih.gov/protein/115307626?sat=13&satkey=12214009, 1 pg.

International Search Report for PCT/US2008/006787 mailed Nov. 24, 2008, 5 pp.

Kanai, R. et al. "Biochemical and Crystallographic Analyses of Maltohexaose-Producing Amylase from Alkalophilic *Bacillus* sp. 707." *Biochemistry* 43(44): 14047-14056, Nov. 1, 2004.

Kimura, K. et al. "Cloning of a gene for maltohexaose producing amylase of an alkalophilic *Bacillus* and hyper-production of the enzyme in *Bacillus subtilis* cells." *Applied Microbiology and Biotechnology* 27(4): 372-377, Jan. 1, 1988.

UniProtKB/Swiss-Prot. Accession No. P19571; Tsukamoto, A, et al, "Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic *Bacillus* sp. #707 and structural similarity to liquefying type alpha-amylases." *AMT6_BACS7*, Feb. 1, 1991, accessed at www.uniprot.org/uniprot/P19571, 3pp.

Tsukamoto, A. et al. "Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic *Bacillus* sp. #707 and structural similarity to liquefying type alpha-amylases." *Biochemical and Biophysical Research Communications* 151(1): 25-31, Feb. 29, 1988.

(Continued)

Primary Examiner — Sheridan Swope

(74) *Attorney, Agent, or Firm* — Danisco US Inc.

(57)

ABSTRACT

Variants of *Bacillus* sp. no. 707 alpha-amylase are provided that are produced more efficiently and thus more economically. Higher fermentation yields are achieved through introducing amino acid variations that promote solubility of the variant in a fermentation broth. Increased solubility allows more enzyme to remain in solution after expression in a host cell. This in turn increases the efficiency with which the expressed variant enzyme can be recovered from the fermentation broth.

30 Claims, 4 Drawing Sheets

(56)

References Cited

OTHER PUBLICATIONS

GenBank Accession No. CAL48155, accessed at www.ncbi.nlm.nih.gov/protein/115307626?sat=13&satkey=12214009; Sep. 22, 2006; *Bacillus* sp.; Bessler, C., et al., "Alpha amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha amylase variants."

WO2006/037484-A; Apr. 13, 2006, Henkel Kommanditgesellschaft Auf Aktien (DE), 1 pg.
UnitProtKB/Swissprot Accession No. P19571, accessed at www.uniprot.org/uniprot/P19571; Feb. 1, 1991; *Bacillus* sp. (strain 707); Tsukamoto, A., et al., "Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic *Bacillus* sp. #707 and structural similarity to liquefying type alpha-amylases." *Biochem. Biophys. Res. Commun.* 151: 25-31 (1998), 3pp.

* cited by examiner

1	11	21	31	41	51
HHNGTNGTMM	QYFEWYLPND	GNHWNRLNSD	ASNLKSKGIT	AVWIPPAWKG	ASQNDVGYGA
HHNGTNGTMM	QYFEWYLPND	GNHWNRLRSD	ASNLKDKGIT	AVWIPPAWKG	ASQNDVGYGA
61	71	81	91	101	111
YDLYDLGEFN	QKGTVRTKYG	TRSQLQAAVT	SLKNNGIQVY	GDVVMNHKGG	ADATEMVRVAV
YDLYDLGEFN	QKGTVRTKYG	TRNQLQAAVT	ALKSNGIQVY	GDVVMNHKGG	ADATEWVRVAV
121	131	141	151	161	171
EVNPNNRNQE	VTGEYTIEAW	TRFDFPGRGN	THSSFKWRWY	HFDGVDWDQS	RRLNNRIYKF
EVNPSNRNQE	VSGDYTIEAW	TKFDFPGRGN	THSNFKWRWY	HFDGVDWDQS	RQLQNRIYKF
181	191	201	211	221	231
RGHGKAWDWE	VDTEGNYDY	LMYADIDMDH	PEVVNELRNW	GVWYTNTLGL	DGFRIDAVKH
RGDGKGWDWE	VDTEGNYDY	LMYADIDMDH	PEVVNELRNW	GVWYTNTLGL	DGFRIDAVKH
241	251	261	271	281	291
IKYSFTRDWI	NHVRSATGKN	MFAVAEFWKN	DLGAIENYLQ	KTNWNHVSVD	VPLHYNLYNA
IKYSFTRDWL	THVRNTTGKN	MFAVAEFWKN	DIGAIENYLS	KTNWNHVSVD	VPLHYNLYNA
301	311	321	331	341	351
SKSGGNYDMR	NIFNGTVVQR	HPSHAVTFVD	NHDSQPPEEAL	ESFVEEWFKP	LAYALTLTRE
SRSGGNYDMR	QIFNGTVVQR	HPTHAVTFVD	NHDSQPPEEAL	ESFVEEWFKP	LAYALTLTRD
361	371	381	391	401	411
QGYPSPVFYGD	YYGIPTHGVP	AMRSKIDPIL	EARQKYAYGK	QNDYLDHHNI	IGWTREGNTA
QGYPSPVFYGD	YYGIPTHGVP	AMKSKIDPIL	EARQKYAYGK	QNDYLDHHNM	IGWTREGNTA
421	431	441	451	461	471
HPNSGLATIM	SDGAGGSKWM	FVGRNKAGQV	WSDITGNRTG	TVTINADGWG	NFSVNGGSVS
HPNSGLATIM	SDGPGGNKWM	YVGRNKAGQV	WRDITGNRSG	TVTINADGWG	NFSVNGGSVS
481					
IWVNK	<i>Bacillus</i> sp. no. 707 α -amylase (SEQ ID NO: 1)				
IWVNN	<i>Bacillus</i> sp. A 7-7 (DSM 12368) α -amylase (SEQ ID NO: 2)				

FIG. 1

Figure 2 Results of SIM with: Sequence 1: *Bacillus* sp. no. 707, (485 residues)
Sequence 2: *Bacillus* sp. no. 7-7, (484 residues)

Using the parameters: Comparison matrix: BLOSUM62, Number of alignments computed: 20, Gap open penalty: 12, Gap extension penalty: 4

93.4% identity in 484 residues overlap; Score: 2567.0; Gap frequency: 0.0%

```
707,      1 HHNGTNGTMMQYFEWYLPNDGNHWNRLNSDASNLSKSGITAVWIPPAWKGASQNDVGYGA
7-7,      1 HHNGTNGTMMQYFEWYLPNDGNHWNRLNSDASNLSKSGITAVWIPPAWKGASQNDVGYGA
          *****

707,     61 YDLYDLGEFNQKGTVRTKYGTRSQQAAVTSLKNNGIQVYGDVVMNHKGGADATEMVRV
7-7,     61 YDLYDLGEFNQKGTVRTKYGTRNQLQAAVTALKSNGIQVYGDVVMNHKGGADATEWVRV
          *****

707,    121 EVNPNNRNQEVGTGEYTLIAWTRDFPFGRGNTHSSEKWRWYHFDGVDWDQSRRLNNRIYKF
7-7,    121 EVNPSNRNQEVSGDYTLIAWTKDFPFGRGNTHSNFKWRWYHFDGVDWDQSRQLQNRIYKF
          ****

707,    181 RGHGKAWDWEVDTENGNYDYLMYADIDMDHPEVVNELRNWGVWYTNLTGLDGERIDAVKH
7-7,    181 RGDGKGWDWEVDTENGNYDYLMYADIDMDHPEVVNELRNWGVWYTNLTGLDGERIDAVKH
          **

707,    241 IKYSFTRDWINHVRSATGKNMFVAEFWKNDLGAIENYLQKTNNWHSVFDVPLHYNLYNA
7-7,    241 IKYSFTRDWLTHVRNTTGKNMFVAEFWKNDLGAIENYLSKTNNWHSVFDVPLHYNLYNA
          *****


707,    301 SKSGGNYDMRNIENGTVVQRHPSHAVTFVDNHDSQPEEALESFVEEWEKPLAYALTLTRE
7-7,    301 SRSGGNYDMRQIENGTVVQRHPHVAVTTFVDNHDSQPEEALESFVEEWEKPLAYALTLTRD
          *


707,    361 QGYPSVFEYGDYYGIPTHGVPAMRSKIDPILEARQKYAYGKQNDYLDHNNIIGWTREGNTA
7-7,    361 QGYPSVFEYGDYYGIPTHGVPAMRSKIDPILEARQKYAYGKQNDYLDHNNMIGWTREGNTA
          *****

707,    421 HPNSGLATIMSDGAGGSKWMEVGRNKAGQVWSDITGNRTGTVTINADGWGNFSVNGGSVS
7-7,    421 HPNSGLATIMSDGPGGNKWMYVGRNKAGQVWRDITGNRSGTVTINADGWGNFSVNGGSVS
          *****

707,    481 IWVN
7-7,    481 IWVN
          ****
```

FIG. 2

**FIG. 3**



Amylase Activity of 707 Amylase Compared to 707 Amylase Variants (R172Q, H183D, S255N, and S36D/S255N) Grown in Shake Flasks Expressed in Arbitrary Units. The # Symbol Represents the Clone Number Assayed.

FIG. 4

1

ALPHA-AMYLASE VARIANTS

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is divisional of U.S. patent application Ser. No. 12/601,759, filed Oct. 14, 2010, now U.S. Pat. No. 8,546,121, which is a U.S. National Stage Application of International Application No. PCT/US2008/06787, filed May 29, 2008, which claims the benefit of U.S. Provisional Application No. 60/924,745, filed May 30, 2007, which are hereby incorporated by reference.

SEQUENCE LISTING

Also attached is a sequence listing comprising SEQ ID NOS: 1-26, which are herein incorporated by reference in their entirety.

FIELD OF THE INVENTION

Disclosed are nucleic acids encoding polypeptides with amylase activity, wherein the polypeptide is modified from a *Bacillus* α -amylase, particularly *Bacillus* sp. no. 707 α -amylase.

BACKGROUND

Starch consists of a mixture of amylose (15-30% w/w) and amylopectin (70-85% w/w). Amylose consists of linear chains of α -1,4-linked glucose units having a molecular weight (MW) from about 60,000 to about 800,000. Amylopectin is a branched polymer containing the same α -1,4-linked glucose units, as well as α -1,6 branch points every 24-30 glucose units; its MW may be as high as 100 million.

Sugars from starch, in the form of concentrated dextrose syrups, are currently produced by an enzyme catalyzed process involving: (1) liquefaction (or thinning) of solid starch with an α -amylase into dextrins having an average degree of polymerization of about 7-10, and (2) saccharification of the resulting liquefied starch, i.e., starch hydrolysate, with amyloglucosidase (also called glucoamylase). The resulting syrup has a high glucose content. Much of the glucose syrup that is commercially produced is subsequently enzymatically isomerized to a dextrose/fructose mixture known as isosyrup.

α -Amylases (EC 3.2.1.1) hydrolyze starch, glycogen, and related polysaccharides by cleaving internal α -1,4-glucosidic bonds at random. These enzymes have a number of important commercial applications, including starch liquefaction, textile desizing, starch modification in the paper and pulp industry, grain processing, backing and brewing. α -Amylases also can be used in automatic dishwashing detergent and laundry detergent formulations, including those containing bleach, to remove starchy stains during washing. The α -amylase from *Bacillus* sp. no. 707 shows particularly advantageous performance when used in these applications. Unfortunately, this α -amylase is not expressed at high levels, complicating its economical manufacture and commercial use.

α -Amylases are isolated from a wide variety of bacterial, fungal, plant and animal sources. Many industrially important α -amylases are isolated from *Bacillus* sp., in part because of the generally high capacity of *Bacillus* to secrete amylases into the growth medium. *Bacillus* sp. A 7-7 (DSM 12368), for instance, secretes α -amylase at advantageously high levels. Although the *Bacillus* sp. A 7-7 α -amylase can be produced economically, the enzyme does not perform as well as the α -amylase from *Bacillus* sp. no. 707. Accordingly, there is a

2

need in the art to express the better performing variant of *Bacillus* sp. no. 707 α -amylase at production levels comparable to, for example, the *Bacillus* sp. A 7-7 α -amylase. Such a variant would be useful in more effective and economical detergent formulations or other formulations.

SUMMARY

Variants of α -amylase are provided that are produced more efficiently and thus more economically. Higher fermentation yields are achieved through introducing amino acid variations that promote solubility of the variant in a fermentation broth. That is, increased solubility allows more enzyme to remain in solution after expression in a host cell. This in turn increases the efficiency with which the expressed variant enzyme can be recovered from the fermentation broth.

In one embodiment, the primary structure of the variant is modified to resemble an α -amylase that is soluble at high concentrations in a fermentation broth. The variant may be a high-performance *Bacillus* sp. no. 707 α -amylase that advantageously can be expressed more economically for use in cleaning formulations and the like. Suitable variants include those with fewer hydrophobic amino acid residues on the enzyme surface, which promote aggregation and precipitation of the enzyme in an aqueous solution.

Accordingly, an object is to provide an isolated variant of a wild-type first α -amylase and an encoding nucleic acid, where

- (a) the α -amylase variant comprises at least one modified amino acid compared to the wild-type first α -amylase;
- (b) the α -amylase variant exhibits α -amylase activity; and
- (c) the at least one modified amino acid is the same as an amino acid found in a corresponding position of an amino acid sequence of a second α -amylase,

where the second α -amylase has a greater solubility than the wild-type first α -amylase, and where the amino acid sequence of the variant α -amylase is different by at least one amino acid from the second α -amylase. In one embodiment, the α -amylase variant is capable of being expressed at a higher level in a host cell, compared to a level of expression of the wild-type first α -amylase.

The α -amylase variant may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or 40 amino acid modifications, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids. The amino acid sequences of the first wild-type α -amylase and the second α -amylase may share at least 60%, 80%, or 90% sequence identity. In one embodiment, the wild-type first α -amylase and the second α -amylase are bacterial α -amylases, e.g., *Bacillus* α -amylases. As a non-limiting example, the wild-type first α -amylase may be a *Bacillus* sp. no. 707 α -amylase [Tsukamoto, A., Kimura, K., Ishii, Y., Takano, T. and Yamane, K. (1988) Nucleotide sequence of the maltohexaose-producing amylase gene from an alkalophilic *Bacillus* sp. #707 and structural similarity to liquefying type alpha-amylases Biochem. Biophys. Res. Commun. 151 (1), 25-31] comprising the amino acid sequence set forth in SEQ ID NO:1 and/or the second α -amylase may be a *Bacillus* sp. A 7-7 (DSM 12368) α -amylase [Bessler, C., Wieland, S., and Maurer, K. H. Alpha amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha amylase variants. Patent: WO 2006037484-A 13 Apr. 2006; HENKEL KOM-MANDITGESELLSCHAFT AUF AKTIEN (DE)] comprising the amino acid sequences set forth SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:7 or SEQ ID NO:8. The modified amino acid of the α -amylase variant may be selected from the group consisting of N28R, S36D, S83N, M116W, R142K,

R172Q, H183D, A186G, N251T, S255N, A256T, F441Y, S452R and K485N, e.g., N28R, S36D, M116W, R172Q, H183D, S255N and A256T.

An object is also to provide an isolated host cell comprising the encoding nucleic acid above, a vector operably linked to the isolated nucleic acid above, and an isolated host cell comprising the same vector. The isolated host cell may be a microorganism, e.g., a bacterium or a fungus. Suitable host cells may be selected from the group consisting of *Bacillus subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. thuringiensis*, *Streptomyces lividans*, or *S. murinus*; or a Gram negative bacterium, wherein said Gram negative bacterium is *Escherichia coli* or a *Pseudomonas* species.

Another object is to provide a detergent additive comprising the α -amylase variant above. The detergent additive may be in the form of a non-dusting granulate, microgranulate, stabilized liquid, or protected enzyme. The detergent additive further may comprise an enzyme selected from the group consisting of a cellulase, protease, aminopeptidase, amylase, carbohydrazase, carboxypeptidase, catalase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, or any combination thereof. In particular, the amylase may be another α -amylase, a β -amylase, an isoamylase, or a glucoamylase.

A detergent composition is provided that comprises the detergent additive above. The detergent composition further may comprise an enzyme from the group consisting of a cellulase, protease, aminopeptidase, amylase, carbohydrazase, carboxypeptidase, catalase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, or any combination thereof.

Another object is to provide a manual or automatic dishwashing composition comprising the α -amylase variant above. The composition further may comprise one or more of a surfactant, detergent builder, complexing agent, polymer, bleaching system, stabilizer, foam booster, suds suppressor, anti-corrosion agent, soil-suspending agent, anti-soil redeposition agent, dye, bactericide, hydrotone, tarnish inhibitor, and perfume. The composition further may comprise an enzyme selected from the group consisting of a cellulase, protease, aminopeptidase, amylase, carbohydrazase, carboxypeptidase, catalase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, or any combination thereof. A method of cleaning dishes comprises administering the manual or automatic dishwashing composition above.

Yet another object is to provide a laundry detergent additive comprising the α -amylase variant above. A laundry detergent composition may comprise the laundry additive and further may comprise one or more of a surfactant, detergent builder,

complexing agent, polymer, bleaching system, stabilizer, foam booster, suds suppressor, anti-corrosion agent, soil-suspending agent, anti-soil redeposition agent, dye, bactericide, hydrotone, optical brightener, fabric conditioner, and perfume. A method of laundering comprises administering the laundry detergent additive above.

Another object is to provide a biofilm-hydrolyzing composition comprising the α -amylase variant above. The biofilm hydrolyzing composition may be in the form of a solution, powder, paste, gel, liquid, ointment, tablet or gel. The composition further may comprise a cellulase, hemicellulase, xylanase, lipase, protease, pectinase, antimicrobial agent, or any combination thereof. A method of hydrolyzing a biofilm comprises administering the composition above for a time sufficient to hydrolyze the biofilm.

Another object is to provide a starch processing composition comprising the α -amylase variant above in an aqueous solution. The starch processing composition further may comprise a glucoamylase, isoamylase, pullulanase, phytase or a combination thereof. A method of processing a starch comprises administering the composition for a time sufficient to process the starch.

Another object is to provide a composition for saccharifying starch comprising the α -amylase variant above in a solution. A method of saccharifying starch comprises administering the composition for a period sufficient to saccharify the starch. A further object is to provide a composition for liquefying starch comprising the α -amylase variant above in a solution. A method of liquefying starch comprises administering the composition for a period sufficient to liquefy the starch.

Yet another object is to provide a textile desizing composition comprising the α -amylase variant above in a solution. The textile desizing composition further may comprise another enzyme. A method of desizing a textile comprises administering the textile desizing composition for a time sufficient to desize the textile.

Another object is to provide a baking composition comprising the α -amylase variant above in a solution or gel. A method of baking comprises administering the baking composition.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are incorporated in and constitute a part of this specification and illustrate various embodiments. In the drawings:

FIG. 1 depicts an amino acid sequence alignment between the mature forms of *Bacillus subtilis* sp. no. 707 α -amylase (SEQ ID NO:1) (Swissprot Accession No. P19571) and *Bacillus* sp. A 7-7 α -amylase (SEQ ID NO:2).

FIG. 2 depicts an SIM amino acid sequence alignment (Xiaoquin Huang and Webb Miller. (1991) A Time-Efficient, Linear-Space Local Similarity Algorithm. *Advances in Applied Mathematics*, vol. 12, pp. 337-357) between the mature forms of *Bacillus subtilis* sp. no. 707 α -amylase (SEQ ID NO:1) (Swissprot Accession No. P19571) and *Bacillus* sp. A 7-7 (DSM 12368) α -amylase (SEQ ID NO:7) (GenBank Accession No. CAL48155). The identical amino acid positions are marked by an asterisk below the sequence alignment.

FIG. 3 shows the diagram for plasmid pICatH-Amy707 used for the expression of *Bacillus* sp. no. 707 amylase variants. pICatH contains the following features: a temperature sensitive origin of replication (ori pE194, for replication in *Bacillus*), replication on from pBR322 (for amplification in *E. coli*), a neomycin resistance gene for selection, and the

native *B. licheniformis* chloramphenicol resistance gene (CAT) for chloramphenicol antibiotic selection, chromosomal integration and cassette amplification.

FIG. 4 depicts a comparison of amylase activity for a series of amylase 707 variants (R172Q, H183D, and S255N) in comparison to the parent enzyme.

DETAILED DESCRIPTION

Variants of α -amylase are provided that are produced more efficiently and thus more economically by modifying amino acid residues important to the solubility of the enzyme. For example, variants of *Bacillus* sp. no. 707 α -amylase are provided that are more soluble than the wild-type *Bacillus* sp. no. 707 α -amylase in a fermentation broth of a host cell expressing the variant. The variants additionally may have a higher solubility in the expression host cell, e.g., in the host cell cytoplasm. Since the *Bacillus* sp. no. 707 α -amylase variants have greater solubility, the variants can be isolated and purified more efficiently from a fermentation broth, for example, and formulations comprising the variants thus can be produced more economically.

Formulations comprising the present *Bacillus* sp. no. 707 α -amylase variants include cleaning formulations (e.g., automatic dishwashing detergent and laundry detergent formulations), biofilm treating formulations, starch processing formulations, textile desizing formulations, baking formulations, and the like. The following details how this can be done and provides compositions and uses for the α -amylase variants produced thereby.

1. DEFINITIONS & ABBREVIATIONS

In accordance with this detailed description, the following abbreviations and definitions apply. It must be noted that as used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an enzyme” includes a plurality of such enzymes and reference to “the formulation” includes reference to one or more formulations and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The following terms are provided below.

1.1 Definitions

“Amylase” means an enzyme that is, among other things, capable of catalyzing the degradation of starch. “Amylase” includes any amylase, such as glucoamylases, α -amylase, β -amylases, and wild-type α -amylases of *Bacillus* sp., such as *B. licheniformis* and *B. subtilis*. Amylases are hydrolases that cleave the α -D-(1 \rightarrow 4) O-glycosidic linkages in starch. Generally, α -amylases (EC 3.2.1.1; α -D-(1 \rightarrow 4)-glucan glucanohydrolase) are defined as endo-acting enzymes cleaving α -D-(1 \rightarrow 4) β -glycosidic linkages within the starch molecule in a random fashion. In contrast, the exo-acting amylolytic enzymes, such as β -amylases (EC 3.2.1.2; α -D-(1-4)-glucan maltohydrolase) and some product-specific amylases like maltogenic α -amylase (EC 3.2.1.133) cleave the starch molecule from the non-reducing end of the substrate. β -Amylases, α -glucosidases (EC 3.2.1.20; α -D-glucoside glucosidase), glucoamylase (EC 3.2.1.3; α -D-(1 \rightarrow 4)-glucan glucosidase), and product-specific amylases can produce malto-oligosaccharides of a specific length from starch.

“ α -Amylase variant,” “ α -amylase variant polypeptide,” and “variant enzyme” mean an α -amylase protein that has an amino acid sequence that has been modified from the amino acid sequence of a wild-type α -amylase. As used herein, “parent enzymes,” “parent sequence,” “parent polypeptide,” “wild-type α -amylase protein,” and “parent polypeptides” mean enzymes and polypeptides from which the α -amylase variant polypeptides are based, e.g., a *Bacillus* sp. no. 707 α -amylase. A wild-type α -amylase occurs naturally. “ α -Amylase variants” differ from a wild-type α -amylase in the amino acid residues of the mature protein, i.e., the protein sequence without a signal sequence. The α -amylase variant can be a fusion protein comprising a mature or variant *Bacillus* sp. no. 707 α -amylase linked to a signal peptide, for example, from another α -amylase. The term “variant” may be used interchangeably with the term “mutant.”

“Variants” refer to polypeptides and nucleic acids. Variants include insertions, substitutions, transversions, truncations, and/or inversions at one or more locations in the amino acid or nucleotide sequence, respectively. Variant nucleic acids can include sequences that are complementary to sequences that are capable of hybridizing to the nucleotide sequences presented herein. For example, a variant sequence is complementary to sequences capable of hybridizing under stringent conditions, e.g., 50° C. and 0.2 \times SSC (1 \times SSC=0.15 M NaCl, 0.015 M Na₃ citrate, pH 7.0), to the nucleotide sequences presented herein. More particularly, the term variant encompasses sequences that are complementary to sequences that are capable of hybridizing under highly stringent conditions, e.g., 65° C. and 0.1 \times SSC, to the nucleotide sequences presented herein.

“Isolated” means that the sequence is at least substantially free from at least one other component that the sequence is naturally associated and found in nature.

“Purified” means that the material is in a relatively pure state, e.g., at least about 90% pure, at least about 95% pure, or at least about 98% pure.

“Thermostable” means the enzyme is more thermostable than a reference enzyme. In the present application, an α -amylase variant is more thermostable than a wild-type *Bacillus* sp. no. 707 α -amylase if the variant has a relatively higher enzymatic activity after a specific interval of time under the same experimental conditions, e.g., the same temperature, substrate concentration, etc. Alternatively, a more thermostable enzyme has a higher heat capacity determined by differential scanning calorimetry, compared to a reference enzyme.

“pH range” means the pH values over which an enzyme exhibits activity.

As used herein, “pH stable” means the enzyme is more stable than a reference enzyme at a particular pH. In the present application, an α -amylase variant is more pH stable than a wild-type *Bacillus* sp. no. 707 α -amylase if the variant has a relatively higher activity after a specific interval of time under the same experimental conditions, e.g., the same pH, etc.

As used herein, “food” includes both prepared food, as well as an ingredient for a food, such as flour.

As used herein, “food ingredient” includes a formulation that is or can be added to a functional food or foodstuff and includes formulations used at low levels in a wide variety of products that require, for example, acidifying or emulsifying. The food ingredient may be in the form of a solution or as a solid, depending on the use and/or the mode of application and/or the mode of administration.

As used herein, “functional food” means food capable of providing not only a nutritional effect and/or a taste satisfaction, but also any further beneficial effect to the consumer.

As used herein, “amino acid sequence” is synonymous with the term “polypeptide” and/or the term “protein.” In some instances, the term “amino acid sequence” is synonymous with the term “peptide”; in some instances, the term “amino acid sequence” is synonymous with the term “enzyme.”

As used herein, “nucleotide sequence” or “nucleic acid sequence” refers to an oligonucleotide sequence or polynucleotide sequence and variants, homologues, fragments and derivatives thereof. The nucleotide sequence may be of genomic, synthetic or recombinant origin and may be double-stranded or single-stranded, whether representing the sense or anti-sense strand. As used herein, the term “nucleotide sequence” includes genomic DNA, cDNA, synthetic DNA, and RNA. Synthesis of nucleotide sequences is well known in the art (See e.g., Beaucage and Caruthers, Tetrahedron Lett., 22:1859-1862 [1981]), including the use of automated synthesizers (See e.g., Needham-VanDevanter et al., Nucl. Acids Res., 12:6159-6168 [1984]). DNA sequences can also be custom made and ordered from a variety of commercial sources.

“Homologue” means an entity having a certain degree of identity or “homology” with the subject amino acid sequences and the subject nucleotide sequences. A “homologous sequence” includes an amino acid sequence at least 75%, 80%, 85% or 90% identical, particularly at least 95%, 96%, 97%, 98% or 99% identical to the subject sequence. Typically, homologues will comprise the same active site residues as the subject amino acid sequence.

As used herein, “hybridization” includes the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies. The α -amylase variant nucleic acid may exist as single- or double-stranded DNA or RNA, an RNA/DNA heteroduplex or an RNA/DNA copolymer. As used herein, “copolymer” refers to a single nucleic acid strand that comprises both ribonucleotides and deoxyribonucleotides. The α -amylase variant nucleic acid may be codon-optimized to further increase expression.

As used herein, a “synthetic” compound is produced by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, α -amylase variant nucleic acids made with optimal codon usage for host organisms, such as the methylotrophic yeasts *Pichia*, *Hansenula*, *Streptomyces*, and *Trichoderma*, e.g., *T. reesei*, or other expression hosts of choice.

As used herein, “transformed cell” includes cells that have been transformed by use of recombinant DNA techniques. Transformation typically occurs by insertion of one or more nucleotide sequences into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence, i.e., is a sequence that is not natural to the cell that is to be transformed, such as a fusion protein.

As used herein, “operably linked” means that the described components are in a relationship permitting them to function in their intended manner. For example, a regulatory sequence operably linked to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

As used herein, “biologically active” refers to a sequence having a similar structural, regulatory or biochemical function as the naturally occurring sequence, although not necessarily to the same degree.

“Solubility” relates to the quantity of a particular substance that can dissolve in a particular solvent. A protein that is more soluble than another can reach a higher concentration in the solvent without precipitating out of solution. A solvent for

this purpose includes any milieu in which the protein may occur, such as an aqueous buffer or salt solution, a fermentation broth, or the cytoplasm of an expression host.

1.2 Abbreviations

The following abbreviations apply unless indicated otherwise:

3D three dimensional
 AE alcohol ethoxylate
 AEO alcohol ethoxylate
 AEOS alcohol ethoxysulfate
 AES alcohol ethoxysulfate
 AFAU acid fungal α -amylase units
 AGU glucoamylase activity unit
 AOS α -olefinsulfonate
 AS alcohol sulfate
 BAA bacterial α -amylase
 cDNA complementary DNA
 CMC carboxymethylcellulose
 DE Dextrose Equivalent
 DNA deoxyribonucleic acid
 DP3 degree of polymerization with three subunits
 DPn degree of polymerization with n subunits
 DS dry solid
 DTPA diethyltriaminopentaacetic acid
 EC enzyme commission for enzyme classification
 EDTA ethylenediaminetetraacetic acid
 EDTMPA ethylenediaminetetramethylene phosphonic acid
 EO ethylene oxide
 EP expressed protein
 F&HC fabric and household care
 HFCS high fructose corn syrup
 HFSS high fructose starch based syrup
 IPTG isopropyl β -D-thiogalactoside
 LAS linear alkylbenzenesulfonate
 LAT *B. licheniformis* α -amylase
 LU Lipase Units
 MW molecular weight
 nm nanometer
 NOBS nonanoyloxybenzenesulfonate
 NTA nitrilotriacetic acid
 PCR polymerase chain reaction
 PEG polyethyleneglycol
 pI isoelectric point
 ppm parts per million
 PVA poly(vinyl alcohol)
 PVP poly(vinylpyrrolidone)
 RAU Reference Amylase Units
 RMS root mean square
 RNA ribonucleic acid
 SAS secondary alkane sulfonates
 1×SSC 0.15 M NaCl, 0.015 M Na₃ citrate, pH 7.0
 SSF simultaneous saccharification and fermentation
 TAED tetraacetythylenediamine
 TNBS trinitrobenzenesulfonic acid
 w/v weight/volume
 w/w weight/weight
 wt wild-type
 μ L microliter

2. α -AMYLASE VARIANTS

The α -amylase variants herein are created from a wild-type α -amylase, e.g., a *Bacillus* sp. no. 707 α -amylase. The present variants have one or more modifications to the amino acid sequence that affect production levels relative to a wild-type α -amylase, such as by increasing the solubility of the variant in a fermentation broth of a host cell expressing the

variant. In this manner, a variant can combine the high performance characteristic of an α -amylase from *Bacillus* sp. no. 707, for example, with the high production levels of an α -amylase of other species or strain. In one embodiment, high production levels are conferred by amino acid variations that improve the aqueous solubility of the α -amylase variant.

For the purpose of this disclosure, an amino acid substitution may be designated R172Q, for example, meaning that an arginine (R) residue at position 172 is replaced with a glutamine (Q) residue, where the amino acids are designated by single letter abbreviations commonly known in the art. The residue position number is the same as used in the *Bacillus* sp. no. 707 α -amylase shown as the top sequence in FIG. 1 (SEQ ID NO:1).

Without being limited by theory, the level of α -amylase expression is believed due in part to the primary sequence of the α -amylase. For instance, specific amino acid residues may promote aggregation and precipitation of the expressed enzyme, lowering the amount of enzyme that is recoverable from a fermentation broth. Systematic variation of the primary sequence of the enzyme through genetic engineering can identify specific amino acid residues that contribute to the level of expression of the α -amylase. The primary sequence of an α -amylase that is expressed at high levels can guide the choice of appropriate amino acid sequence modifications. For example, the primary sequence of the *Bacillus* sp. no. 707 α -amylase differs by 33 amino acids from the primary sequence of the highly expressed α -amylase from *Bacillus* sp. A 7-7 (DSM 12368). For the purpose of this disclosure, “*Bacillus* sp. A 7-7 (DSM 12368)” is synonymous with “*Bacillus* sp. A 7-7.” One or more of these 33 amino acids is believed to affect the expression level through affecting aggregation and precipitation of the expressed α -amylase. Accordingly, one or more of these 33 amino acids in the *Bacillus* sp. no. 707 α -amylase sequence can be substituted so that the variant will contain one or more amino acids corresponding to the sequence of the highly expressed *Bacillus* sp. A 7-7 α -amylase. It is expected that such a variant will be expressed at a higher level.

Alternatively, amino acids that contribute to expression levels may be identified by substituting one or more amino acids in the *Bacillus* sp. A 7-7 α -amylase sequence to correspond to the sequence of the more poorly expressed *Bacillus* sp. no. 707 α -amylase. In this case, the variant is expected to be expressed at a lower level if the substitution affects expression.

Again without being limited by theory, it is generally expected that amino acid residues that contribute to the aggregation and precipitation of the enzyme are exposed on the enzyme surface. In particular, it is expected that hydrophobic areas on the protein surface induce the aggregation process. 3D (three dimensional) structural modeling can identify those substitutions, e.g., to amino acids on the protein surface, most likely to affect expression. Amino acid substitutions can be evaluated individually or in groups of two or more. A combinatorial library, made by methods known in the art, can be used to create variants having multiple amino acid substitutions.

The present variants differ from the wild-type α -amylase sequence by the substitution, addition, or deletion of one or more amino acids. For example, a variant α -amylase may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or 40 amino acid modifications, while retaining α -amylase activity. For example, a variant of *Bacillus* sp. no. 707 α -amylase can possess one or more amino acid substitutions at any of the aforementioned 33 amino acid positions, so that its sequence more closely resembles the *Bacillus* sp. A

7-7 α -amylase sequence. In one embodiment, a “variant” specifically excludes a sequence that differs from a wild-type sequence only in the first amino acid residue of the mature protein.

The primary sequence of any highly expressed α -amylase can guide the choice of amino acid sequence modifications that yield high-expression variants. For this purpose, an α -amylase with high sequence identity with a *Bacillus* sp. no. 707 α -amylase is particularly suitable because a minimal number of residues can be tested to determine which residue(s) affect expression. A *Bacillus* sp. A 7-7 α -amylase, for example, shares about a 93% sequence identity with the *Bacillus* sp. no. 707 α -amylase. A suitable *Bacillus* sp. A 7-7 α -amylase is disclosed in FIG. 1 (SEQ ID NO:2; GenBank Accession No. CAL48155). Another suitable *Bacillus* sp. A 7-7 α -amylase (SEQ ID NO:3; GenBank Accession No. CAD26710) differs by two residues, D236G and Y353C, from the *Bacillus* sp. A 7-7 α -amylase sequence shown in SEQ ID NO:2. Other suitable α -amylases include any α -amylases that are expressed at higher levels than the *Bacillus* sp. no. 707 α -amylase, particularly those α -amylases that share relatively high sequence identity with *Bacillus* sp. no. 707 α -amylase. The variant will not be identical in amino acid sequence as the highly expressed α -amylase, but will differ from this sequence by at least one amino acid. Amino acid substitutions include, but are not limited to, N28R, S36D, S83N, S91A, N94S, M116W, N125S, T132S, E134D, R142K, S154N, R172Q, N174Q, H183D, A186G, I250L, N251T, S255N, A256T, L272I, Q280S, K302R, N311Q, S323T, E360D, R383K, I410M, A434P, S437N, F441Y, S452R, T459S, and K485N. Not all of these substitutions will confer equally useful properties. For example, the substitutions A186G and A434P advantageously reduce hydrophobicity but also are expected to destabilize the variant. Similarly, the I250L substitution is made to an amino acid that is not exposed to solvent; therefore, this substitution is expected to affect stability with little or no effect on solubility. Additional substitutions may be made to the same residue. For example, S452K, S452N, or S452D may produce better results than S452R. Various amino acid substitutions are set forth at Table 1, infra.

2.1 α -Amylase Variant Characterization

Enzyme variants can be characterized by their nucleic acid and primary polypeptide sequences, by 3D structural modeling, and/or by their specific activity. Additional characteristics of the α -amylase variant include stability, calcium ion (Ca^{2+}) dependence, pH range, oxidation stability, and thermostability. In one aspect, the α -amylase variants are expressed at higher levels than the wild-type α -amylase, while retaining the performance characteristics of the wild-type α -amylase. Levels of expression and enzyme activity can be assessed using standard assays known to the artisan skilled in this field. In another aspect, variants demonstrate improved performance characteristics relative to the wild-type enzyme, such as improved stability at high temperatures (i.e., 70-120° C.), and/or pH extremes (i.e., pH 4.0 to 6.0 or pH 8.0 to 11.0), and/or calcium concentrations below 60 ppm.

An expression characteristic means an altered level of expression of the variant, when the variant is produced in a particular host cell. Expression generally relates to the amount of active variant that is recoverable from a fermentation broth using standard techniques known in this art over a given amount of time. Expression also can relate to the amount or rate of variant produced within the host cell or

secreted by the host cell. Expression also can relate to the rate of translation of the mRNA encoding the variant enzyme.

Altered Ca^{2+} stability means the stability of the enzyme under Ca^{2+} depletion has been altered i.e., increased or decreased. Mutations of importance include those that alter Ca^{2+} stability, in particular improved Ca^{2+} stability at high pH, i.e., pH 8.0 to 10.5.

In a further aspect, important mutations exhibit altered specific activity, especially at temperatures from 10-60° C., particularly 20-50° C., and more particularly 30-40° C., for use in cleaning compositions. For baking products, important mutations may exhibit altered specific activity at higher temperature ranges.

α -Amylase variants also may have altered oxidation stability, in particular higher oxidation stability, in comparison to the parent α -amylase. For example, increased oxidation stability is advantageous in detergent compositions, and decreased oxidation stability may be advantageous in composition for starch liquefaction.

The variant α -amylase may be more thermostable than the wild-type α -amylase. Such α -amylase variants are advantageous for use in baking or other processes that require elevated temperatures. For example, a thermostable α -amylase variant can degrade starch at temperatures of about 55° C. to about 80° C. or more. A thermostable α -amylase variant may retain its activity after exposure to temperatures of up to about 95° C.

The α -amylase variant polypeptides described herein can also have mutations that extend half-life relative to the parent enzyme by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more, particularly at elevated temperatures of about 55° C. to about 95° C. or more, particularly at about 80° C. In one embodiment, the α -amylase variant can be heated for about 1-10 minutes at 80° C. or higher.

The α -amylase variants may have exo-specificity, measured by exo-specificity indices described herein, for example. α -Amylase variants include those having higher or increased exo-specificity compared to the parent enzymes or polypeptides from which they were derived, optionally when measured under identical conditions. Thus, for example, the α -amylase variant polypeptides may have an exo-specificity index 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 500%, 1000%, 5000%, 10,000% or higher compared to their parent polypeptides.

In one aspect, the α -amylase variant polypeptide encoded by the nucleic acid has the same pH stability as the parental sequence. In another aspect, the variant comprises a mutation that confers a greater pH stability range or shifts the pH range to a desired area for the end commercial purpose of the enzyme. For example, in one embodiment, the variant can degrade starch at about pH 5.0 to about pH 10.5. The α -amylase variant polypeptide may have a longer half-life or higher activity (depending on the assay) compared to the parent polypeptide under identical conditions, or the α -amylase variant may have the same activity as the parent polypeptide. The α -amylase variant polypeptide also may have about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or longer half-life compared to their parent polypeptide under identical pH conditions. Alternatively, or in addition, the enzyme variant may have higher specific activity compared to the parent polypeptide under identical pH conditions.

In another aspect, a nucleic acid complementary to a nucleic acid encoding any of the α -amylase variants set forth herein is provided. Additionally, a nucleic acid capable of hybridizing to the complement is provided. In another embodiment, the sequence for use in the methods and compositions described here is a synthetic sequence. It includes,

but is not limited to, sequences made with optimal codon usage for expression in host organisms, such as the methylophilic yeasts *Pichia* and *Hansenula*.

3. PRODUCTION OF α -AMYLASE VARIANTS

A DNA sequence encoding the enzyme variant produced by methods described herein, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a suitable promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

3.1 Vectors

The recombinant expression vector carrying the DNA sequence encoding an α -amylase variant may be any vector that may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, mini-chromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. The integrated gene may also be amplified to create multiple copies of the gene in the chromosome by use of an amplifiable construct driven by antibiotic selection or other selective pressure, such as an essential regulatory gene or by complementation of an essential metabolic pathway gene.

An expression vector typically includes the components of a cloning vector, e.g., an element that permits autonomous replication of the vector in the selected host organism and one or more phenotypically detectable markers for selection purposes. The expression vector normally comprises control nucleotide sequences encoding a promoter, operator, ribosome binding site, translation initiation signal and optionally, a repressor gene or one or more activator genes. In one aspect, all the signal sequences used target the material to the cell culture media for easier enzyme collection and optionally purification. The procedures used to ligate the DNA construct encoding an α -amylase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (see e.g., Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd ed., Cold Spring Harbor, 1989 and 3rd ed., 2001).

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence that shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an α -amylase variant, especially in a bacterial host, are the promoter of the lac operon of *E. coli*, the *Streptomyces coelicolor* agarase gene *dagA* or *celA* promoters, various *Bacillus*-derived promoters, such as the promoters of the *Bacillus licheniformis*, *Bacillus* sp. no. 707, or *Bacillus* sp. A 7-7 α -amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* α -amylase (*amyQ*), and the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes, etc. For transcription in a fungal

host, examples of useful promoters are those derived from the gene encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral α -amylase, *A. niger* acid stable α -amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase, or *A. nidulans* acetamidase. When the gene encoding the α -amylase variant polypeptide is expressed in a bacterial species such as *E. coli*, a suitable promoter can be selected, for example, from a bacteriophage promoter including a T7 promoter and a phage lambda promoter. Examples of suitable promoters for the expression in a yeast species include but are not limited to the Gal 1 and Gal 10 promoters of *Saccharomyces cerevisiae* and the *Pichia pastoris* AOX1 or AOX2 promoters. For expression in *Trichoderma reesei*, the CBHII promoter also may be used.

The expression vector may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the α -amylase variant. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter. The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1, pICatH, and pIJ702.

The vector may also comprise a selectable marker, e.g., a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or a gene which confers antibiotic resistance, e.g., ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD*, and *xxsC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation as known in the art. See, e.g., WO 91/17243.

3.2 Variant Expression and Host Organisms

While intracellular expression or solid state fermentation may be advantageous in some respects, e.g., when using certain bacteria or fungi as host cells, it is generally advantageous if the expression of the variant is extracellular and into the culture medium. In general, the *Bacillus* α -amylases mentioned herein comprise a signal sequence that permits secretion of the expressed protease into the culture medium. If desirable, this signal sequence may be replaced by a different signal sequence, which is conveniently accomplished by substitution of the DNA sequences encoding the respective signal sequence. The signal sequences are typically characterized as having three domains, an N-terminal domain, a H-domain, and a C-terminal domain and range from 18 to 35 residues in length.

The mature protein can be in the form initially of a fusion protein to a pre-protein derived from another *Bacillus* sp. or from the same species as the parental sequence. To secrete proteins in a *B. licheniformis* host cell, for example, the signal peptide of *B. licheniformis* α -amylase is frequently used; however, signal proteins from other *Bacillus* α -amylases can also be substituted. Useful signal peptides include those from *Bacillus* sp. no. 707 or *Bacillus* sp. A 7-7, for example.

An isolated cell, either comprising a DNA construct or an expression vector, is advantageously used as a host cell in the recombinant production of an α -amylase variant. The cell may be transformed with the DNA construct encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration

is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

Examples of suitable bacterial host organisms are Gram positive bacterial species such as Bacillaceae, including *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. lautus*, *B. megaterium*, and *B. thuringiensis*; *Streptomyces* sp., such as *S. murinus*; lactic acid bacterial species including *Lactococcus* sp., such as *L. lactis*; *Lactobacillus* sp., including *L. reuteri*; *Leuconostoc* sp.; *Pediococcus* sp.; and *Streptococcus* sp. Still other useful hosts include *Bacillus* sp. A 7-7, for example. Alternatively, strains of a Gram negative bacterial species belonging to Enterobacteriaceae, including *E. coli*, or to Pseudomonadaceae can be selected as the host organism.

A suitable yeast host organism can be selected from biotechnologically relevant yeasts species, such as, but not limited to, *Pichia* sp., *Hansenula* sp., *Kluyveromyces* sp., *Yarrowia* sp., *Saccharomyces* sp., including *S. cerevisiae*, or a species belonging to *Schizosaccharomyces*, such as *S. pombe*. A strain of the methylotrophic yeast species *Pichia pastoris* can be used as the host organism. Alternatively, the host organism can be a *Hansenula* species. Suitable host organisms among filamentous fungi include species of *Aspergillus*, e.g., *A. niger*, *A. oryzae*, *A. tubigensis*, *A. awamori*, or *A. nidulans*. Alternatively, a strain of *Fusarium* sp., e.g., *Fusarium oxysporum* or *Rhizomucor* sp., such as *R. miehei*, can be used as the host organism. Other suitable yeasts include *Thermomyces* sp. and *Mucor* sp. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known in the art. A suitable procedure for transforming *Aspergillus* host cells, for example, is described in EP 238023.

In a yet further aspect, a method of producing an α -amylase variant is provided, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium. The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the α -amylase variant. Suitable media and media components are available from commercial suppliers or may be prepared according to published recipes, e.g., as described in catalogues of the American Type Culture Collection (ATCC). Exemplary culture media include, but are not limited to, those for fed-batch fermentations performed in a three thousand liter (3,000 L) stirred tank fermentor. The media used would be that most suitable for the host cell being used, for example the media discussed below for culturing *Bacillus* sp. no. 707. The growth medium in that case can consist of corn steep solids and soy flour as sources of organic compounds, along with inorganic salts as a source of sodium, potassium, phosphate, magnesium and sulfate, as well as trace elements. Typically, a carbohydrate source such as glucose is also part of the initial medium. Once the culture has established itself and begins growing, the carbohydrate is metered into the tank to maintain the culture as is known in the art. Samples are removed from the fermentor at regular intervals to measure enzyme titer using, for example, a colorimetric assay method.

The fermentation process is halted when the enzyme production rate stops increasing according to the measurements.

An α -amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulfate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

Host cells may be cultured under suitable conditions which allow expression of the α -amylase variant proteins. Expression of the proteins may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by addition of an inducer substance, e.g., dexamethasone, IPTG, or Sepharose, to the culture medium, for example. Polypeptides can also be produced recombinantly in an in vitro cell-free system, such as the TnTTM (Promega) rabbit reticulocyte system.

An α -amylase variant expressing host also can be cultured under aerobic conditions in the appropriate medium for the host. Shaking or a combination of agitation and aeration can be provided, with production occurring at the appropriate temperature for that host, e.g., from about 30° C. to about 75° C., depending on the needs of the host and production of the desired α -amylase variant. Culturing can occur from about 12 to about 100 hours or greater (and any hour value there between) or more particularly from 24 to 72 hours. Typically, the culture broth is at a pH of about 5.5 to about 8.0, again depending on the culture conditions needed for the host cell relative to production of the α -amylase variant.

4. PURIFICATION OF α -AMYLASE VARIANTS

Fermentation, separation, and concentration techniques are known in the art and conventional methods can be used in order to prepare the concentrated α -amylase variant containing solution. After fermentation, a fermentation broth is obtained, and the microbial cells and various suspended solids, including residual raw fermentation materials, are removed by conventional separation techniques to obtain an amylase solution. Filtration, centrifugation, microfiltration, rotary vacuum drum filtration, followed by ultra-filtration, extraction or chromatography, or the like are generally used.

It is desirable to concentrate the solution containing the α -amylase variant to optimize recovery, since the use of unconcentrated solutions requires increased incubation time to collect precipitates containing the purified α -amylase variant. The solution is concentrated using conventional techniques until the desired enzyme level is obtained. Concentration of the enzyme variant containing solution may be achieved by any of the techniques discussed above. In one embodiment, rotary vacuum evaporation and/or ultrafiltration is used. Alternatively, ultrafiltration can be used.

By "precipitation agent" for purposes of purification is meant a compound effective to precipitate the α -amylase variant from the concentrated enzyme variant solution in solid form, whatever its nature may be, i.e., crystalline, amorphous, or a blend of both. Precipitation can be performed using, for example, a metal halide precipitation agent. Metal halide precipitation agents include: alkali metal chlorides, alkali metal bromides and blends of two or more of these metal halides. The metal halide may be selected from the group consisting of sodium chloride, potassium chloride, sodium bromide, potassium bromide and blends of two or

more of these metal halides. Suitable metal halides include sodium chloride and potassium chloride, particularly sodium chloride, which can further be used as a preservative.

The metal halide precipitation agent is used in an amount effective to precipitate the α -amylase variant. The selection of at least an effective amount and an optimum amount of metal halide effective to cause precipitation of the enzyme variant, as well as the conditions of the precipitation for maximum recovery including incubation time, pH, temperature and concentration of α -amylase variant, will be readily apparent to one of ordinary skill in the art after routine testing.

Generally, at least about 5% w/v (weight/volume) to about 25% w/v of metal halide is added to the concentrated enzyme variant solution, and usually at least 8% w/v. Generally, no more than about 25% w/v of metal halide is added to the concentrated enzyme variant solution and usually no more than about 20% w/v. The optimal concentration of the metal halide precipitation agent will depend, among others, on the nature of the specific α -amylase variant and on its concentration in the concentrated α -amylase variant solution.

Another alternative to effect precipitation of the enzyme is to use of organic compounds, which can be added to the concentrated enzyme variant solution. The organic compound precipitating agent can include: 4-hydroxybenzoic acid, alkali metal salts of 4-hydroxybenzoic acid, alkyl esters of 4-hydroxybenzoic acid, and blends of two or more of these organic compounds. The addition of said organic compound precipitation agents can take place prior to, simultaneously with or subsequent to the addition of the metal halide precipitation agent, and the addition of both precipitation agents, organic compound and metal halide, may be carried out sequentially or simultaneously. For further descriptions, see, e.g., U.S. Pat. No. 5,281,526 to Genencor International, Inc., for example.

Generally, the organic compound precipitation agents are selected from the group consisting of alkali metal salts of 4-hydroxybenzoic acid, such as sodium or potassium salts, and linear or branched alkyl esters of 4-hydroxybenzoic acid, wherein the alkyl group contains from 1 to 12 carbon atoms, and blends of two or more of these organic compounds. The organic compound precipitations agents can be for example linear or branched alkyl esters of 4-hydroxybenzoic acid, wherein the alkyl group contains from 1 to 10 carbon atoms, and blends of two or more of these organic compounds. Suitable organic compounds include linear alkyl esters of 4-hydroxybenzoic acid, wherein the alkyl group contains from 1 to 6 carbon atoms, and blends of two or more of these organic compounds. Methyl esters of 4-hydroxybenzoic acid, propyl ester of 4-hydroxybenzoic acid, butyl ester of 4-hydroxybenzoic acid, ethyl ester of 4-hydroxybenzoic acid and blends of two or more of these organic compounds can also be used. Additional organic compounds also include, but are not limited to, 4-hydroxybenzoic acid methyl ester (methyl PARABEN) and 4-hydroxybenzoic acid propyl ester (propyl PARABEN), which are also amylase preservative agents.

Addition of the said organic compound precipitation agent provides the advantage of high flexibility of the precipitation conditions with respect to pH, temperature, α -amylase variant concentration, precipitation agent concentration, and time of incubation.

The organic compound precipitation agent is used in an amount effective to improve precipitation of the enzyme variant by means of the metal halide precipitation agent. The selection of at least an effective amount and an optimum amount of organic compound precipitation agent, as well as the conditions of the precipitation for maximum recovery including incubation time, pH, temperature and concentra-

tion of enzyme variant, will be readily apparent to one of ordinary skill in the art, in light of the present disclosure, after routine testing.

Generally, at least 0.01% w/v of organic compound precipitation agent is added to the concentrated enzyme variant solution and usually at least 0.02% w/v. Generally, no more than 0.3% w/v of organic compound precipitation agent is added to the concentrated enzyme variant solution and usually no more than 0.2% w/v.

The concentrated enzyme variant solution, containing the metal halide precipitation agent and, in one aspect, the organic compound precipitation agent, is adjusted to a pH that necessarily will depend on the enzyme variant to be purified. Generally, the pH is adjusted to a level near the isoelectric point (pI) of the amylase. For example, the pH can be adjusted within a range of about 2.5 pH units below the pI to about 2.5 pH units above the pI. The pH may be adjusted accordingly if the pI of the variant differs from the wild-type pI.

The incubation time necessary to obtain a purified enzyme variant precipitate depends on the nature of the specific enzyme variant, the concentration of enzyme, and the specific precipitation agent(s) and its (their) concentration. Generally, the time effective to precipitate the enzyme variant is between about 1 to about 30 hours; usually it does not exceed about 25 hours. In the presence of the organic compound precipitation agent, the time of incubation can still be reduced to less than about 10 hours, and in most cases even about 6 hours.

Generally, the temperature during incubation is between about 4° C. and about 50° C. Usually, the method is carried out at a temperature between about 10° C. and about 45° C., and particularly between about 20° C. and about 40° C. The optimal temperature for inducing precipitation varies according to the solution conditions and the enzyme variant or precipitation agent(s) used.

The overall recovery of purified enzyme variant precipitate, and the efficiency with which the process is conducted, is improved by agitating the solution comprising the enzyme variant, the added metal halide and the added organic compound. The agitation step is done both during addition of the metal halide and the organic compound, and during the subsequent incubation period. Suitable agitation methods include mechanical stirring or shaking, vigorous aeration, or any similar technique.

After the incubation period, the purified enzyme variant is then separated from the dissociated pigment and other impurities and collected by conventional separation techniques, such as filtration, centrifugation, microfiltration, rotary vacuum filtration, ultrafiltration, press filtration, cross membrane microfiltration, cross flow membrane microfiltration or the like. Cross membrane microfiltration can be one method used. Further purification of the purified enzyme variant precipitate can be obtained by washing the precipitate with water. For example, the purified enzyme variant precipitate is washed with water containing the metal halide precipitation agent, for example, with water containing the metal halide and the organic compound precipitation agents.

During the culturing, thermostable amylase extracellularly accumulates in the culture broth. For the isolation and purification of the desired α -amylase variant, the culture broth is centrifuged or filtered to eliminate cells, and the resulting cell-free liquid is used for the purification of the enzyme. In one embodiment, the cell-free broth is subjected to salting out using ammonium sulfate at about 70% saturation; the 70% saturation-precipitation fraction is then dissolved in a buffer and applied to a column such as a Sephadex G-100 column, and eluted to recover the enzyme variant active fraction. For

further purification, a conventional procedure such as ion exchange chromatography may be used.

Purified enzyme variants are useful for all applications in which the enzyme variants are generally utilized. For example, they can be used in laundry detergents and spot removers, in the food industry, in starch processing and baking, and in pharmaceutical compositions as digestive aids. They can be made into a final product that is either liquid (solution, slurry) or solid (granular, powder).

Alternatively, the enzyme product can be recovered and a floccing agent is added to the media in order to remove cells and cell debris by filtration or centrifugation without further purification of the enzyme.

The α -amylase variants produced and purified by the methods described above can be used in a variety of useful industrial applications. The variants possess valuable properties facilitating applications related to fabric and household care (F&HC). For example, a variant can be used as a component in washing, dishwashing and hard-surface cleaning detergent compositions. Variants also are useful in the production of sweeteners and ethanol from starch, and/or for textile desizing. Variant α -amylases are particularly useful in starch-conversion processes, including starch liquefaction and/or saccharification processes, as described, for example, in WO 2005/111203 and U.S. Published Application No. 2006/0014265 (Genencor International, Inc.). These various uses of the α -amylase variants are described in more detail below.

5. CLEANING AND DISHWASHING COMPOSITIONS AND USE

The α -amylase variants discussed herein can be formulated in detergent compositions for use in cleaning dishes or other cleaning compositions, for example. These can be gels, powders or liquids. The compositions can comprise the α -amylase variant alone, other amylolytic enzymes, other cleaning enzymes, and other components common to cleaning compositions.

Thus, a dishwashing detergent composition can comprise a surfactant. The surfactant may be anionic, non-ionic, cationic, amphoteric or a mixture of these types. The detergent can contain 0% to about 90% by weight of a non-ionic surfactant, such as low- to non-foaming ethoxylated propoxylated straight-chain alcohols.

In the detergent applications, α -amylase variants are usually used in a liquid composition containing propylene glycol. The α -amylase variant can be solubilized in propylene glycol, for example, by circulating in a 25% volume/volume propylene glycol solution containing 10% calcium chloride.

The dishwashing detergent composition may contain detergent builder salts of inorganic and/or organic types. The detergent builders may be subdivided into phosphorus-containing and non-phosphorus-containing types. The detergent composition usually contains about 1% to about 90% of detergent builders. Examples of phosphorus-containing inorganic alkaline detergent builders, when present, include the water-soluble salts, especially alkali metal pyrophosphates, orthophosphates, and polyphosphates. An example of phosphorus-containing organic alkaline detergent builder, when present, includes the water-soluble salts of phosphonates. Examples of non-phosphorus-containing inorganic builders, when present, include water-soluble alkali metal carbonates, borates, and silicates, as well as the various types of water-insoluble crystalline or amorphous aluminosilicates, of which zeolites are the best-known representatives.

Examples of suitable organic builders include the alkali metal; ammonium and substituted ammonium; citrates; suc-

cinates; malonates; fatty acid sulphonates; carboxymethoxy succinates; ammonium polyacetates; carboxylates; polycarboxylates; aminopolycarboxylates; polyacetyl carboxylates; and polyhydroxysulphonates.

Other suitable organic builders include the higher molecular weight polymers and copolymers known to have builder properties, for example appropriate polyacrylic acid, polymaleic and polyacrylic/polymaleic acid copolymers, and their salts.

The cleaning composition may contain bleaching agents of the chlorine/bromine-type or the oxygen-type. Examples of inorganic chlorine/bromine-type bleaches are lithium, sodium or calcium hypochlorite, and hypobromite, as well as chlorinated trisodium phosphate. Examples of organic chlorine/bromine-type bleaches are heterocyclic N-bromo- and N-chloro-imides such as trichloroisocyanuric, tribromoisocyanuric, dibromoisocyanuric, and dichloroisocyanuric acids, and salts thereof with water-solubilizing cations such as potassium and sodium. Hydantoin compounds are also suitable.

The cleaning composition may contain oxygen bleaches, for example in the form of an inorganic persalt, optionally with a bleach precursor or as a peroxy acid compound. Typical examples of suitable peroxy bleach compounds are alkali metal perborates, both tetrahydrates and monohydrates, alkali metal percarbonates, persulfates, and perphosphates. Suitable activator materials include tetraacetylenediamine (TAED) and glycerol triacetate. Enzymatic bleach activation systems may also be present, such as perborate or percarbonate, glycerol triacetate and perhydrolase, as disclosed in WO 2005/056783, for example.

The cleaning composition may be stabilized using conventional stabilizing agents for the enzyme(s), e.g., a polyol such as, e.g., propylene glycol, a sugar or a sugar alcohol, lactic acid, boric acid, or a boric acid derivative (e.g., an aromatic borate ester). The cleaning composition may also contain other conventional detergent ingredients, e.g., deflocculant material, filler material, foam depressors, anti-corrosion agents, soil-suspending agents, sequestering agents, anti-soil redeposition agents, dehydrating agents, dyes, bactericides, fluorescent agents, thickeners, and perfumes.

Finally, the α -amylase variants may be used in conventional dishwashing detergents, e.g., in any of the detergents described in the following patent publications, with the consideration that the α -amylase variants disclosed herein are used instead of, or in addition to, any α -amylase disclosed in the listed patents and published applications: CA 2006687, GB 2200132, GB 2234980, GB 2228945, DE 3741617, DE 3727911, DE 4212166, DE 4137470, DE 3833047, DE 4205071, WO 93/25651, WO 93/18129, WO 93/04153, WO 92/06157, WO 92/08777, WO 93/21299, WO 93/17089, WO 93/03129, EP 481547, EP 530870, EP 533239, EP 554943, EP 429124, EP 346137, EP 561452, EP 318204, EP 318279, EP 271155, EP 271156, EP 346136, EP 518719, EP 518720, EP 518721, EP 516553, EP 561446, EP 516554, EP 516555, EP 530635, EP 414197, and U.S. Pat. Nos. 5,112,518; 5,141,664; and 5,240,632.

6. LAUNDRY DETERGENT COMPOSITIONS AND USE

According to the embodiment, one or more α -amylase variants may typically be a component of a detergent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or a protected enzyme. Non-dusting granulates may be produced, e.g., as disclosed in U.S. Pat. Nos. 4,106,991 and

4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products; (polyethyleneglycol, PEG) with mean molar weights of 1,000 to 20,000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in, for example, GB Patent No. 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in U.S. Pat. No. 5,879,920 (Genencor International, Inc.) or EP 238216, for example. Polyols have long been recognized as stabilizers of proteins as well as for improving the solubility of proteins. See, e.g., Kaushik et al., "Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose" *J. Biol. Chem.* 278: 26458-65 (2003) and references cited therein; and M. Conti et al., "Capillary isoelectric focusing: the problem of protein solubility," *J. Chromatography* 757: 237-245 (1997).

The detergent composition may be in any convenient form, e.g., as gels, powders, granules, pastes, or liquids. A liquid detergent may be aqueous, typically containing up to about 70% of water, and 0% to about 30% of organic solvent, it may also be in the form of a compact gel type containing only about 30% water.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0% to about 50% of anionic surfactant, such as linear alkylbenzene-sulfonate (LAS); α -olefinsulfonate (AOS); alkyl sulfate (fatty alcohol sulfate) (AS); alcohol ethoxysulfate (AEOS or AES); secondary alkanesulfonates (SAS); α -sulfo fatty acid methyl esters; alkyl- or alkenylsuccinic acid; or soap. The composition may also contain 0% to about 40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyltrimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide, as described in WO 92/06154, for example.

The detergent composition may additionally comprise one or more other enzymes, such as lipase, cutinase, protease, cellulase, peroxidase, and/or laccase in any combination.

The detergent may contain about 1% to about 65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g., SKS-6 from Hoechst). The detergent may also be unbuild, i.e., essentially free of detergent builder. Enzymes may be used in any composition compatible with the stability of the enzyme. Enzymes can be protected against generally deleterious components by known forms of encapsulation, as by granulation or sequestration in hydro gels, for example. Enzymes and specifically α -amylases either with or without the starch binding domains are not limited to laundry and dishwashing applications, but may find use in surface cleaners and ethanol production from starch or biomass.

21

The detergent may comprise one or more polymers. Examples include carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system, which may comprise a H_2O_2 source such as perborate or percarbonate optionally combined with a peracid-forming bleach activator, such as TAED or nonanoyloxybenzenesulfonate (NOBS). Alternatively, the bleaching system may comprise peroxy acids of the amide, imide, or sulfone type, for example. The bleaching system can also be an enzymatic bleaching system where a perhydrolase activates peroxide, such as that described in WO 2005/056783.

The enzymes of the detergent composition may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol; a sugar or sugar alcohol; lactic acid; boric acid or a boric acid derivative, such as an aromatic borate ester; and the composition may be formulated as described in WO 92/19709 and WO 92/19708, for example.

The detergent may also contain other conventional detergent ingredients such as fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, or perfume, for example. The pH (measured in aqueous solution at use concentration) is usually neutral or alkaline, e.g., pH about 7.0 to about 11.0.

The α -amylase variant may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the detergent composition, the α -amylase variant may be added in an amount corresponding to 0.00001-1.0 mg (calculated as pure enzyme protein) of α -amylase variant per liter of wash liquor. Particular forms of detergent compositions comprising the α -amylase variants can be formulated to include:

(1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising linear alkylbenzenesulfonate (calculated as acid) about 7% to about 12%; alcohol ethoxysulfate (e.g., C_{12-18} alcohol, 1-2 ethylene oxide (EO)) or alkyl sulfate (e.g., C_{16-18}) about 1% to about 4%; alcohol ethoxylate (e.g., C_{14-15} alcohol, 7 EO) about 5% to about 9%; sodium carbonate (e.g., Na_2CO_3) about 14% to about 20%; soluble silicate, about 2 to about 6%; zeolite (e.g., $NaAlSiO_4$) about 15% to about 22%; sodium sulfate (e.g., Na_2SO_4) 0% to about 6%; sodium citrate/citric acid (e.g., $C_6H_5Na_3O_7/C_6H_8O_7$) about 0% to about 15%; sodium perborate (e.g., $NaBO_3 \cdot H_2O$) about 11% to about 18%; TAED about 2% to about 6%; carboxymethylcellulose (CMC) and 0% to about 2%; polymers (e.g., maleic/acrylic acid, copolymer, PVP, PEG) 0-3%; enzymes (calculated as pure enzyme) 0.0001-0.1% protein; and minor ingredients (e.g., suds suppressors, perfumes, optical brightener, photobleach) 0-5%.

(2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising linear alkylbenzenesulfonate (calculated as acid) about 6% to about 11%; alcohol ethoxysulfate (e.g., C_{12-18} alcohol, 1-2 EO) or alkyl sulfate (e.g., C_{16-18}) about 1% to about 3%; alcohol ethoxylate (e.g., C_{14-15} alcohol, 7 EO) about 5% to about 9%; sodium carbonate (e.g., Na_2CO_3) about 15% to about 21%; soluble silicate, about 1% to about 4%; zeolite (e.g., $NaAlSiO_4$) about 24% to about 34%; sodium sulfate (e.g., Na_2SO_4) about 4% to about 10%; sodium citrate/citric acid (e.g., $C_6H_5Na_3O_7/C_6H_8O_7$) 0% to about 15%; carboxymethylcellulose (CMC) 0% to about 2%; polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) 1-6%; enzymes (calculated as

22

pure enzyme protein) 0.0001-0.1%; minor ingredients (e.g., suds suppressors, perfume) 0-5%.

(3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising linear alkylbenzenesulfonate (calculated as acid) about 5% to about 9%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO) about 7% to about 14%; Soap as fatty acid (e.g., C_{16-22} fatty acid) about 1 to about 3%; sodium carbonate (as Na_2CO_3) about 10% to about 17%; soluble silicate, about 3% to about 9%; zeolite (as $NaAlSiO_4$) about 23% to about 33%; sodium sulfate (e.g., Na_2SO_4) 0% to about 4%; sodium perborate (e.g., $NaBO_3 \cdot H_2O$) about 8% to about 16%; TAED about 2% to about 8%; phosphonate (e.g., EDTMPA) 0% to about 1%; carboxymethylcellulose (CMC) 0% to about 2%; polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) 0-3%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; minor ingredients (e.g., suds suppressors, perfume, optical brightener) 0-5%.

(4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising linear alkylbenzenesulfonate (calculated as acid) about 8% to about 12%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO) about 10% to about 25%; sodium carbonate (as Na_2CO_3) about 14% to about 22%; soluble silicate, about 1% to about 5%; zeolite (e.g., $NaAlSiO_4$) about 25% to about 35%; sodium sulfate (e.g., Na_2SO_4) 0% to about 10%; carboxymethylcellulose (CMC) 0% to about 2%; polymers (e.g., maleic/acrylic acid copolymer, PVP, PEG) 1-3%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., suds suppressors, perfume) 0-5%.

(5) An aqueous liquid detergent composition comprising linear alkylbenzenesulfonate (calculated as acid) about 15% to about 21%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO or C_{12-15} alcohol, 5 EO) about 12% to about 18%; soap as fatty acid (e.g., oleic acid) about 3% to about 13%; alkenylsuccinic acid (C_{12-14}) 0% to about 13%; aminoethanol about 8% to about 18%; citric acid about 2% to about 8%; phosphonate 0% to about 3%; polymers (e.g., PVP, PEG) 0% to about 3%; borate (e.g., B_4O_7) 0% to about 2%; ethanol 0% to about 3%; propylene glycol about 8% to about 14%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., dispersants, suds suppressors, perfume, optical brightener) 0-5%.

(6) An aqueous structured liquid detergent composition comprising linear alkylbenzenesulfonate (calculated as acid) about 15% to about 21%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO, or C_{12-15} alcohol, 5 EO) 3-9%; soap as fatty acid (e.g., oleic acid) about 3% to about 10%; zeolite (as $NaAlSiO_4$) about 14% to about 22%; potassium citrate about 9% to about 18%; borate (e.g., B_4O_7) 0% to about 2%; carboxymethylcellulose (CMC) 0% to about 2%; polymers (e.g., PEG, PVP) 0% to about 3%; anchoring polymers (e.g., lauryl methacrylate/acrylic acid copolymer); molar ratio 25:1, MW 3800) 0% to about 3%; glycerol 0% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., dispersants, suds suppressors, perfume, optical brighteners) 0-5%.

(7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising fatty alcohol sulfate about 5% to about 10%; ethoxylated fatty acid monoethanolamide about 3% to about 9%; soap as fatty acid 0-3%; sodium carbonate (e.g., Na_2CO_3) about 5% to about 10%; soluble silicate, about 1% to about 4%; zeolite (e.g., $NaAlSiO_4$) about 20% to about 40%; sodium sulfate (e.g., Na_2SO_4) about 2% to about 8%; sodium perborate (e.g., $NaBO_3 \cdot H_2O$) about 12% to about 18%; TAED about 2% to about 7%; polymers (e.g., maleic/acrylic acid copolymer,

PEG) about 1% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., optical brightener, suds suppressors, perfume) 0-5%.

(8) A detergent composition formulated as a granulate comprising linear alkylbenzenesulfonate (calculated as acid) about 8% to about 14%; ethoxylated fatty acid monoethanolamide about 5% to about 11%; soap as fatty acid 0% to about 3%; sodium carbonate (e.g., Na_2CO_3) about 4% to about 10%; soluble silicate, about 1% to about 4%; zeolite (e.g., NaAlSiO_4) about 30% to about 50%; sodium sulfate (e.g., Na_2SO_4) about 3% to about 11%; sodium citrate (e.g., $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$) about 5% to about 12%; polymers (e.g., PVP, maleic/acrylic acid copolymer, PEG) about 1% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., suds suppressors, perfume) 0-5%.

(9) A detergent composition formulated as a granulate comprising linear alkylbenzenesulfonate (calculated as acid) about 6% to about 12%; nonionic surfactant about 1% to about 4%; soap as fatty acid about 2% to about 6%; sodium carbonate (e.g., Na_2CO_3) about 14% to about 22%; zeolite (e.g., NaAlSiO_4) about 18% to about 32%; sodium sulfate (e.g., Na_2SO_4) about 5% to about 20%; sodium citrate (e.g., $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$) about 3% to about 8%; sodium perborate (e.g., $\text{NaBO}_3 \cdot \text{H}_2\text{O}$) about 4% to about 9%; bleach activator (e.g., NOBS or TAED) about 1% to about 5%; carboxymethylcellulose (CMC) 0% to about 2%; polymers (e.g., polycarboxylate or PEG) about 1% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., optical brightener, perfume) 0-5%.

(10) An aqueous liquid detergent composition comprising linear alkylbenzenesulfonate (calculated as acid) about 15% to about 23%; alcohol ethoxysulfate (e.g., C_{12-15} alcohol, 2-3 EO) about 8% to about 15%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO, or C_{12-15} alcohol, 5 EO) about 3% to about 9%; soap as fatty acid (e.g., lauric acid) 0% to about 3%; aminoethanol about 1% to about 5%; sodium citrate about 5% to about 10%; hydrotrope (e.g., sodium toluenesulfonate) about 2% to about 6%; borate (e.g., B_4O_7) 0% to about 2%; carboxymethylcellulose 0% to about 1%; ethanol about 1% to about 3%; propylene glycol about 2% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., polymers, dispersants, perfume, optical brighteners) 0-5%.

(11) An aqueous liquid detergent composition comprising linear alkylbenzenesulfonate (calculated as acid) about 20% to about 32%; alcohol ethoxylate (e.g., C_{12-15} alcohol, 7 EO, or C_{12-15} alcohol, 5 EO) 6-12%; aminoethanol about 2% to about 6%; citric acid about 8% to about 14%; borate (e.g., B_4O_7) about 1% to about 3%; polymer (e.g., maleic/acrylic acid copolymer, anchoring polymer, such as lauryl methacrylate/acrylic acid copolymer) 0% to about 3%; glycerol about 3% to about 8%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., hydrotropes, dispersants, perfume, optical brighteners) 0-5%.

(12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising anionic surfactant (linear alkylbenzenesulfonate, alkyl sulfate, α -olefinsulfonate, α -sulfo fatty acid methyl esters, alkane-sulfonates, soap) about 25% to about 40%; nonionic surfactant (e.g., alcohol ethoxylate) about 1% to about 10%; sodium carbonate (e.g., Na_2CO_3) about 8% to about 25%; soluble silicates, about 5% to about 15%; sodium sulfate (e.g., Na_2SO_4) 0% to about 5%; zeolite (NaAlSiO_4) about 15% to about 28%; sodium perborate (e.g., $\text{NaBO}_3 \cdot \text{H}_2\text{O}$) 0% to about 20%; bleach activator (TAED or NOBS) about 0% to about

5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; minor ingredients (e.g., perfume, optical brighteners) 0-3%.

(13) Detergent compositions as described in compositions 1)-12) supra, wherein all or part of the linear alkylbenzenesulfonate is replaced by ($\text{C}_{12}-\text{C}_{18}$) alkyl sulfate.

(14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising ($\text{C}_{12}-\text{C}_{18}$) alkyl sulfate about 9% to about 15%; alcohol ethoxylate about 3% to about 6%; polyhydroxy alkyl fatty acid amide about 1% to about 5%; zeolite (e.g., NaAlSiO_4) about 10% to about 20%; layered disilicate (e.g., SK56 from Hoechst) about 10% to about 20%; sodium carbonate (e.g., Na_2CO_3) about 3% to about 12%; soluble silicate, 0% to about 6%; sodium citrate about 4% to about 8%; sodium percarbonate about 13% to about 22%; TAED about 3% to about 8%; polymers (e.g., polycarboxylates and PVP) 0% to about 5%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., optical brightener, photobleach, perfume, suds suppressors) 0-5%.

(15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/L comprising ($\text{C}_{12}-\text{C}_{18}$) alkyl sulfate about 4% to about 8%; alcohol ethoxylate about 11% to about 15%; soap about 1% to about 4%; zeolite MAP or zeolite A about 35% to about 45%; sodium carbonate (as Na_2CO_3) about 2% to about 8%; soluble silicate, 0% to about 4%; sodium percarbonate about 13% to about 22%; TAED 1-8%; carboxymethylcellulose (CMC) 0% to about 3%; polymers (e.g., polycarboxylates and PVP) 0% to about 3%; enzymes (calculated as pure enzyme protein) 0.0001-0.1%; and minor ingredients (e.g., optical brightener, phosphonate, perfume) 0-3%.

(16) Detergent formulations as described in 1)-15) supra, which contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for already specified bleach systems.

(17) Detergent compositions as described supra in 1), 3), 7), 9), and 12), wherein perborate is replaced by percarbonate.

(18) Detergent compositions as described supra in 1), 3), 7), 9), 12), 14), and 15), which additionally contains a manganese catalyst.

(19) Detergent composition formulated as a non-aqueous detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxyated primary alcohol, a builder system (e.g., phosphate), an enzyme(s), and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

In another embodiment, the 2,6- β -D-fructan hydrolase can be incorporated in detergent compositions and used for removal/cleaning of biofilm present on household and/or industrial textile/laundry.

The detergent composition may for example be formulated as a hand or machine laundry detergent composition, including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the detergent composition can comprise 2,6- β -D-fructan hydrolase, one or more α -amylase variants, and one or more other cleaning enzymes, such as a protease, a lipase, a cutinase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, a laccase, and/or a peroxidase, and/or combinations thereof. In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (e.g., pH-optimum, compatibility with other enzymatic and

non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Proteases: suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable. The protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus* sp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309 (see, e.g., U.S. Pat. No. 6,287,841), subtilisin 147, and subtilisin 168 (see, e.g., WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and *Fusarium* proteases (see, e.g., WO 89/06270 and WO 94/25583). Examples of useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/20115. Suitable commercially available protease enzymes include Alcalase®, Savinase®, Esperase®, and Kannase™ (Novozymes, formerly Novo Nordisk A/S); Maxatase®, Maxacal™, Maxapem™, Properase™, Purafect®, Purafect OxP™, FN2™, and FN3™ (Genencor International, Inc.).

Lipases: suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include, but are not limited to, lipases from *Humicola* (synonym *Thermomyces*), e.g. *H. lanuginosa* (*T. lanuginosus*) (see, e.g., EP 258068 and EP 305216) and *H. insolens* (see, e.g., WO 96/13580); a *Pseudomonas* lipase (e.g., from *P. alcaligenes* or *P. pseudoalcaligenes*; see, e.g., EP 218 272), *P. cepacia* (see, e.g., EP 331 376), *P. stutzeri* (see, e.g., GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (see, e.g., WO 95/06720 and WO 96/27002), *P. wisconsinensis* (see, e.g., WO 96/12012); a *Bacillus* lipase (e.g., from *B. subtilis*; see, e.g., Dartois et al. *Biochimica Biophysica Acta*, 1131: 253-360 (1993)), *B. stearothermophilus* (see, e.g., JP 64/744992), or *B. pumilus* (see, e.g., WO 91/16422). Additional lipase variants contemplated for use in the formulations include those described, for example, in: WO 92/05249, WO 94/01541, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079, WO 97/07202, EP 407225, and EP 260105. Some commercially available lipase enzymes include Lipolase® and Lipolase® Ultra (Novozymes, formerly Novo Nordisk A/S).

Polyesterases: Suitable polyesterases include, but are not limited to, those described in WO 01/34899 (Genencor International, Inc.) and WO 01/14629 (Genencor International, Inc.), and can be included in any combination with other enzymes discussed herein.

Amylases: The compositions can be combined with other α -amylases, such as a non-variant α -amylase. These can include commercially available amylases, such as but not limited to Duramyl®, Termamyl™, Fungamyl® and BAN™ (Novozymes, formerly Novo Nordisk A/S), Rapidase®, and Purastar® (Genencor International, Inc.).

Cellulases: Cellulases can be added to the compositions. Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g., the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in U.S. Pat. Nos. 4,435,307; 5,648,263; 5,691,178; 5,776,757; and WO 89/09259, for example. Exemplary cellulases contemplated for use are those having color care benefit for the textile. Examples of such cellulases are cellulases described in EP 0495257; EP 531 372; WO 99/25846 (Genencor International, Inc.), WO 96/34108 (Genencor International, Inc.), WO 96/11262; WO 96/29397;

and WO 98/08940, for example. Other examples are cellulase variants, such as those described in WO 94/07998; WO 98/12307; WO 95/24471; PCT/DK98/00299; EP 531 315; U.S. Pat. Nos. 5,457,046; 5,686,593; and 5,763,254. Commercially available cellulases include Celluzyme® and Carezyme® (Novozymes, formerly Novo Nordisk A/S); Clazinase™ and Puradax® HA (Genencor International, Inc.); and KAC-500(B)™ (Kao Corporation).

Peroxidases/Oxidases: Suitable peroxidases/oxidases contemplated for use in the compositions include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from *Coprinus*, e.g., from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive, i.e., a separate additive or a combined additive, can be formulated as a granulate, liquid, slurry, etc. Suitable granulate detergent additive formulations include non-dusting granulates.

Non-dusting granulates may be produced, e.g., as disclosed in U.S. Pat. Nos. 4,106,991 and 4,661,452 and optionally may be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (e.g., polyethyleneglycol, PEG) with mean molar weights of 1,000 to 20,000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591, for example. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238 216.

The detergent composition may be in any convenient form, e.g., a bar, tablet, gel, powder, granule, paste, or liquid. A liquid detergent may be aqueous, typically containing up to about 70% water, and 0% to about 30% organic solvent. Compact detergent gels containing 30% or less water are also contemplated. The detergent composition comprises one or more surfactants, which may be non-ionic, including semi-polar, anionic, cationic, or zwitterionic, or any combination thereof. The surfactants are typically present at a level of from 0.1% to 60% by weight.

When included therein the detergent typically will contain from about 1% to about 40% of an anionic surfactant, such as linear alkylbenzenesulfonate, α -olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, α -sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid, or soap.

When included therein, the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl-N-alkyl derivatives of glucosamine ("glucamides").

The detergent may contain 0% to about 65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraacetic acid (EDTA), diethylenetri-

aminepentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g., SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates, e.g., polyacrylates, maleic/acrylic acid copolymers), and lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system that may comprise a source of H_2O_2 , such as perborate or percarbonate, which may be combined with a peracid-forming bleach activator (e.g., tetraacetylenediamine or nonanoyloxybenzenesulfonate). Alternatively, the bleaching system may comprise peroxyacids (e.g., the amide-, imide-, or sulfone-type peroxyacids). The bleaching system can also be an enzymatic bleaching system.

The enzyme(s) of the detergent composition may be stabilized using conventional stabilizing agents, e.g., polyol (e.g., propylene glycol or glycerol), a sugar or sugar alcohol, lactic acid, boric acid, a boric acid derivative (e.g., an aromatic borate ester), or a phenyl boronic acid derivative (e.g., 4-formylphenyl boronic acid). The composition may be formulated as described in WO 92/19709 and WO 92/19708.

The detergent may also contain other conventional detergent ingredients such as e.g., fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

It is contemplated that in the detergent compositions, the enzyme variants may be added in an amount corresponding to about 0.01 to about 100 mg of enzyme protein per liter of wash liquor, particularly about 0.05 to about 5.0 mg of enzyme protein per liter of wash liquor, or even more particularly in 0.1 to about 1.0 mg of enzyme protein per liter of wash liquor.

6.1 Methods of Assessing Detergent Compositions

Numerous α -amylase cleaning assays exist. Exemplary description of testing cleaning includes the following. A "swatch" is a piece of material such as a fabric that has a stain applied thereto. The material can be, for example, fabrics made of cotton, polyester or mixtures of natural and synthetic fibers. Alternatively, the material can be paper, such as filter paper or nitrocellulose, or a piece of a hard material, such as ceramic, metal, or glass. For α -amylases, the stain is starch based, but can include blood, milk, ink, grass, tea, wine, spinach, gravy, chocolate egg, cheese, clay, pigment, oil, or mixtures of these compounds. In one embodiment, the α -amylase variant is tested in a BMI (blood/milk/ink) assay.

A "smaller swatch" is a piece of the swatch that has been cut with a single hole punch device, or a custom manufactured 96-hole punch device, where the pattern of the multi-hole punch is matched to standard 96-well microtiter plates, or has been otherwise removed from the swatch. The swatch can be of textile, paper, metal, or other suitable material. The smaller swatch can have the stain affixed either before or after it is placed into the well of a 24-, 48- or 96-well microtiter plate. The smaller swatch also can be made by applying a stain to a small piece of material. For example, the smaller swatch can be a piece of fabric with a stain $\frac{1}{8}$ " or 0.25" in diameter. The custom manufactured punch is designed in such a manner that it delivers 96 swatches simultaneously to all wells of a 96-well plate. The device allows delivery of more than one swatch per well by simply loading the same 96-well plate

multiple times. Multi-hole punch devices can be conceived to deliver simultaneously swatches to any format plate, including, but not limited to, 24-well, 48-well, and 96-well plates. In another conceivable method, the soiled test platform can be a bead made of either metal, plastic, glass, ceramic, or other suitable material that is coated with the soil substrate. The one or more coated beads are then placed into wells of 96-, 48-, or 24-well plates or larger formats, containing suitable buffer and enzyme. In this case, supernatant can be examined for released soil either by direct absorbance measurement or after a secondary color development reaction. Analysis of the released soil might also be taken by mass spectral analysis.

In one embodiment, a treatment protocol provides control over degree of fixation of a stain. As a result, it is possible to produce swatches that, for example, release varying amounts of stain when washed in the absence of the enzyme being tested. The use of fixed swatches leads to a dramatic improvement of the signal-to-noise ratio in the wash assays. Furthermore, by varying the degree of fixation, one can generate stains that give optimum results under the various cleaning conditions.

Swatches having stains of known "strength" on various types of material are commercially available (EMPA, St. Gallen, Switzerland; wfk—Testgewebe GmbH, Krefeld Germany; or Center for Test Materials, Vlaardingen, The Netherlands) and/or can be made by the practitioner (Morris and Prato, *Textile Research Journal* 52(4): 280-286 (1982)). Swatches can comprise, for example, a cotton-containing fabric containing a stain made by blood/milk/ink (BMI), spinach, grass, or chocolate/milk/soot. A BMI stain can be fixed to cotton with 0.0003% to 0.3% hydrogen peroxide, for example. Other combinations include grass or spinach fixed with 0.001% to 1% glutaraldehyde, gelatin and Coomassie stain fixed with 0.001% to 1% glutaraldehyde, or chocolate, milk and soot fixed with 0.001% to 1% glutaraldehyde.

The swatch can also be agitated during incubation with the enzyme and/or detergent formulation. Wash performance data is dependent on the orientation of the swatches in the wells (horizontal versus vertical), particularly in the 96-well plate. This would indicate that mixing was insufficient during the incubation period. Although there are a number of ways to ensure sufficient agitation during incubation, a plate holder in which the microtiter plate is sandwiched between two plates of aluminum can be constructed. This can be as simple as placing, for example, an adhesive plate sealer over the wells then clamping the two aluminum plates to the 96-well plate with any type of appropriate, commercially available clamps. It can then be mounted in a commercial incubator shaker. Setting the shaker to about 400 rpm results in very efficient mixing, while leakage or cross-contamination is efficiently prevented by the holder.

Trinitrobenzenesulfonic acid (TNBS) can be used to quantify the concentration of amino groups in the wash liquor. This can serve as a measure of the amount of protein that was removed from the swatch (see, e.g., Cayot and Tainturier, *Anal. Biochem.* 249: 184-200 (1997)). However, if a detergent or an enzyme sample leads to the formation of unusually small peptide fragments (for example, from the presence of peptidases in the sample), then one will obtain a larger TNBS signal, i.e., more "noise."

Another means of measuring wash performance of blood/milk/ink that is based on ink release that can be quantified by measuring the absorbance of the wash liquor. The absorbance can be measured at any wavelength between 350 and 800 nm. In one embodiment, the wavelength is measured at 410 nm or 620 nm. The wash liquor can also be examined to determine the wash performance on stains containing grass, spinach,

gelatin or Coomassie stain. Suitable wavelengths for these stains include 670 nm for spinach or grass and 620 nm for gelatin or Coomassie. For example, an aliquot of the wash liquor (typically 100-150 μ L from a 96-well microplate, for example) is removed and placed in a cuvette or multiwell microplate. This is then placed in a spectrophotometer and the absorbance is read at an appropriate wavelength. The system also can be used to determine a suitable enzyme and/or detergent composition for dish washing, for example, using a blood/milk/ink stain on a suitable substrate, such as cloth, plastic or ceramic.

In one aspect, a BMI stain is fixed to cotton by applying 0.3% hydrogen peroxide to the BMI/cotton swatch for 30 minutes at 25° C. or by applying 0.03% hydrogen peroxide to the BMI/cotton swatch for 30 minutes at 60° C. Smaller swatches of approximately 0.25" are cut from the BMI/cotton swatch and placed in the wells of a 96-well microtiter plate. Into each well, a known mixture of a detergent composition and an enzyme such as a variant protein is placed. After placing an adhesive plate sealer onto the top of the microtiter plate, the microtiter plate is clamped to an aluminum plate and agitated on an orbital shaker at approximately 250 rpm for about 10 to 60 minutes. At the end of this time, the supernatants are transferred to wells in a new microtiter plate and the absorbance of the ink at 620 nm is measured. This can be similarly tests with spinach stains or grass stains fixed to cotton by applying 0.01% glutaraldehyde to the spinach/cotton swatch or grass/cotton swatch for 30 minutes at 25° C. The same can be done with chocolate, milk, and/or soot stains.

7. BIOFILM REMOVAL COMPOSITIONS AND USE

The composition may comprise one variant α -amylase as the major enzymatic component, e.g., a mono-component composition for use in removing biofilms. Alternatively, the composition may comprise multiple enzymatic activities, such as multiple amylases, or a cocktail of enzymes including an aminopeptidase, amylase (β - or α - or gluco-amylase), carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and/or xylanase, or any combination thereof for removing biofilms. The additional enzyme(s) may be producible by means of a microorganism belonging to the genus *Aspergillus*, e.g., *A. aculeatus*, *A. awamori*, *A. niger*, or *A. oryzae*; or *Trichoderma*; *Humicola*, e.g., *H. insolens*; or *Fusarium*, e.g., *F. bactridioides*, *F. cerealis*, *F. crookwellense*, *F. culmorum*, *F. graminearum*, *F. graminum*, *F. heterosporum*, *F. negundi*, *F. oxysporum*, *F. reticulatum*, *F. roseum*, *F. sambucinum*, *F. sarcocroum*, *F. sulphureum*, *F. toruloseum*, *F. trichothecioides*, or *F. venenatum*.

The α -amylase variant comprising compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the α -amylase variant containing composition may be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition may be stabilized in accordance with methods known in the art.

Examples are given below of uses of the polypeptide compositions. The dosage of the α -amylase variant containing composition and other conditions under which the composi-

tion is used may be determined on the basis of methods known in the art. The α -amylase variants are further contemplated for use in a composition along with a 2,6- β -D-fructan hydrolase or variant thereof.

One aspect is disintegration and/or removal of biofilm. The term "disintegration" as used herein is to be understood as hydrolysis of polysaccharides in a biofilm matrix connecting and binding together individual microbial cells in the biofilm, whereby the microbial cells can be released and removed from the biofilm. The biofilm may be present at a surface, and the disintegration of the biofilm can be achieved by bringing the surface in contact with an aqueous medium, e.g., by immersing, covering or splashing, where the aqueous medium comprises an α -amylase variant and optionally one or more other enzymes responsible for breaking down biofilms, such as but not limited to 2,6- β -D-fructan hydrolase. The composition can be used to hydrolyse slime, e.g., in white waters in the pulping and paper industry.

The α -amylase variant may be present in the amount of 0.0001 to 10,000 mg/L, 0.001-1000 mg/L, 0.01-100 mg/L, or even 0.1-10 mg/L. Additional enzymes and enzyme variants may be present in similar amounts or less. The process may be performed at temperatures from about ambient temperature to about 70° C. A suitable temperature range is from about 30° C. to about 60° C., e.g., about 40° C. to about 50° C.

A suitable pH for the hydrolyzing biofilms lies within from about 3.5 to about 8.5. A particularly suitable pH range is from about 5.5 to about 8, e.g. from about 6.5 to about 7.5. The contact time or reaction time for the enzyme variant to effectively removing a biofilm may vary considerably, depending on the biofilm properties and the frequency of which a surface is treated with the enzyme variant alone or in combination with other enzymes, such as 2,6- β -D-fructan hydrolase, but a suitable reaction time lies within about 0.25 to about 25 hours. A particularly suitable reaction time is from about 1 to about 10 hours, e.g., about 2 hours.

Additional enzymes can be combined with the α -amylase variants and 2,6- β -D-fructan hydrolases, including, but not limited to, cellulases, hemicellulases, xylanases, other amylases including other α -amylases, lipases, proteases, and/or pectinases. The enzymes can further be combined with antimicrobial agents such as enzymatic or non-enzymatic biocides. An enzymatic biocide may be a composition comprising an oxidoreductase, e.g., a laccase or a peroxidase, especially haloperoxidase, and optionally an enhancing agent, such as an alkyl syringate, as described in WO 97/42825 and DK 97/1273, for example.

The surface from which a biofilm is to be removed and/or cleaned off may be a hard surface, which by definition relates to any surface which is essentially non-permeable to microorganisms. Examples are surfaces made from metal, e.g., stainless steel alloys, plastics/synthetic polymers, rubber, board, glass, wood, paper, textile, concrete, rock, marble, gypsum and ceramic materials which optionally may be coated with paint, enamel, polymers and the like. Accordingly, the surface may be a member of a system holding, transporting, processing, or contacting aqueous solutions, such as water supply systems, food processing systems, cooling systems, chemical processing systems, pharmaceutical processing systems, or wood processing system, such as found in the pulp and/or paper industry. Accordingly, the enzyme variants and compositions containing the enzyme variants are useful in a conventional cleaning-in-place (C-I-P) system. The surface may be a member of a system unit such as pipes, tanks, pumps, membranes, filters, heat exchangers, centrifuges, evaporators, mixers, spray towers, valves and reactors. The surface may also be or be a part of utensils used

in the medical science and industry such as contaminated endoscopes, prosthetic devices or medical implants.

The compositions for biofilm removal also are contemplated for preventing so-called bio-corrosion occurring when a metal surface, e.g., a pipeline, is attacked by a microbial biofilm. The compositions disintegrate the biofilm, thereby preventing the microbial cells of the biofilm from creating a biofilm environment that would corrode the metal surface to which it is attached.

7.1 Oral Care Compositions

Additional applications for anti-biofilm compositions include oral care. Surfaces thus include teeth with dental plaque. Accordingly, the variant enzymes can be used for compositions, e.g., toothpaste, and processes for making a medicament comprising an enzyme variant for disintegration of plaque present on a human or animal tooth. A further use is disintegration of biofilm from mucous membranes, such as biofilm in lungs in patients suffering from cystic fibrosis. The surface also may be other surfaces of biological origin, e.g., skin, teeth, hair, nails, or may be contaminated contact lenses.

Other enzymes useful in oral care compositions include, but are not limited to, 2,6- β -D-fructan hydrolase; dextranase; mutanases; oxidases, such as glucose oxidase; L-amino acid oxidase; peroxidases, such as *Coprinus* sp. peroxidases described in WO 95/10602 or lactoperoxidase; haloperoxidases, especially haloperoxidase from *Curvularia* sp., in particular *C. verruculosa* and *C. inaequalis*; laccases; proteases, such as papain; acidic protease (e.g., the acidic proteases described in WO 95/02044); endoglucosidases; lipases; amylases, including amyloglucosidases, such as AMGTM (Novozymes, formerly Novo Nordisk A/S); anti-microbial enzymes; and mixtures thereof.

The oral care composition may have any suitable physical form, i.e., powder, paste, gel, liquid, ointment, tablet, etc. An "oral care composition" includes a composition that can be used for maintaining or improving the oral hygiene in the mouth of humans and animals by preventing dental caries, preventing the formation of dental plaque and tartar, removing dental plaque and tartar, preventing and/or treating dental diseases, etc. Oral care compositions also encompass products for cleaning dentures, artificial teeth, and the like. Examples of oral care compositions include toothpaste, dental cream, gel or tooth powder, odontic mouthwashes, pre- or post brushing rinse formulations, chewing gum, lozenges, and candy. Toothpastes and tooth gels typically include abrasive polishing materials, foaming agents, flavoring agents, humectants, binders, thickeners, sweetening agents, whitening/bleaching/stain removing agents, water, and optionally enzymes. Mouthwashes, including plaque-removing liquids, typically comprise a water/alcohol solution, flavor, humectant, sweetener, foaming agent, colorant, and optionally enzymes.

Abrasive polishing material may also be incorporated into the oral care composition. Accordingly, abrasive polishing material can include alumina and hydrates thereof, such as α -alumina trihydrate; magnesium trisilicate; magnesium carbonate; kaolin; aluminosilicates, such as calcined aluminum silicate and aluminum silicate; calcium carbonate; zirconium silicate; and also powdered plastics, such as polyvinyl chloride; polyamides; polymethyl methacrylate; polystyrene; phenol-formaldehyde resins; melamine-formaldehyde resins; urea-formaldehyde resins; epoxy resins; powdered polyethylene; silica xerogels; hydrogels and aerogels and the like. Also suitable as abrasive agents are calcium pyrophosphate; water-insoluble alkali metaphosphates; dicalcium phosphate

and/or its dihydrate, dicalcium orthophosphate; tricalcium phosphate; particulate hydroxyapatite and the like. It is also possible to employ mixtures of these substances. Depending on the oral care composition, the abrasive product may be present at about 0% to about 70% by weight, for example, from about 1% to about 70%. For toothpastes, the abrasive material content typically lies in the range of 10% to 70% by weight of the final toothpaste.

Humectants are employed to prevent loss of water from toothpastes, for example. Suitable humectants for use in oral care compositions include glycerol; polyol; sorbitol; polyethylene glycols (PEG); propylene glycol; 1,3-propanediol; 1,4-butanediol; hydrogenated partially hydrolyzed polysaccharides and the like and mixtures thereof. Humectants are in general present at 0% to about 80% or about 5% to about 70% by weight in toothpaste.

Silica, starch, tragacanth gum, xanthan gum, extracts of Irish moss, alginates, pectin, cellulose derivatives, such as hydroxyethyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl cellulose, polyacrylic acid and its salts, polyvinylpyrrolidone, are examples of suitable thickeners and binders that help stabilize a dentifrice product. Thickeners may be present in toothpaste creams and gels at about 0.1% to about 20% by weight, and binders at about 0.01 to about 10% by weight of the final product.

A foaming agent can be used, including soap, anionic, cationic, non-ionic, amphoteric and/or zwitterionic surfactants. These may be present at levels of 0% to about 15%, about 0.1 to about 13%, or even about 0.25% to about 10% by weight of the final product. Surfactants are only suitable to the extent that they do not inactivate the present enzymes. Surfactants include fatty alcohol sulfates, salts of sulphonated mono-glycerides or fatty acids having 10 to 20 carbon atoms, fatty acid-albumen condensation products, salts of fatty acids amides and taurines, and/or salts of fatty acid esters of isethionic acid.

Suitable sweeteners include saccharin for use in a formulation. Flavors, such as spearmint, also are usually present in low amounts, such as from about 0.01% to about 5% by weight, especially from about 0.1% to about 5%. Whitening/bleaching agents include H_2O_2 and may be added in amounts less than about 5% or from about 0.25% to about 4%, calculated by the weight of the final product. The whitening/bleaching agents may be an enzyme, such as an oxidoreductase. Examples of suitable teeth bleaching enzymes are described in WO 97/06775. Water is usually added in an amount giving the composition, e.g. toothpaste, a flowable form. Water-soluble anti-bacterial agents, such as chlorhexidine digluconate, hexetidine, alexidine, Triclosan[®], quaternary ammonium anti-bacterial compounds and water-soluble sources of certain metal ions such as zinc, copper, silver and stannous (e.g., zinc, copper and stannous chloride, and silver nitrate) also may be included. Additional compounds that can be used include a fluoride source, dyes/colorants, preservatives, vitamins, pH-adjusting agents, anti-caries agents, desensitizing agents, etc.

Enzymes are also useful in the oral care compositions described above. Enzymes provide several benefits when used for cleansing of the oral cavity. Proteases break down salivary proteins, which are adsorbed onto the tooth surface and form the pellicle, the first layer of resulting plaque. Proteases along with lipases destroy bacteria by lysing proteins and lipids which form the structural components of bacterial cell walls and membranes. Dextranase and other carbohydrases, such as the 2,6- β -D-fructan hydrolase, break down the organic skeletal structure produced by bacteria that forms a matrix for bacterial adhesion. Proteases and amylases not

only prevent plaque formation, but also prevent the development of mineralization by breaking-up carbohydrate-protein complexes that bind calcium.

A toothpaste typically may comprise the following ingredients (in weight % of the final toothpaste composition): abrasive material to about 70%; humectant: 0% to about 80%; thickener: about 0.1% to about 20%; binder: about 0.01% to about 10%; sweetener: about 0.1% to about 5%; foaming agent: 0% to about 15%; whitener: 0% to about 5%; and enzymes: about 0.0001% to about 20%. In one embodiment, a toothpaste has a pH in the range from about 6.0 to about 8.0, and comprises: about 10% to about 70% abrasive material; 0% to about 80% humectant; 0.1% to about 20% thickener; 0.01% to about 10% binder; about 0.1% to about 5% sweetener; 0% to about 15% foaming agent; 0% to about 5% whitener; and about 0.0001% to about 20% enzymes. These enzymes include α -amylase variants alone or in combination with other enzymes, such as 2,6- β -D-fructan hydrolase, and optionally other types of enzymes mentioned above.

A mouthwash typically may comprise the following ingredients (in weight % of the final mouth wash composition): 0% to about 20% humectant; 0% to about 2% surfactant; 0% to about 5% enzymes; 0% to about 20% ethanol; 0% to about 2% other ingredients (e.g., flavor, sweetener active ingredients such as fluorides). The composition can also contain from about 0% to about 70% water. The mouthwash composition may be buffered with an appropriate buffer, e.g. sodium citrate or phosphate in the pH-range of about 6.0 to about 7.5. The mouthwash may be in none-diluted form, i.e., must be diluted before use. The oral care compositions may be produced using any conventional method known to the art of oral care.

8. STARCH PROCESSING COMPOSITIONS AND USE

In another aspect, compositions with the disclosed α -amylase variants can be utilized for starch liquefaction and/or saccharification. Starch processing is useful for producing sweetener, producing alcohol for fuel or drinking (i.e., potable alcohol), producing a beverage, processing cane sugar, or producing desired organic compounds, e.g., citric acid, itaconic acid, lactic acid, gluconic acid, ketones, amino acids, antibiotics, enzymes, vitamins, and hormones. Conversion of starch to fructose syrups normally consists of three consecutive enzymatic processes: a liquefaction process, a saccharification process, and an isomerization process. During the liquefaction process, a variant α -amylase degrades starch to dextrins by at pH between about 5.5 and about 6.2 and at temperatures of about 95° C. to about 160° C. for a period of approximately 2 hours. About 1 mM of calcium (40 ppm free calcium ions) typically is added to optimize enzyme stability under these conditions. Other α -amylase variants may require different conditions.

After the liquefaction process, the dextrins can be converted into dextrose by addition of a glucoamylase (e.g., AMG™) and optionally a debranching enzyme, such as an isoamylase or a pullulanase (e.g., Promozyme®). Before this step, the pH is reduced to a value below about 4.5, maintaining the high temperature (above 95° C.), and the liquefying α -amylase variant activity is denatured. The temperature is lowered to 60° C., and a glucoamylase and a debranching enzyme can be added. The saccharification process proceeds typically for about 24 to about 72 hours.

After the saccharification process, the pH is increased to a value in the range of about 6.0 to about 8.0, e.g., pH 7.5, and the calcium is removed by ion exchange. The dextrose syrup

is then converted into high fructose syrup using an immobilized glucose isomerase (such as Sweetzyme®), for example.

The α -amylase variant may provide at least one improved enzymatic property for conducting the process of liquefaction. For example, the variant α -amylase may have a higher activity, or it may have a reduced requirement for calcium. Addition of free calcium is required to ensure adequately high stability of the α -amylase; however, free calcium strongly inhibits the activity of the glucose isomerase. Accordingly, the calcium should be removed prior to the isomerization step, by means of an expensive unit operation, to an extent that reduces the level of free calcium to below 3-5 ppm. Cost savings can be obtained if such an operation could be avoided, and the liquefaction process could be performed without addition of free calcium ions. Thus, α -amylase variants that do not require calcium ions or that have a reduced requirement for calcium are particularly advantageous. For example, a less calcium-dependent α -amylase variant, which is stable and highly active at low concentrations of free calcium (<40 ppm) can be utilized in the composition and procedures. Such an α -amylase variant should have a pH optimum in the range of about 4.5 to about 6.5, e.g., about pH 4.5 to about pH 5.5. The α -amylase variants can be used alone to provide specific hydrolysis or can be combined with other amylases to provide a "cocktail" with a broad spectrum of activity.

The starch to be processed may be a highly refined starch quality, for instance, at least 90%, at least 95%, at least 97%, or at least 99.5% pure. Alternatively, the starch can be a more crude starch containing material comprising milled whole grain, including non-starch fractions such as germ residues and fibers. The raw material, such as whole grain, is milled to open up the structure and allow further processing. Two milling processes are suitable: wet and dry milling. Also, corn grits, and milled corn grits may be applied. Dry milled grain will comprise significant amounts of non-starch carbohydrate compounds, in addition to starch. When such a heterogeneous material is processed by jet cooking, often only a partial gelatinization of the starch is achieved. Accordingly, α -amylase variants having a high activity towards ungelatinized starch are advantageously applied in a process comprising liquefaction and/or saccharification jet cooked dry milled starch.

A variant α -amylase having a superior hydrolysis activity during the liquefaction process advantageously increases the efficiency of the saccharification step (see WO 98/22613) and the need for glucoamylase during the saccharification step. The glucoamylase advantageously is present in an amount of no more than, or even less than, 0.5 glucoamylase activity unit (AGU)/g DS (i.e., glucoamylase activity units per gram of dry solids). The glucoamylase may be derived from a strain within *Aspergillus* sp., *Talaromyces* sp., *Pachykytospora* sp., or *Trametes* sp., with exemplary examples being *Aspergillus niger*, *Talaromyces emersonii*, *Trametes cingulata*, or *Pachykytospora papyracea*. In one embodiment, the process also comprises the use of a carbohydrate-binding domain of the type disclosed in WO 98/22613.

In yet another aspect, the process may comprise hydrolysis of a slurry of gelatinized or granular starch, in particular hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below the initial gelatinization temperature of the granular starch. In addition to being contacted with an α -amylase variant, the starch may be contacted with one or more enzyme selected from the group consisting of a fungal α -amylase (EC 3.2.1.1), a β -amylase (EC 3.2.1.2), and a glucoamylase (EC 3.2.1.3). In an embodiment further another amylolytic enzyme or a debranching enzyme, such as an

35

isoamylase (EC 3.2.1.68), or a pullulanases (EC 3.2.1.41) may be added to the α -amylase variant.

In one embodiment, the process is conducted at a temperature below the initial gelatinization temperature. Such processes are often conducted at least at 30° C., at least 31° C., at least 32° C., at least 33° C., at least 34° C., at least 35° C., at least 36° C., at least 37° C., at least 38° C., at least 39° C., at least 40° C., at least 41° C., at least 42° C., at least 43° C., at least 44° C., at least 45° C., at least 46° C., at least 47° C., at least 48° C., at least 49° C., at least 50° C., at least 51° C., at least 52° C., at least 53° C., at least 54° C., at least 55° C., at least 56° C., at least 57° C., at least 58° C., at least 59° C., or at least 60° C. The pH at which the process is conducted may be in the range of about 3.0 to about 7.0, from about 3.5 to about 6.0, or from about 4.0 to about 5.0. One aspect contemplates a process comprising fermentation with a yeast, for example, to produce ethanol at a temperature around 32° C., such as from 30° C. to 35° C. In another aspect, the process comprises simultaneous saccharification and fermentation with a yeast to produce ethanol or with another suitable fermentation organism to produce a desired organic compound, for example, at a temperature from 30° C. to 35° C., e.g., at around 32° C. In the above fermentation processes, the ethanol content reaches at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, or at least about 16% ethanol.

The starch slurry to be used in any of the above aspects may have about 20% to about 55% dry solids granular starch, about 25% to about 40% dry solids granular starch, or about 30% to about 35% dry solids granular starch. The enzyme variant converts the soluble starch into a soluble starch hydrolysate of the granular starch in the amount of at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

In another embodiment, the α -amylase variant is used in a process for liquefaction or saccharification of a gelatinized starch, including, but not limited to, gelatinization by jet cooking. The process may comprise fermentation to produce a fermentation product, e.g., ethanol. Such a process for producing ethanol from starch-containing material by fermentation comprises: (i) liquefying the starch-containing material with an α -amylase variant; (ii) saccharifying the liquefied mash obtained; and (iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism. Optionally the process further comprises recovery of the ethanol. The saccharification and fermentation processes may be carried out as a simultaneous saccharification and fermentation (SSF) process. During the fermentation, the ethanol content reaches at least about 7%, at least about 8%, at least about 9%, at least about 10% such as at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least 15%, or at least 16% ethanol.

The starch to be processed in the above aspects may be obtained from tubers, roots, stems, legumes, cereals or whole grain. More specifically, the granular starch may be obtained from corns, cobs, wheat, barley, rye, milo, sago, cassava, tapioca, sorghum, rice, peas, bean, banana, or potatoes. Specially contemplated are both waxy and non-waxy types of corn and barley.

As used herein, the term "liquefaction" or "liquefy" means a process by which starch is converted to less viscous and shorter chain dextrans. Generally, this process involves gelatinization of starch simultaneously with or followed by the addition of an α -amylase variant. Additional liquefaction-

36

inducing enzymes optionally may be added. As used herein, the term "primary liquefaction" refers to a step of liquefaction when the slurry's temperature is raised to or near its gelatinization temperature. Subsequent to the raising of the temperature, the slurry is sent through a heat exchanger or jet to temperatures from about 90-150° C., e.g., 100-110° C. Subsequent to application to a heat exchange or jet temperature, the slurry is held for a period of 3-10 minutes at that temperature. This step of holding the slurry at 90-150° C. is termed primary liquefaction.

As used herein, the term "secondary liquefaction" refers to the liquefaction step subsequent to primary liquefaction (heating to 90-150° C.), when the slurry is allowed to cool to room temperature. This cooling step can be 30 minutes to 180 minutes, e.g. 90 minutes to 120 minutes. As used herein, the term "minutes of secondary liquefaction" refers to the time that has elapsed from the start of secondary liquefaction to the time that the Dextrose Equivalent (DE) is measured.

Another aspect contemplates the additional use of a β -amylase in the composition comprising the α -amylase variant. β -amylases (EC 3.2.1.2) are exo-acting maltogenic amylases, which catalyze the hydrolysis of 1,4- α -glucosidic linkages into amylose, amylopectin, and related glucose polymers, thereby releasing maltose. β -amylases have been isolated from various plants and microorganisms (Fogarty et al., PROGRESS IN INDUSTRIAL MICROBIOLOGY, Vol. 15, pp. 112-115, 1979). These β -amylases are characterized by having optimum temperatures in the range from 40° C. to 65° C., and optimum pH in the range from about 4.5 to about 7.0. Contemplated β -amylases include, but are not limited to, β -amylases from barley Spezyme® BBA 1500, Spezyme® DBA, Optimal™ ME, Optimal™ BBA (Genencor International, Inc.); and Novozym™ WBA (Novozymes A/S).

Another enzyme contemplated for use in the composition is a glucoamylase (EC 3.2.1.3). Glucoamylases are derived from a microorganism or a plant. For example, glucoamylases can be of fungal or bacterial origin. Exemplary bacterial glucoamylases are *Aspergillus* glucoamylases, in particular *A. niger* G1 or G2 glucoamylase (Boel et al. (1984), EMBO J. 3(5): 1097-1102), or variants thereof, such as disclosed in WO 92/00381 and WO 00/04136; *A. awamori* glucoamylase (WO 84/02921); *A. oryzae* glucoamylase (Agric. Biol. Chem. (1991), 55(4): 941-949), or variants or fragments thereof.

Other contemplated *Aspergillus* glucoamylase variants include variants to enhance the thermal stability: G137A and G139A (Chen et al. (1996), Prot. Eng. 9: 499-505); D257E and D293E/Q (Chen et al. (1995), Prot. Eng. 8: 575-582); N182 (Chen et al. (1994), Biochem. J. 301: 275-281); disulphide bonds, A246C (Fierobe et al. (1996), Biochemistry, 35: 8698-8704); and introduction of Pro residues in positions A435 and S436 (Li et al. (1997) Protein Eng. 10: 1199-1204). Other contemplated glucoamylases include *Talaromyces* glucoamylases, in particular derived from *T. emersonii* (WO 99/28448), *T. leycettanus* (U.S. Pat. No. RE 32,153), *T. dupontii*, or *T. thermophilus* (U.S. Pat. No. 4,587,215). Contemplated bacterial glucoamylases include glucoamylases from the genus *Clostridium*, in particular *C. thermoamylolyticum* (EP 135138) and *C. thermohydrosulfuricum* (WO 86/01831). Suitable glucoamylases include the glucoamylases derived from *Aspergillus oryzae*, such as a glucoamylase having 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or even 90% homology to the amino acid sequence shown in SEQ ID NO:2 in WO 00/04136. Also suitable are commercial glucoamylases, such as AMG 200L; AMG 300 L; SAN™ SUPER and AMG™ E (Novozymes); OPTIDEX® 300 (Genencor International, Inc.); AMIGASE™ and AMIGASE™ PLUS (from DSM); G-ZYME® G900 (Enzyme Bio-Sys-

tems); and G-ZYME® G990 ZR (*A. niger* glucoamylase and low protease content). Glucoamylases may be added in an amount of 0.02-2.0 AGU/g DS or 0.1-1.0 AGU/g DS, e.g., 0.2 AGU/g DS.

Additional enzyme variants can be included in the composition. Two or more α -amylase variants can be used alone or in combination with other enzymes discussed herein. For example, a third enzyme may be another α -amylase, e.g., a yeast α -amylase, or another α -amylase variant. These can be *Bacillus* α -amylases or non-*Bacillus* α -amylases.

Another enzyme that can optionally be added is a debranching enzyme, such as an isoamylase (EC 3.2.1.68) or a pullulanase (EC 3.2.1.41). Isoamylase hydrolyses α -1,6-D-glucosidic branch linkages in amylopectin and β -limit dextrans and can be distinguished from pullulanases by the inability of isoamylase to attack pullulan and by the limited action of isoamylase on α -limit dextrans. Debranching enzymes may be added in effective amounts well known to the person skilled in the art.

The exact composition of the products of the process depends on the combination of enzymes applied, as well as the type of granular starch processed. The soluble hydrolysate may be maltose with a purity of at least about 85%, at least about 90%, at least about 95.0%, at least about 95.5%, at least about 96.0%, at least about 96.5%, at least about 97.0%, at least about 97.5%, at least about 98.0%, at least about 98.5%, at least about 99.0% or at least about 99.5%. Alternatively, the soluble starch hydrolysate is glucose, or the starch hydrolysate has a DE (glucose percent of total solubilized dry solids) of at least 94.5%, at least 95.0%, at least 95.5%, at least 96.0%, at least 96.5%, at least 97.0%, at least 97.5%, at least 98.0%, at least 98.5%, at least 99.0% or at least 99.5%. In one embodiment, a process of manufacturing ice creams, cakes, candies, canned fruit uses a specialty syrup containing a mixture of glucose, maltose, DP3 and DPn.

Two milling processes are suitable: wet milling and dry milling. In dry milling, the whole kernel is milled and used. Wet milling gives a good separation of germ and meal (starch granules and protein) and is usually used when the starch hydrolysate is used in production of syrups. Both dry and wet milling are well known in the art of starch processing and also are contemplated for use with the compositions and methods disclosed. The process may be conducted in an ultrafiltration system where the retentate is held under recirculation in presence of enzymes, raw starch and water, where the permeate is the soluble starch hydrolysate. Another method is the process conducted in a continuous membrane reactor with ultrafiltration membranes, where the retentate is held under recirculation in presence of enzymes, raw starch and water, and where the permeate is the soluble starch hydrolysate. Also contemplated is the process conducted in a continuous membrane reactor with microfiltration membranes and where the retentate is held under recirculation in presence of enzymes, raw starch and water, and where the permeate is the soluble starch hydrolysate.

In one regard, the soluble starch hydrolysate of the process is subjected to conversion into high fructose starch-based syrup (HFSS), such as high fructose corn syrup (HFCS). This conversion can be achieved using a glucose isomerase, particularly a glucose isomerase immobilized on a solid support. Contemplated isomerases included the commercial products Sweetzyme®, IT (Novozymes A/S); G-zyme® IMGI, and G-zyme® G993, Ketomax®, G-zyme® G993, G-zyme® G993 liquid, and GenSweet® IGI.

In another aspect, the soluble starch hydrolysate of produced yields production of fuel or potable ethanol. In the process of the third aspect the fermentation may be carried out

simultaneously or separately/sequential to the hydrolysis of the granular starch slurry. When the fermentation is performed simultaneously with the hydrolysis, the temperature can be between 30° C. and 35° C., particularly between 31° C. and 34° C. The process may be conducted in an ultrafiltration system where the retentate is held under recirculation in presence of enzymes, raw starch, yeast, yeast nutrients and water and where the permeate is an ethanol containing liquid. Also contemplated is the process conducted in a continuous membrane reactor with ultrafiltration membranes and where the retentate is held under recirculation in presence of enzymes, raw starch, yeast, yeast nutrients and water and where the permeate is an ethanol containing liquid.

The soluble starch hydrolysate of the process may also be used for production of a fermentation product comprising fermenting the treated starch into a fermentation product, such as citric acid, monosodium glutamate, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta-lactone, or sodium erythorbate.

The amylolytic activity of the α -amylase variant may be determined using potato starch as substrate. This method is based on the break-down of modified potato starch by the enzyme, and the reaction is followed by mixing samples of the starch/enzyme solution with an iodine solution. Initially, a blackish-blue color is formed, but during the break-down of the starch the blue color gets weaker and gradually turns into a reddish-brown, which is compared to a colored glass standard.

9. TEXTILE DESIZING COMPOSITIONS AND USE

Also contemplated are compositions and methods of treating fabrics (e.g., to desize a textile) using one or more of the α -amylase variants. The α -amylase variants can be used in any fabric-treating method, which are well known in the art (see, e.g., U.S. Pat. No. 6,077,316). For example, in one aspect, the feel and appearance of a fabric is improved by a method comprising contacting the fabric with an enzyme variant in a solution. In one aspect, the fabric is treated with the solution under pressure.

In one aspect, the enzymes are applied during or after the weaving of textiles, or during the desizing stage, or one or more additional fabric processing steps. During the weaving of textiles, the threads are exposed to considerable mechanical strain. Prior to weaving on mechanical looms, warp yarns are often coated with sizing starch or starch derivatives in order to increase their tensile strength and to prevent breaking. The α -amylase variant can be applied to remove these sizing starch or starch derivatives. After the textiles have been woven, a fabric can proceed to a desizing stage. This can be followed by one or more additional fabric processing steps. Desizing is the act of removing size from textiles. After weaving, the size coating should be removed before further processing the fabric in order to ensure a homogeneous and wash-proof result. Also provided is a method of desizing comprising enzymatic hydrolysis of the size by the action of an enzyme variant. The α -amylase variant can be used alone or with other desizing chemical reagents and/or desizing enzymes to desize fabrics, including cotton-containing fabrics, as detergent additives, e.g., in aqueous compositions. The α -amylase variant can also be used in compositions and methods for producing a stonewashed look on indigo-dyed denim fabric and garments. For the manufacture of clothes, the fabric can be cut and sewn into clothes or garments, which are afterwards finished. In particular, for the manufacture of denim jeans, different enzymatic finishing methods have

been developed. The finishing of denim garment normally is initiated with an enzymatic desizing step, during which garments are subjected to the action of amylolytic enzymes to provide softness to the fabric and make the cotton more accessible to the subsequent enzymatic finishing steps. The α -amylase variant can be used in methods of finishing denim garments (e.g., a "bio-stoning process"), enzymatic desizing and providing softness to fabrics, and/or finishing process.

10. COMPOSITIONS AND METHODS FOR BAKING AND FOOD PREPARATION

For the commercial and home use of flour for baking and food production, it is important to maintain an appropriate level of α -amylase activity in the flour. A level of activity that is too high may result in a product that is sticky and/or doughy and unmarketable; but flour with insufficient α -amylase activity may not contain enough sugar for proper yeast function, resulting in dry, crumbly bread. Accordingly, an α -amylase variant polypeptide, by itself or in combination with another α -amylase(s), may be added to the flour to augment the level of endogenous α -amylase activity in flour. The α -amylase typically has a temperature optimum in the presence of starch in the ranges of 30-90° C., 50-80° C., 55-75° C., or 60-70° C., for example. The temperature optimum may be measured in a 1% solution of soluble starch at pH 5.5.

In addition to the use of grains and other plant products in baking, grains such as barley, oats, wheat, as well as plant components, such as corn, hops, and rice are used for brewing, both in industry and for home brewing. The components used in brewing may be unmalted or may be malted, i.e., partially germinated, resulting in an increase in the levels of enzymes, including α -amylase. For successful brewing, adequate levels of α -amylase enzyme activity are necessary to ensure the appropriate levels of sugars for fermentation. An α -amylase variant polypeptide, by itself or in combination with another α -amylase(s), accordingly may be added to the components used for brewing.

As used herein, the term "flour" means milled or ground cereal grain. The term "flour" also may mean Sago or tuber products that have been ground or mashed. In some embodiments, flour may also contain components in addition to the milled or mashed cereal or plant matter. An example of an additional component, although not intended to be limiting, is a leavening agent. Cereal grains include wheat, oat, rye, and barley. Tuber products include tapioca flour, cassava flour, and custard powder. The term "flour" also includes ground corn flour, maize-meal, rice flour, whole-meal flour, self-rising flour, tapioca flour, cassava flour, ground rice, enriched flour, and custard powder.

As used herein, the term "stock" means grains and plant components that are crushed or broken. For example, barley used in beer production is a grain that has been coarsely ground or crushed to yield a consistency appropriate for producing a mash for fermentation. As used herein, the term "stock" includes any of the aforementioned types of plants and grains in crushed or coarsely ground forms. The methods described herein may be used to determine α -amylase activity levels in both flours and stock.

An α -amylase variant polypeptide further can be added alone or in a combination with other amylases to prevent or retard staling, i.e., crumb firming of baked products. The amount of anti-staling amylase will typically be in the range of 0.01-10 mg of enzyme protein per kg of flour, e.g., 1-10 mg/kg. Additional anti-staling amylases that can be used in combination with an α -amylase variant polypeptide include an endo-amylase, e.g., a bacterial endo-amylase from *Bacil-*

lus. The additional amylase can be a maltogenic α -amylase (EC 3.2.1.133), e.g., from *Bacillus*. Novamyl® is a suitable maltogenic α -amylase from *B. stearothermophilus* strain NCIB 11837 and is described in Christophersen et al., *Starch*, 50(1): 39-45 (1997). Other examples of anti-staling endo-amylases include bacterial α -amylases derived from *Bacillus*, such as *B. licheniformis* or *B. amyloliquefaciens*. The anti-staling amylase may be an exo-amylase, such as β -amylase, e.g., from plant sources, such as soy bean, or from microbial sources, such as *Bacillus*.

The baking composition comprising an α -amylase variant polypeptide further can comprise a phospholipase. The phospholipase may have A₁ or A₂ activity to remove fatty acid from the phospholipids, forming a lyso-phospholipid. It may or may not have lipase activity, i.e., activity on triglycerides. The phospholipase typically has a temperature optimum in the range of 30-90° C., e.g., 30-70° C. The added phospholipases can be of animal origin, for example, from pancreas, e.g., bovine or porcine pancreas, snake venom or bee venom. Alternatively, the phospholipase may be of microbial origin, e.g., from filamentous fungi, yeast or bacteria, such as the genus or species *Aspergillus*, *A. niger*; *Dictyostelium*, *D. discoideum*; *Mucor*, *M. javanicus*, *M. mucedo*, *M. subtilissimus*; *Neurospora*, *N. crassa*; *Rhizomucor*, *R. pusillus*; *Rhizopus*, *R. arrhizus*, *R. japonicus*, *R. stolonifer*; *Sclerotinia*, *S. libertiana*; *Trichophyton*, *T. rubrum*; *Whetzelinia*, *W. sclerotiorum*; *Bacillus*, *B. megaterium*, *B. subtilis*; *Citrobacter*, *C. freundii*; *Enterobacter*, *E. aerogenes*, *E. cloacae*; *Edwardsiella*, *E. tarda*; *Etwinia*, *E. herbicola*; *Escherichia*, *E. coli*; *Klebsiella*, *K. pneumoniae*; *Proteus*, *P. vulgaris*; *Providencia*, *P. stuartii*; *Salmonella*, *S. typhimurium*; *Serratia*, *S. liquefaciens*, *S. marcescens*; *Shigella*, *S. flexneri*; *Streptomyces*, *S. violeceoruber*; *Yersinia*, *Y. enterocolitica*; *Fusarium*, *F. oxysporum*, strain DSM 2672), for example.

A phospholipase is added in an amount that improves the softness of the bread during the initial period after baking, particularly the first 24 hours. The amount of phospholipase will typically be in the range of 0.01-10 mg of enzyme protein per kg of flour, e.g., 0.1-5 mg/kg. That is, phospholipase activity generally will be in the range of 20-1000 Lipase Unit (LU)/kg of flour, where a Lipase Unit is defined as the amount of enzyme required to release 1 μ mol butyric acid per minute at 30° C., pH 7.0, with gum arabic as emulsifier and tributyrin as substrate.

Compositions of dough generally comprise wheat meal or wheat flour and/or other types of meal, flour or starch such as corn flour, cornstarch, rye meal, rye flour, oat flour, oatmeal, soy flour, sorghum meal, sorghum flour, potato meal, potato flour or potato starch. The dough may be fresh, frozen or par-baked. The dough can be a leavened dough or a dough to be subjected to leavening. The dough may be leavened in various ways, such as by adding chemical leavening agents, e.g., sodium bicarbonate or by adding a leaven, i.e., fermenting dough. Dough also may be leavened by adding a suitable yeast culture, such as a culture of *Saccharomyces cerevisiae* (baker's yeast), e.g., a commercially available strain of *S. cerevisiae*.

The dough may also comprise other conventional dough ingredients, e.g., proteins, such as milk powder, gluten, and soy; eggs (either whole eggs, egg yolks or egg whites); an oxidant, such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine; a sugar; or a salt, such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate. The dough further may comprise fat, e.g., triglyceride, such as granulated fat or shortening. The dough further may comprise an emulsifier such as mono- or diglycerides,

diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin. In particular, the dough can be made without addition of emulsifiers.

Optionally, an additional enzyme may be used together with the anti-staling amylase and the phospholipase. The additional enzyme may be a second amylase, such as an amyloglucosidase, a β -amylase, a cyclodextrin glucanotransferase, or the additional enzyme may be a peptidase, in particular an exopeptidase, a transglutaminase, a lipase, a cellulase, a hemicellulase, in particular a pentosanase such as xylanase, a protease, a protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, for example, a glucanotransferase, a branching enzyme (1,4- α -glucan branching enzyme), a 4- α -glucanotransferase (dextrin glycosyltransferase) or an oxidoreductase, e.g., a peroxidase, a laccase, a glucose oxidase, a pyranose oxidase, a lipoxigenase, an L-amino acid oxidase or a carbohydrate oxidase. The additional enzyme may be of any origin, including mammalian and plant, and particularly of microbial (bacterial, yeast or fungal) origin and may be obtained by techniques conventionally used in the art.

The xylanase is typically of microbial origin, e.g., derived from a bacterium or fungus, such as a strain of *Aspergillus*, in particular of *A. aculeatus*, *A. niger* (e.g., WO 91/19782), *A. awamori* (e.g., WO 91/18977), or *A. tubigensis* (e.g., WO 92/01793); from a strain of *Trichoderma*, e.g., *T. reesei*, or from a strain of *Humicola*, e.g., *H. insolens* (e.g., WO 92/17573). Pentopan® and Novozym 384® are commercially available xylanase preparations produced from *Trichoderma reesei*. The amyloglucosidase may be an *A. niger* amyloglucosidase (such as AMG®). Other useful amylase products include Grindamyl® A 1000 or A 5000 (available from Grindsted Products, Denmark). The glucose oxidase may be a fungal glucose oxidase, in particular an *Aspergillus niger* glucose oxidase (such as Gluzyme®). An exemplary protease is Neutrase®. An exemplary lipase can be derived from strains of *Thermomyces* (*Humicola*), *Rhizomucor*, *Candida*, *Aspergillus*, *Rhizopus*, or *Pseudomonas*, in particular from *Thermomyces lanuginosus* (*Humicola lanuginosa*), *Rhizomucor miehei*, *Candida antarctica*, *Aspergillus niger*, *Rhizopus delemar* or *Rhizopus arrhizus* or *Pseudomonas cepacia*. In specific embodiments, the lipase may be Lipase A or Lipase B derived from *Candida antarctica* as described in WO 88/02775, for example, or the lipase may be derived from *Rhizomucor miehei* as described in EP 238,023, for example, or *Humicola lanuginosa*, described in EP 305,216, for example, or *Pseudomonas cepacia* as described in EP 214,761 and WO 89/01032, for example.

The process may be used for any kind of baked product prepared from dough, either of a soft or a crisp character, either of a white, light or dark type. Examples are bread, particularly white, whole-meal or rye bread, typically in the form of loaves or rolls, French baguette-type bread, pita bread, tortillas, cakes, pancakes, biscuits, cookies, pie crusts, crisp bread, steamed bread, pizza and the like.

In another embodiment, an α -amylase variant polypeptide may be used in a pre-mix, comprising flour together with an anti-staling amylase, a phospholipase and a phospholipid. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g., any of the additives, including enzymes, mentioned above. In one aspect, the α -amylase variant polypeptide is a component of an enzyme preparation comprising an anti-staling amylase and a phospholipase, for use as a baking additive.

The enzyme preparation is optionally in the form of a granulate or agglomerated powder. The preparation can have a narrow particle size distribution with more than 95% (by weight) of the particles in the range from 25 to 500 μ m. Granulates and agglomerated powders may be prepared by conventional methods, e.g., by spraying the α -amylase variant polypeptide onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size. The carrier may be soluble or insoluble, e.g., a salt (such as NaCl or sodium sulfate), a sugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy.

Another aspect contemplates the enveloping of particles comprising an α -amylase variant polypeptide, i.e., α -amylase particles. To prepare the enveloped α -amylase particles, the enzyme is contacted with a food grade lipid in sufficient quantity so as to suspend all of the α -amylase particles. Food grade lipids, as used herein, may be any naturally organic compound that is insoluble in water but is soluble in non-polar organic solvents such as hydrocarbon or diethyl ether. Suitable food grade lipids include, but are not limited to, triglycerides either in the form of fats or oils which are either saturated or unsaturated. Examples of fatty acids and combinations thereof which make up the saturated triglycerides include, but are not limited to, butyric (derived from milk fat), palmitic (derived from animal and plant fat), and/or stearic (derived from animal and plant fat). Examples of fatty acids and combinations thereof which make up the unsaturated triglycerides include, but are not limited to, palmitoleic (derived from animal and plant fat), oleic (derived from animal and plant fat), linoleic (derived from plant oils), and/or linolenic (derived from linseed oil). Other suitable food grade lipids include, but are not limited to, monoglycerides and diglycerides derived from the triglycerides discussed above, phospholipids and glycolipids.

The food grade lipid, particularly in the liquid form, is contacted with a powdered form of the α -amylase particles in such a fashion that the lipid material covers at least a portion of the surface of at least a majority, e.g., 100% of the α -amylase particles. Thus, each α -amylase particle is individually enveloped in a lipid. For example, all or substantially all of the α -amylase particles are provided with a thin, continuous, enveloping film of lipid. This can be accomplished by first pouring a quantity of lipid into a container, and then slurrying the α -amylase particles so that the lipid thoroughly wets the surface of each α -amylase particle. After a short period of stirring, the enveloped α -amylase particles, carrying a substantial amount of the lipids on their surfaces, are recovered. The thickness of the coating so applied to the particles of α -amylase can be controlled by selection of the type of lipid used and by repeating the operation in order to build up a thicker film, when desired.

The storing, handling and incorporation of the loaded delivery vehicle can be accomplished by means of a packaged mix. The packaged mix can comprise the enveloped α -amylase. However, the packaged mix may further contain additional ingredients as required by the manufacturer or baker. After the enveloped α -amylase has been incorporated into the dough, the baker continues through the normal production process for that product.

The advantages of enveloping the α -amylase particles are two-fold. First, the food grade lipid protects the enzyme from thermal denaturation during the baking process for those enzymes that are heat labile. Consequently, while the α -amylase is stabilized and protected during the proving and baking stages, it is released from the protective coating in the final baked good product, where it hydrolyzes the glucosidic link-

ages in polyglucans. The loaded delivery vehicle also provides a sustained release of the active enzyme into the baked good. That is, following the baking process, active α -amylase is continually released from the protective coating at a rate that counteracts, and therefore reduces the rate of, staling mechanisms.

In general, the amount of lipid applied to the α -amylase particles can vary from a few percent of the total weight of the α -amylase to many times that weight, depending upon the nature of the lipid, the manner in which it is applied to the α -amylase particles, the composition of the dough mixture to be treated, and the severity of the dough-mixing operation involved.

The loaded delivery vehicle, i.e., the lipid-enveloped enzyme, is added to the ingredients used to prepare a baked good in an effective amount to extend the shelf-life of the baked good. The baker computes the amount of enveloped α -amylase, prepared as discussed above, that will be required to achieve the desired anti-staling effect. The amount of the enveloped α -amylase required is calculated based on the concentration of enzyme enveloped and on the proportion of α -amylase to flour specified. A wide range of concentrations has been found to be effective, although, as has been discussed, observable improvements in anti-staling do not correspond linearly with the α -amylase concentration, but above certain minimal levels, large increases in α -amylase concentration produce little additional improvement. The α -amylase concentration actually used in a particular bakery production could be much higher than the minimum necessary in order to provide the baker with some insurance against inadvertent under-measurement errors by the baker. The lower limit of enzyme concentration is determined by the minimum anti-staling effect the baker wishes to achieve.

A method of preparing a baked good may comprise: (a) preparing lipid-coated α -amylase particles, wherein substantially 100 percent of the α -amylase particles are coated; (b) mixing a dough containing flour; (c) adding the lipid-coated α -amylase to the dough before the mixing is complete and terminating the mixing before the lipid coating is removed from the α -amylase; (d) proofing the dough; and (e) baking the dough to provide the baked good, wherein the α -amylase is inactive during the mixing, proofing and baking stages and is active in the baked good.

The enveloped α -amylase can be added to the dough during the mix cycle, e.g., near the end of the mix cycle. The enveloped α -amylase is added at a point in the mixing stage that allows sufficient distribution of the enveloped α -amylase throughout the dough; however, the mixing stage is terminated before the protective coating becomes stripped from the α -amylase particle(s). Depending on the type and volume of dough, and mixer action and speed, anywhere from one to six minutes or more might be required to mix the enveloped α -amylase into the dough, but two to four minutes is average. Thus, several variables may determine the precise procedure. First, the quantity of enveloped α -amylase should have a total volume sufficient to allow the enveloped α -amylase to be spread throughout the dough mix. If the preparation of enveloped α -amylase is highly concentrated, additional oil may need to be added to the pre-mix before the enveloped α -amylase is added to the dough. Recipes and production processes may require specific modifications; however, good results generally can be achieved when 25% of the oil specified in a bread dough formula is held out of the dough and is used as a carrier for a concentrated enveloped α -amylase when added near the end of the mix cycle. In bread or other baked goods, recipes which have extremely low fat content (such as French-style breads), it has been found that an enveloped

α -amylase mixture of approximately 1% of the dry flour weight is sufficient to admix the enveloped α -amylase properly with the dough, but the range of percentages that may work is extremely wide and depends on the formula, finished product, and production methodology requirements of the individual baker. Second, the enveloped α -amylase suspension should be added to the mix with enough time remaining in the mix cycle for complete mixture into the dough, but not so early that excessive mechanical action will strip the protective lipid coating from a large proportion of the enveloped α -amylase particles.

In another embodiment, bacterial α -amylase (BAA) is added to the lipid-coated particles comprising an α -amylase variant polypeptide. BAA reduces bread to a gummy mass due to its excessive thermostability and retained activity in the fully baked loaf of bread; however, when BAA is incorporated into the lipid-coated particles, substantial additional anti-staling protection is obtained, even at very low BAA dosage levels. For example, BAA dosages of 150 RAU (Reference Amylase Units) per 100 pounds of flour have been found to be effective. In one embodiment, between about 50 to 2000 RAU of BAA is added to the lipid-coated enzyme product. This low BAA dosage level, combined with the ability of the protective coating to keep enzyme in the fully-baked loaf from free contact with the starches (except when water vapor randomly releases the enzyme from its coating), helps to achieve very high levels of anti-staling activity without the negative side-effects of BAA.

It will be apparent to those skilled in the art that various modifications and variation can be made to the compositions and methods of using same without departing from the spirit or scope of the intended use. Thus, it is the modifications and variations provided they come within the scope of the appended claims and their equivalents.

All references cited above are herein incorporated by reference in their entirety for all purposes.

EXAMPLES

Example 1

As an initial step in the development of an α -amylase variant, an α -amylase was chosen that exhibited advantageous performance characteristics in the various formulations described above. A representative α -amylase is from *Bacillus* sp. no. 707 (SEQ ID NO:1, residues 34-518 of Swissprot Accession No. P19571).

Next, an α -amylase was identified that exhibits superior expression in a host cell and that has relatively close sequence identity to the *Bacillus* sp. no. 707 α -amylase. Such an α -amylase is the *Bacillus* sp. A 7-7 (DSM 12368) α -amylase (SEQ ID NO:2; see also GenBank Accession No. CAL48155, SEQ ID NO:7).

A comparison of the mature amino acid sequences of these α -amylases is shown in FIG. 1 and below, where the top sequence is from *Bacillus* sp. no. 707 α -amylase (SEQ ID NO: 1) and the bottom sequence is from *Bacillus* sp. A 7-7 (DSM 12368) α -amylase (SEQ ID NO: 2). Only 33 amino acid positions differ in the 485 amino acid sequence, providing a sequence identity in the mature proteins of about 93%. The amino acid positions that differ in the two sequences are highlighted below.

1	11	21	31	41	51
HHNGTNGTMM	QYFEWYLPND	GNHWNRLNSD	ASNLKSKGIT	AVWIPPAPWK	ASQNDVGYGA
HHNGTNGTMM	QYFEWYLPND	GNHWNRLNSD	ASNLKDKGIT	AVWIPPAPWK	ASQNDVGYGA
61	71	81	91	101	111
YDLYDLGEFN	QKGTVRTKYG	TRFQLOAAVT	SLKNGIQVY	GDVVMNHKGG	ADATEKVRVAV
YDLYDLGEFN	QKGTVRTKYG	TRFQLOAAVT	SLKNGIQVY	GDVVMNHKGG	ADATEKVRVAV
121	131	141	151	161	171
EVNPNRNRQE	VTGEYTIKAW	TRFDPPGRGN	THSEFKWRWY	HFDGVDWDQS	RRLNNRIYKF
EVNPNRNRQE	VTGEYTIKAW	TRFDPPGRGN	THSEFKWRWY	HFDGVDWDQS	RRLNNRIYKF
181	191	201	211	221	231
RCHGKAWDWE	VDTEGNYDY	LMYADIDMDH	PEVVNELRNW	GVWYTNLTGL	DGFRIDAVKH
RCHGKAWDWE	VDTEGNYDY	LMYADIDMDH	PEVVNELRNW	GVWYTNLTGL	DGFRIDAVKH
241	251	261	271	281	291
IKYSFTRDWE	NHVRNATGKN	MFAVAEFWKN	DKGAIENYLG	KTNWNHVSVD	VPLHYNLYNA
IKYSFTRDWE	NHVRNATGKN	MFAVAEFWKN	DKGAIENYLG	KTNWNHVSVD	VPLHYNLYNA
301	311	321	331	341	351
SKSGGNYDMR	QIFNGTVVQR	HPCHAVTFVD	NHDSQPPEAL	ESFVEEWFKP	LAYALTLTRQ
SKSGGNYDMR	QIFNGTVVQR	HPCHAVTFVD	NHDSQPPEAL	ESFVEEWFKP	LAYALTLTRQ
361	371	381	391	401	411
QGYPVSVFYGD	YYGIPTHGVP	AMKSKIDPIL	EARQKYAYGK	QNDYLDHHNM	IGWTREGNTA
QGYPVSVFYGD	YYGIPTHGVP	AMKSKIDPIL	EARQKYAYGK	QNDYLDHHNM	IGWTREGNTA
421	431	441	451	461	471
HPNSGLATIM	SDGAGGCKWM	EVGRNKAGQV	WRDITGNRSG	TVTINADGWG	NFSVNGGSVS
HPNSGLATIM	SDGAGGCKWM	EVGRNKAGQV	WRDITGNRSG	TVTINADGWG	NFSVNGGSVS
481	IWVNN <i>Bacillus</i> sp. no. 707 α -amylase (SEQ ID NO: 1)				
IWVNN	<i>Bacillus</i> sp. a 7-7 (DSM 12368) α -amylase (SEQ ID NO: 2)				

Example 2

Amino acids that differ in the two sequences are then evaluated for the potential effect on expression of the substitution of the amino acid found in the *Bacillus* sp. no. 707 α -amylase with the amino acid found in *Bacillus* sp. A 7-7 (DSM 12368) α -amylase. In this case, a 3D structural model was created for each proposed variant, where the 3D structural model was based on known α -amylase crystal structures. The 3D structural model for *Bacillus* sp. no. 707 α -amylase has a Protein Database Brookhaven PDB/RSCB

Protein Data Bank Accession Number of 1 WPC. The structural model was used to evaluate the exposure of a particular amino acid to solvent and the extent to which a given substitution would destabilize the protein structure. Finally, the structural model was used to predict the effect of a particular substitution on the hydrophobicity of the enzyme surface for the variant. It is expected that substitutions of amino acids that are exposed to the solvent and that decrease the hydrophobicity of the protein will improve the expression of the variant. Table 1 below lists the various possible amino acid changes and assesses each in light of these criteria.

TABLE 1

Amino acid substitution	Location in Domain/Secondary Structure	Expected relative beneficial effect of substitution	Further description
N28R	A/ α -helix	++	totally solvent exposed, R might be less polar
S36D	A/ α -helix	++	solvent exposed, D will increase solubility
S83N	A/ α -helix	+	fully solvent exposed, S->N is a minor change
S91A	A/ α -helix	-	close to 28, A might make the situation worse
N94S	A/ α -helix	-	again same area, S is not a big change
M116W	B/ β -sheet	++	very exposed, M is anyway problematic (prone to oxidation)
N125S	B	-	small change, no effect on solubility
T132S	B	-	minor change, a bit closer to active site
E134D	B	-	fully solvent exposed, no big effect expected
R142K	B/ β -sheet	+	might reduce hydrophobicity, K is a minor change
S154N	B	-	small change, minor effect
R172Q	B	++	prominent solvent exposed
N174Q	B	-	even closer, but very minor change
H183D	B	++	very solvent exposed on top of a little extension
A186G	B	+	this minor change reduces hydrophobicity, but might be de-stabilizing
I250L	A/ α -helix	-	buried residue, stability rather than solubility

TABLE 1-continued

Amino acid substitution	Location in Domain/Secondary Structure	Expected relative beneficial effect of substitution	Further description
N251T	A/ α -helix	+	solvent exposed, but small change
S255N	A/ α -helix	++	extremely solvent exposed, slight reduction of hydrophobicity
A256T	A/ α -helix	++	extremely solvent exposed, improvement of solubility
L272I	A/ α -helix	-	hydrophobic-hydrophobic exchange, no effect
Q280S	A/ α -helix	-	partially buried, expect no big change
K302R	A/ α -helix	-	fully solvent exposed, R is more hydrophobic than K
N311Q	A/ α -helix	-	solvent exposed, but minor change
S323T	A	-	close to C domain, solvent exposed, small change
E360D	A	-	interface C-domain, solvent exposed, minor change
R383K	A/ α -helix	-	close to C-domain, fully solvent exposed, minor change
I410M	C/ β -sheet	-	hydrophobic area, partially buried, M = negative change in stability
A434P	C	-	hydrophobicity will be increased, might be stabilising
S437N	C/ β -sheet	-	solvent exposed, small change, no effect expected
F441Y	C/ β -sheet	+	solvent exposed, slight improvement of solubility
S452R	C/ β -sheet	+	fully solvent exposed, R is not the best, K, N or D might be better
T459S	C	-	solvent exposed, small change
K485N	C	+	big change, not fully solvent exposed

Example 3

Based on the structural modeling disclosed above, the following substitutions are expected to be particularly advantageous: N28R, S36D, M116W, R172Q, H183D, S255N and A256T. Also expected to be advantageous are the substitutions S83N, R142K, A186G, N251T, F441Y, S452R and K485N. Substitutions can be made by protein engineering techniques well known in the art, as described, for example, in Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd ed., Cold Spring Harbor, 1989 and 3rd ed., 2001. Variants are expressed and purified by the techniques described above, for example. Variants are further evaluated by specific activity and by the level of variant protein recovered from the fermentation broth, compared to the wild-type protein.

Variants may contain single amino acid substitutions or combinations of substitutions, including substitutions of all of the 14 residues disclosed above or subsets thereof. Subsets of mutations can be made and tested using combinatorial libraries of mutants. For example, a nucleotide encoding the protein having all 14 mutations may be digested into fragments with a restriction endonuclease, where each restriction fragment encodes one or more mutation. A library can be

constructed by randomly mixing various mutated and wild-type gene fragments and ligating them together, using ligation procedures well known in the art. The resulting nucleic acids are selected that encode the full length protein with various subsets of mutations.

Example 4

Construction of 707 Amylase Mutants for Improved Expression

Six Amy707 amylase mutants (N28R, S36D, R172Q, H183D, S255N and A256T) and one double mutation (S36D/S255N) were constructed to improve their expression.

A codon optimized, synthetic *Bacillus* sp. no. 707 amylase gene was ordered from GeneArt Inc. (Toronto, Canada) and cloned as a XhoI fragment (PCR with primers EBS2XhoI_RV and PlatXho5_FW) into vector pICatH (FIG. 20 in patent WO/2005/052146). The orientation of the Amy707 gene with respect to the CAT gene was determined by PCR and one clone in which both genes had the same orientation (ori1) was selected and designated pICatH-Amy707(ori1) (FIG. 3).

EBS2XhoI_RV:

(SEQ ID NO: 9)

5'TGG AAT CTC GAG GTT TTA TCC TTT ACC TTG TCT CC 3'

Plat5XhoI_FW:

(SEQ ID NO: 10)

5' CCC CCG CTC GAG GCT TTT CTT TTG GAA GAA AAT ATA GGG AAA ATG

GTA CTT GTT AAA AAT TCG GAA TAT TTA TAC AAT ATC ATA TGT TTC

ACA TTG AAA GGG G 3'

49

pICatH-Amy707(ori1) was transformed into a competent *B. subtilis* strain (BG3594comK). The *B. subtilis* strain was made competent by induction of the comK gene under the control of a xylose inducible promoter (Hahn et al., Mol. Microbiol., 21:763-775 [1996]).

pICatH-Amy707(ori) plasmid DNA was isolated from *B. subtilis* cells using Qiagen miniprep kit. Dam methylation of plasmid pICatH-Amy707 amylase was performed using 50 uL miniprep DNA (~10-20 ng/uL), 10 uL dam methylase 10× buffer (NEB), 0.2 uL of S-adenosyl methionine, 4 uL of dam methylase, 36 uL of sterile water at 37° C. for 4 hours. The reaction product was isolated using QiaQuik (Qiagen columns) and the plasmid DNA eluted in 30 uL buffer EB (Qiagen).

The methylated pICatH-707 amylase plasmid was subjected to Quick-Change Multi-Site mutagenesis (QCMS) using the QuikChange® XL Multi Site-Directed Mutagenesis kit from Stratagene, La Jolla, Calif. The reaction mixture was prepared following manufacturer's recommendations, and consisted of: 15 µL sterile water, 2.54 reaction buffer, 1 µL dNTP mix, 0.5 µL, Quik solution, 0.5 µL forward primer (25 uM), 0.5 µL reverse primer (25 uM), 4 µL pICatH-707 amylase methylated and purified plasmid (~20-30 ng total), 1 µL PfuTurbo® DNA polymerase, for a total of 25 uL. Cycling conditions: 95° C. 1 min 1×; 95° C. 1 min 1×, 55° C. 1 min 1×, 65° C. 18 min 30× (X denoted number of cycles).

The primers used were as follows:

707N28R-F (SEQ ID NO: 11) 30
5' ACCATT GGA ACC GCC TGC GCA GCG AT 3'

707N28R-R (SEQ ID NO: 12)
5' CAG GTT GCT CGC ATC GCT GCG CAG GC 3'

707S36D-F (SEQ ID NO: 13)
5' GAT GCG AGC AAC CTG AAA GAT AAA GG 3'

707S36D-R (SEQ ID NO: 14) 40
5' ACT GCT GTG ATG CCT TTA TCT TTC AGG TT3'

707R172Q-F (SEQ ID NO: 15)
5' GAT TGG GAT CAA AGC CGC CAG CTG AAC A3'

707R172Q-R (SEQ ID NO: 16) 45
5' AGA TGC GGT TGT TCA GCT GGC GGC TTT3'

707H183D-F (SEQ ID NO: 17)
5' ATC TAT AAA TTT CGC GGC GAT GGC AAA3' 50

707H183D-R (SEQ ID NO: 18)
5' CAA TCC CAT GCT TTG CCA TCG CCG CGA3'

707S255N-F (SEQ ID NO: 19) 55
5' TGG ATC AAT CAT GTC AGA AAC GCG ACG3'

707S255N-R (SEQ ID NO: 20)
5' CAT ATT TTT GCC CGT CGC GTT TCT GAC3'

707A256T-F (SEQ ID NO: 21)
5' CAA TCA TGT CAG AAG CAC GAC GGG CAA A3'

707A256T-R (SEQ ID NO: 22) 65
5' CAT ATT TTT GCC CGT CGT GCT TCT GAC3'

50

Following QCMS PCR, 1 uL of restriction enzyme DpnI was added to the QCMS reaction and incubated at 37° C. for 4 hours. An additional 0.5 uL of DpnI was added and the reactions incubated at 37° C. for an additional 2 hours. 1 uL DpnI-digested QCMS reaction in 5 uL of sample buffer was incubated at 95° C. for 3 min, cooled to 4° C. and amplified using rolling circle amplification (RCA) TempliPhi kit (Amersham Cat #256400). 5 uL of reaction buffer and 0.2 uL of Phi29 polymerase were added to the DpnI-digested QCMS reaction and incubated for 30° C. for 16 hrs. After completion of reaction, the enzyme was inactivated as per Amersham's protocol.

The rolling circle amplification reactions were diluted 10 fold in deionized water and 2 uL of DNA was used to transform 100 uL of *Bacillus subtilis* (genotype: ΔaprE, ΔnprE, Δepr, ΔispA, Δbpr, degU^{ts}32, oppA, ΔspoIIIE3501, amyE::xylRPxylAcomK-ermC) competent cells and induced with xylose. The transformation reactions were plated onto LB Agar+10 ppm neomycin+1% insoluble starch plates and grown at 37° C. overnight.

Four colonies for each mutagenesis reaction were selected and individually resuspended in 20 uL of sterile water in microtiter plates and used for colony PCR using puReTaq Ready-To-Go PCR Beads (GE Healthcare). The reaction consisted of 2 uL of cell suspension, 22 uL of water, and 0.5 uL each of 707 PCR F1 & R1 primers (each as 25 uM stock, sequences listed below) and PureTaq beads.

707 PCR F1: (SEQ ID NO: 23)
5' GCA AGT TCA CCA TGC AGT GTG TGA C 3'

707 PCR R1: (SEQ ID NO: 24)
5' TAT CAA GCT TAT CGA TAC CGT CGA C 3'

Cycling conditions were: 95° C. 4 min 1×; 95° C. 1 min, 53° C. 1 min., 72° C. 1 min, 25×: 72° C. 5 min 1×. An agarose gel was run to confirm that the Colony PCR reaction had been successful. ExoSAP-IT (GE Healthcare) was used to remove primers and dNTPS. 5 uL of PCR product was added to 2 uL of ExoSAP-IT reagent and the reaction incubated at 37° C. for 15 min followed by 80° C. for 15 min.

Clones were sent to Sequetech Corporation (Mountain View, Calif.) for sequencing analysis using the following primers:

707 seq F1: (SEQ ID NO: 25)
5' CGA TTG TGA GGA GTG GCT TGT G 3'

707 seq R1: (SEQ ID NO: 26)
5' CTT ATC GAT ACC GTC GAC CCT C 3'

Clones (N28R-1, S36D-4, R172Q-4, H183D-1, S255N-7, or A256T-2) were streaked on LB plates supplemented with 5 ug/mL chloramphenicol and 1% insoluble starch and grown at 37° C. overnight. The plasmids were isolated using standard techniques.

The host *B. licheniformis* (Δmpr, Δapr, Δcat) was transformed with a plasmid vector from one of the previously sequenced clones using a protoplast method in a manner known per se. Transformants were obtained for the Amy707 amylase, N28R, S36D, R172Q, H183D, and S255N. All transformant strains had the gene of interest (either Amy707 or a variant) integrated into the host genome and the plasmid DNA looped out.

51

Example 5

Protein Expression in Shake Flasks

The transformed *B. licheniformis* cells were amplified to 75 ug/mL chloramphenicol (CMP) by using shake flasks in a stepwise manner from 5 ug/mL CMP to 75 ug/mL CMP and then plated until single, starch clearing colonies were obtained. Transformants obtained for R172Q, H183D and S36D/S255N in *B. licheniformis* cells were integrated, looped out, and amplified to grow at 50 ug/mL CMP. Transformants obtained for N28R, S36D, and S255N in *B. licheniformis* were integrated and looped-out and grown at 5 ug/mL CMP.

For growth in shake flasks, single colonies of variants were picked, inoculated in a tall glass tube containing 5 mL LB+chloramphenicol at appropriate concentration, and grown for 5-6 hours to yield a preculture. 250 mL baffled shake flasks were filled with 50 mL shake flask culture media (potassium phosphate based, 4% lactose, 2% Nutrisoy) and inoculated with 1 mL preculture and incubated at 37° C. at 250 rpm for 90 hours. Aliquots were subjected to centrifugation to collect culture supernatant, which was assayed for amylase activity or frozen at -20° C. until further use.

Example 6

In this example, the amylase activity of *Bacillus* sp. no. 707 amylase and 707 amylase single position variants (R172Q,

52

H183D, and S255N) and two-position variant (S36D/S255N) expressed in *B. licheniformis* and grown in shake flasks was tested using Megazyme Ceralpha Assay as described below.

Megazyme Ceralpha Assay for Amylase Activity

This assay is a modification of the published protocols for Megazyme endo alpha-amylase Kit K-CERA 08/05 (AOAC Method 2002.01, Megazyme International Ireland). Reagent vials contain the substrate, which is non-reducing end-blocked p-nitrophenyl maltoheptaoside (BPNPG7, 54.5 mg) and thermostable alpha glucosidase (125 U at pH 6.0). To perform the assay, entire contents of one vial are dissolved in 10.0 mL of distilled water. 2 mL aliquots were stored frozen in 15 mL screw cap tubes. 6 mL assay buffer (50 mM Na malate, 2.6 mM CaCl₂, 50 mM NaCl, 0.002% Triton X-100, pH 6.7) was added to each tube prior to use. 0.79 mL substrate solution in buffer was added to a (preferably masked) cuvette. The cuvette was placed in the holder and a blank reading was obtained. Ten µL enzyme samples (diluted in assay buffer) were then added to the cuvette and the assay started. Absorbance per minute was measured at 400 nm or 410 nm and the values corrected for dilution and protein concentration. The amylase activity for each variant is reported in arbitrary units and shown in FIG. 4.

All references cited above are herein incorporated by reference in their entirety for all purposes.

SEQUENCE LISTING

SEQ ID NO: 1

Sequence of a mature α-amylase from *Bacillus subtilis* sp. no. 707
HHNGTNGTMM QYFEWYLPND GNHWNRLNSD ASNLKSKGIT AVWIPPAAWK ASQNDVG YGA
YDLYDLGEFN QKGTVRTKYG TRSQLQAAVT SLKNNGIQVY GDVVMNHKGG ADATFEMVRV
EVNPNNRNQE VTGEYITIEAW TRPDFPGRGN THSSFKWRWY HFDGVDWDQS RRLNNRIYKF
RGHGKAWDWE VDTENGNYDY LMYADIDMDH PEVVNELRNW GWWYNTLTGL DGFRIDAVKH
IKYSFTRDWI NHVRSATGKN MFAVAEFWKN DLGAIENYLQ KTNWNHVSVD VPLHYNLYNA
SKSGGNYDMR NIFNGTVVQR HPSHAVTFVD NHDSQPPEAL ESFVEEWFKP LAYALTLTRE
QGYPSVFYGD YYGIPTHGVP AMRSKIDPIL EARQKYAYGK QNDYLDHNNI IGWTRREGNTA
HPNSGLATIM SDGAGGSKWM FVGRNKAGQV WSDITGNRTG TVTINADGWG NFSVNGGSVS
IWNK

SEQ ID NO: 2

Sequence of a mature α-amylase from *Bacillus* sp. A 7-7 (DSM 12368)
HHNGTNGTMM QYFEWYLPND GNHWNRLNSD ASNLKDKGIT AVWIPPAAWK ASQNDVG YGA
YDLYDLGEFN QKGTVRTKYG TRNQLQAAVT ALKSNGIQVY GDVVMNHKGG ADATFEMVRV
EVNPNNRNQE VSGDYITIEAW TKPDFPGRGN THSNFKWRWY HFDGVDWDQS RQLQNRIYKF
RGDGKAWDWE VDTENGNYDY LMYADIDMDH PEVVNELRNW GWWYNTLTGL DGFRIDAVKH
IKYSFTRDWL THVRNTTGKN MFAVAEFWKN DIGAIENYLS KTNWNHVSVD VPLHYNLYNA
SRSGGNYDMR QIFNGTVVQR HPTHAVTFVD NHDSQPPEAL ESFVEEWFKP LAYALTLTRD
QGYPSVFYGD YYGIPTHGVP AMRSKIDPIL EARQKYAYGK QNDYLDHNNI IGWTRREGNTA
HPNSGLATIM SDGPGGNKWM YVGRNKAGQV WRDITGNRSG TVTINADGWG NFSVNGGSVS
IWNV

SEQ ID NO: 3

Full length amino acid sequence of a α-amylase from *Bacillus* sp. A 7-7 (DSM 12368)
MRKRKNGLIS ILLAFLLVLT SIPFTSANVE AHNGTNGTMM MQYFEWYLPN DGNHWNRLRS
DASNLKDKGI TAVWIPPAAWK GASQNDVG YG AYDLYDLGEF NQKGTVRTKY GTRNQLQAAV
TALKSNGIQV YGDVVMNHKG GADATEWVRA VEVNPNNRNQ EVSGDYITIEA WTKPDFPGRG
NTHSNFKWRW YHFDGVDWDQ SRQLQNRIYK FRGDGKGDW EVDTENGNYD YLMYADIDMD
HPEVVNELRN WGVWYNTLTGL LDGFRIDAVK HIKYSFTRDW LTHVRNTTGK NMFVAEFWK
NDIGAIENYL SKTNWNHVSF DVPLHYNLYN ASRSGGNYDM RQIFNGTVVQ RHPTHAVTFV
DNHDSQPPEA LESFVEEWFK PLAYALTLTR DQGYPSVFYG DYYGIPTHGV PAMRSKIDPI
LEARQKYAYG QNDYLDHNN MIGWTRREGNT AHPNSGLATI MSDGPGGNKW MYVGRNKAGQ
VWRDITGNRS GTVTINADGW GNFSVNGGSV SIWVNN

SEQ ID NO: 4

Nucleotide sequence for *Bacillus* sp. no. 707 α-amylase (sequence corresponding to signal peptide is underlined)
ATGAAAATGAGAACAGGAAAAAGGGTTTTTAAAGTATTTATTAGCGTCTTATGGTGATTACTTCAA
TACCGTTTACTTTAGTAGATGTAGAAGCACATCATAACGGTACGAACGGGACAATGATGCAATACTTTGA
ATGGTATCTACCTAATGACGGGAATCATTGGAATCGATTAACTCTGATGCGAGTAACTTAAAGCAAAA
GGGATTACAGCGGTGTGGATTCTCCAGCATGGAAGGGCGCTTCTCAAATGACGTAGGATACGGAGCCT

- continued

SEQUENCE LISTING

ATGACCTGTATGATCTGGGAGAATTTAATCAAAAAGGTACCGTCCGTACAAAATATGGAACACGTAGTCA
 GTTACAAGCTCGCGTAACCTCCTTAAAAAATTAATGGAATTCAGTATATGGTGACGTTGTTATGAATCAC
 AAAGGTGGCGCAGACGCTACTGAAATGGTAAGGGCCGTGAAGTGAATCCCAATAACCGTAACCAAGAAG
 TGACTGGTGAATATACCATTGAAGCTTGGACTAGATTGATTTTCCAGGGCGAGGAAATACTCATTCTAG
 CTTTAAATGGAGATGGTATCATTGATGGTGTGGATTGGGATCAGTCACGTAGACTGAACAATCGCATC
 TATAAATTGAGGTCATGGCAAAGCTTGGGATTGGGAAGTTGATACGGAATAATGGTAATTATGATTATT
 TAATGTACGCTGATATTGATATGGATCACCAGAGTAGTAAATGAATTAAGAAATGGGGTGTGTTGGTA
 CACAACACATTAGGACTCGATGGATTTAGAATAGATGCGGTTAAACATATAAAGTATAGCTTTACGCGC
 GATTGGATTAATCAGTTAGAAGTGCAACAGGTAAAAATATGTTTGGCGTTGCTGAGTTTGGGAAGAATG
 ATTTAGGTGCAATTGAAAACATCTGCGAGAAAACAACTGGAACCATTCAGTCTTTGATGTGCCGTTTACA
 TTATAATCTTTTATAATGCATCAAAAAGCGGAGGGAACATATGATATGCGAAACATATTTAATGGAACGGTT
 GTTCAACGACATCCAGTCATGCTGTAACATTTGTTGATAATCATGATTGCGAGCCTGAAGAAGCATTAG
 AATCTTTTGTGGAAGAATGGTTTAAACCATTAGCGTATGCGCTTACATTAACGCGTGAACAGGATACCC
 TTCTGTATTTTACGGAGATTATTATGGGATTCCAACACATGGAGTGCCAGCAATGAGATCAAAAATCGAT
 CCGATTTTAGAAGCACGTCAAAAGTATGCATACGGAACCAAAATGATTACTTAGACCATCATATATCA
 TTGGTTGGACGCGTGAAGGGAATACAGCACACCCCAATTCAAGTCTAGCTACCATCATGCTGATGGAGC
 GGGTGAAGTAAAGTGAATGTTTGTGGGCGTAATAAGGCTGGTCAAGTATGGAGTGATATTACAGGAAAC
 CGTACAGGTACGGTTACAATCAATGCAGACGGTTGGGCAATTTCTCTGTGAATGGAGGTCAGTTTCTA
 TTTGGGTCAACAAA

SEQ ID NO: 5

Nucleotide sequence of mature α -amylase from *Bacillus* sp. A 7-7 (DSM 12368)
 CACCATAATG GCACAAATGG AACATGATG CAATATTTTG AATGGTATTT GCCAAATGAC GGTAATCATT
 GGAATAGATT AAGATCAGAT GCAAGTAATC TTAAAGATAA AGGGATTACA GCGGTTTGA TACCACCTGC
 TTGGAAAGGG GCTTCTCAA ATGATGTAGG GTATGGAGCC TATGATCTGT ATGATTTAGG AGAATTCAT
 CAAAAGGAA CCGTACGTAC AAGTACGGA ACCCGTAATC AATTACAAGC TGCAGTAACC GCCTTAAAA
 GTAATGGTAT TCAAGTATAC GGAGATGTCG TAATGAATCA TAAGGGTGA GCGGATGCCA CTGAGTGGGT
 TCGAGCGGTT GAAGTGAACC CAAGTAATCG TAATCAAGAA GTCTCTGGTG ATTATACGAT TGAGGCTTGG
 ACTAAGTTTG ATTTTCTCG TCGAGGTAAT ACCCACTCTA ACTTTAAATG GAGATGGTAT CATTTTCGATG
 GTGTAGATTG GGATCAGTCA CGTCAATTGC AGAATCGAAT CTATAAATTC AGAGGAGATG GAAAAGGTTG
 GGACTGGGAA GTTGATACAG AGAACGGAAA CTATGACTAT CTAATGTACG CGGATATTGA TATGGATCAC
 CCTGAAGTAG TGAATGAACT CAGAACTGG GGTGTATGGT ATACCAATAC ACTGGGGCTA GACGGGTTCA
 GAATAGATGC GGTAAAACAT ATAAAAATA GCTTTACTCG TGATTGGCTT ACTCACGTTA GAAATACGAC
 AGGTAAAAAT ATGTTTGCAG TTGCAGAGTT CTGGAAGAAT GACATAGGTG CAATTGAAAA TTACTTAAGT
 AAAACAAATT GGAATCATTC AGTTTTTGAT GTGCCCTGC ATTATAACCT TTATAATGCA TCGAGAAGTG
 GTGGCAATTA TGATATGAG CAAATATTTA ATGGAACAGT TGTTCAAGA CATCCTACAC ATGCTGTAA
 ATTTGTTGAT AACCATGATT CACAGCCGGA AGAAGCCCTA GAGTCATTG TTGAAGAGTG GTTCAAACCG
 TTAGCGTATG CTCTCACACT AACACGTGAT CAAGGATATC CTTCCGTTTT TTATGGAGAT TATTATGGGA
 TTCCGACGCA TGGGTATCCA GCAATGAAAT CTAAGATTGA TCCGATTTTA GAAGCACGTC AAAAGTATGC
 GTACGGAAAA CAAATGATT ATTTGGATCA CCATAATATG ATTGGCTGGA CGCGTGAAGG TAATACAGCA
 CATCCCAACT CAGCACTAGC AACTATTATG TCGGATGGCC CAGGAGGAAA TAAATGGATG TATGTTGGGC
 GTAATAAGGC TGGACAAGTT TGGAGAGATA TTACAGGAAA TCGCTCAGGT ACGGTGACGA TTAACGCAGA
 TGGGTGGGGT AATTTTCTG TAAATGGTGG GTCTGTATCT ATATGGGTAA AT

SEQ ID NO: 6

Nucleotide sequence of full length α -amylase from *Bacillus* sp. A 7-7
 (DSM 12368)

1 ATGACGATGA GAAAACGTAA AAATGGATTA ATCAGTATTC TATTGGCATT TTTGTTGGTA
 61 CTTACATCAA TACCTTTTAC TTCAGCAAAC GTAGAAGCAC ACCATAATGG CACAAATGGA
 121 ACAATGATGC AATATTTTGA ATGGTATTTG CCAATGACG GTAATCATTG GAATAGATTA
 181 AGATCAGATG CAAGTAATCT TAAAGATAAA GGGATTACAG CGGTTTGGAT ACCACCTGCT
 241 TGGAAAGGGG CTTCTCAAAT TGATGTAGGG TATGGAGCCT ATGATCTGTA TGATTAGGA
 301 GAATTCATC AAAAAAGGAA CGTACGTACA AAGTACGGAA CCCGTAAATCA ATTACAAGCT
 361 GCAGTAACCG CCTTAAAAAG TAATGGTATT CAAGTATACG GAGATGTCTG AATGAATCAT
 421 AAGGGTGGAG CGGATGCCAC TGAGTGGGTT CGAGCGGTTG AAGTGAACCC AAGTAATCGT
 481 AATCAAGAAG TCTCTGGTGA TTATACGATT GAGGCTTGA CTAAGTTTGA TTTTCTGGT
 541 CGAGGTAATA CCCACTCTAA CTTTAAATGG AGATGGTATC ATTTTCGATG TGATAGATTG
 601 GATCAGTCAC GTCAATTGCA GAATCGAATC TATAAATTC GAGGAGATGG AAAAGGTTGG
 661 GACTGGGAAG TTGATACAGA GAACGGAAAC TATGACTATC TAATGTACGC GGATATTGAT
 721 ATGGATCACC CTGAAGTAGT GAATGAACCT AGAAACTGGG GTGTATGGTA TACCAATACA
 781 CTGGGGCTAG ACGGGTTCAG AATAGATGCG GTAAAACATA TAAATATAG CTTTACTCGT
 841 GATTGGCTTA CTCACGTTAG AAATACGACA GGTAATAATA TGTTTGCAGT TGCAGAGTTC
 901 TGGAAAGATG ACATAGGTGC AATTGAAAA TACTTAAGTA AAACAAATTG GAATCATTCA
 961 GTTTTGTGAT TATGCTGCA TTATACCTT TATAATGCAT CGAGAAGTGG TGGCAATTAT
 1021 GATATGAGGC AAATATTTAA TGAACAGATT GTTCAGAGAC ATCCTACACA TGCTGTAAAC
 1081 TTTGTTGATA ACCATGATT CACAGCCGAA GAAGCCCTAG AGTCATTGTT TGAAGAGTGG
 1141 TTCAAACCGT TAGCGTATGC TCTCACACTA ACACGTGATC AAGGATATCC TTCCGTTTTT
 1201 TATGGAGATT ATATGGGAT TCCGACGCAT GGTGTACCAG CAATGAAATC TAAGATTGAT
 1261 CCGATTTTAG AAGCACGTCA AAAGTATGCG TACGGAACAA AAAATGATTA TTTGGATCAC
 1321 CATAATATGA TTGGCTGGAC GCGTGAAGGT AATACAGCAC ATCCCAACTC AGGACTAGCA
 1381 ACTATTATGT CGGATGGCCC AGGAGGAAAT AAATGGATGT ATGTTGGGCG TAATAAGGCT
 1441 GGACAAGTTT GGAGAGATAT TACAGGAAAT CGCTCAGGTA CGGTGACGAT TAACGCAGAT
 1501 GGTGTTGGTA ATTTTCTGTT AAATGGTGGG TCTGTATCTA TATGGGTAA T

- continued

SEQUENCE LISTING

SEQ ID NO: 7

GenBank CAL48155

HHNGTNGTMM QYFEWYLPND GNHWNRLRSD ASNLKDKGIT AVWIPPAAWK ASQNDVGYGA
 YDLYDLGEFN QKGTVRTKYG TRNQLQAAVT ALKSNGIQVY GDVVMNHKGG ADATEWVRVAV
 EVNPSNRNQE VSGDYTIEAW TKFDFFPGRGN THSNFKWRWY HFDGVDWDQS RQLQNRRIYKF
 RGDGKGWDWE VDTENGNYDY LMYADIDMDH PEVVNELRNW GVWYNTNLGL DGFRIDAVKH
 IKYSFTRDWL THVRNTTGKN MFAVAEFWKN DIGAIENYLS KTNWNHVSVD VPLHYNLYNA
 SRSGGNYDMR QIFNGTVVQR HPTHAVTFVD NHDSQPEEAL ESFVEEWFKP LAYALTLTRD
 QGYPSVFYGD YYGIPTHGVP AMKSKIDPIL EARQKYAYGK QNDYLDHHNM IGWTRREGNTA
 HPNSGLATIM SDGPGGNKWM YVGRNKAGQV WRDITGNRSG TVTINADGWG NFSVNGGSVS
 IWWN

SEQ ID NO: 8

full length CAL48155, including signal sequence

MTMRKRKNGL ISILLAFLLV LTSIPFTSAN VEAHHNGTNG TMMQYFEWYL PNDGNHWNRL
 RSDASNLDKDK GITAVWIPPA WKGASQNDVG YGAYDLYDLG EFNQKGTVRT KYGTRNQLQA
 AVTALKSNGI QVYGDVVMNH KGGADATEWV RAVEVNPSNR NQEVSGDYTI EAWTKDFDPG
 RGNTHSNFKW RWHFDGVDW DQSRQLQNRI YKFRGDGKGW DWEVDTEGN YDLYMYADID
 MDHPEVVNEL RNWGVWYNT LGLDGFPRIDA VKHIKYSFTR DWLTHVRNTT GKNMFVAEAF
 WKNDIGAIEN YLSKTNWNHS VFDVPLHYNL YNASRSGGNY DMRQIFNGTV VQRHPTHAVT
 FVDNHDSQPE EALSFVEEW FKPLAYALTL TRDQGYPSVF YGDYYGIPTH GVPAMKSKID
 PILEARQKYA YGKQNDYLDH HNMIGWTREG NTAHPNSGLA TIMSDGPGGN KWMYVGRNKA
 GQVWRDITGN RSGTVTINAD GWGNFSVNGG SVSIWWN

SEQ ID NO: 9

Synthetic nucleotide EBS2XhoI_RV

TGG AAT CTC GAG GTT TTA TCC TTT ACC TTG TCT CC

SEQ ID NO: 10

Synthetic nucleotide Plat5XhoI_FW:

CCC CCG CTC GAG GCT TTT CTT TTG GAA GAA AAT ATA GGG AAA ATG GTA CTT
 GTT AAA AAT TCG GAA TAT TTA TAC AAT ATC ATA TGT TTC ACA TTG AAA GGG G

SEQ ID NO: 11

Synthetic nucleotide 707N28R-F

ACCATT GGA ACC GCC TGC GCA GCG AT

SEQ ID NO: 12

Synthetic nucleotide 707N28R-R

CAG GTT GCT CGC ATC GCT GCG CAG GC

SEQ ID NO: 13

Synthetic nucleotide 707S36D-F

GAT GCG AGC AAC CTG AAA GAT AAA GG

SEQ ID NO: 14

Synthetic nucleotide 707S36D-R

ACT GCT GTG ATG CCT TTA TCT TTC AGG TT

SEQ ID NO: 15

Synthetic nucleotide 707R172Q-F

GAT TGG GAT CAA AGC CGC CAG CTG AAC A

SEQ ID NO: 16

Synthetic nucleotide 707R172Q-R

AGA TGC GGT TGT TCA GCT GGC GGC TTT

SEQ ID NO: 17

Synthetic nucleotide 707H183D-F

ATC TAT AAA TTT CGC GGC GAT GGC AAA

SEQ ID NO: 18

Synthetic nucleotide 707H183D-R

CAA TCC CAT GCT TTG CCA TCG CCG CGA

SEQ ID NO: 19

Synthetic nucleotide 707S255N-F

TGG ATC AAT CAT GTC AGA AAC GCG ACG

SEQ ID NO: 20

Synthetic nucleotide 707S255N-R

CAT ATT TTT GCC CGT CGC GTT TCT GAC

SEQ ID NO: 21

Synthetic nucleotide 707A256T-F

CAA TCA TGT CAG AAG CAC GAC GGG CAA A

-continued

SEQUENCE LISTING

SEQ ID NO: 22
 Synthetic nucleotide 707A256T-R
 CAT ATT TTT GCC CGT CGT GCT TCT GAC

SEQ ID NO: 23
 Synthetic nucleotide 707 PCR F1
 GCA AGT TCA CCA TGC AGT GTG TGA C

SEQ ID NO: 24
 Synthetic nucleotide 707 PCR R1
 TAT CAA GCT TAT CGA TAC CGT CGA C

SEQ ID NO: 25
 Synthetic nucleotide 707 seq F1
 CGA TTG TGA GGA GTG GCT TGT G

SEQ ID NO: 26
 Synthetic nucleotide 707 seq R1
 CTT ATC GAT ACC GTC GAC CCT C

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 27

<210> SEQ ID NO 1

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 1

His	His	Asn	Gly	Thr	Asn	Gly	Thr	Met	Met	Gln	Tyr	Phe	Glu	Trp	Tyr	1		5		10		15
Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Asn	Ser	Asp	Ala	Ser	20		25		30		
Asn	Leu	Lys	Ser	Lys	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala	Trp	35		40		45		
Lys	Gly	Ala	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr	50		55		60		
Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly	65		70		75		80
Thr	Arg	Ser	Gln	Leu	Gln	Ala	Ala	Val	Thr	Ser	Leu	Lys	Asn	Asn	Gly	85		90		95		
Ile	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala	Asp	100		105		110		
Ala	Thr	Glu	Met	Val	Arg	Ala	Val	Glu	Val	Asn	Pro	Asn	Asn	Arg	Asn	115		120		125		
Gln	Glu	Val	Thr	Gly	Glu	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Arg	Phe	Asp	130		135		140		
Phe	Pro	Gly	Arg	Gly	Asn	Thr	His	Ser	Ser	Phe	Lys	Trp	Arg	Trp	Tyr	145		150		155		160
His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Arg	Leu	Asn	Asn	Arg	165		170		175		
Ile	Tyr	Lys	Phe	Arg	Gly	His	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Asp	180		185		190		
Thr	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Ile	Asp	Met	195		200		205		
Asp	His	Pro	Glu	Val	Val	Asn	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp	Tyr	210		215		220		

-continued

Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His
 225 230 235 240
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala
 245 250 255
 Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu
 260 265 270
 Gly Ala Ile Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val
 275 280 285
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly
 290 295 300
 Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg
 305 310 315 320
 His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro
 325 330 335
 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala
 340 345 350
 Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr
 355 360 365
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Arg Ser
 370 375 380
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys
 385 390 395 400
 Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu
 405 410 415
 Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
 420 425 430
 Gly Ala Gly Gly Ser Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly
 435 440 445
 Gln Val Trp Ser Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile
 450 455 460
 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser
 465 470 475 480
 Ile Trp Val Asn Lys
 485

<210> SEQ ID NO 2

<211> LENGTH: 485

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 2

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr
 1 5 10 15
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser
 20 25 30
 Asn Leu Lys Asp Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp
 35 40 45
 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
 50 55 60
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
 65 70 75 80
 Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ala Leu Lys Ser Asn Gly
 85 90 95
 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
 100 105 110

-continued

Ala	Thr	Glu	Trp	Val	Arg	Ala	Val	Glu	Val	Asn	Pro	Ser	Asn	Arg	Asn
		115					120					125			
Gln	Glu	Val	Ser	Gly	Asp	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Lys	Phe	Asp
	130					135					140				
Phe	Pro	Gly	Arg	Gly	Asn	Thr	His	Ser	Asn	Phe	Lys	Trp	Arg	Trp	Tyr
145					150					155					160
His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Gln	Leu	Gln	Asn	Arg
			165					170						175	
Ile	Tyr	Lys	Phe	Arg	Gly	Asp	Gly	Lys	Gly	Trp	Asp	Trp	Glu	Val	Asp
			180					185					190		
Thr	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Ile	Asp	Met
		195					200					205			
Asp	His	Pro	Glu	Val	Val	Asn	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp	Tyr
	210					215					220				
Thr	Asn	Thr	Leu	Gly	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys	His
225					230					235					240
Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Leu	Thr	His	Val	Arg	Asn	Thr
				245					250					255	
Thr	Gly	Lys	Asn	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp	Ile
			260					265					270		
Gly	Ala	Ile	Glu	Asn	Tyr	Leu	Ser	Lys	Thr	Asn	Trp	Asn	His	Ser	Val
		275					280					285			
Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Arg	Ser	Gly
	290					295					300				
Gly	Asn	Tyr	Asp	Met	Arg	Gln	Ile	Phe	Asn	Gly	Thr	Val	Val	Gln	Arg
305					310					315					320
His	Pro	Thr	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln	Pro
				325					330					335	
Glu	Glu	Ala	Leu	Glu	Ser	Phe	Val	Glu	Glu	Trp	Phe	Lys	Pro	Leu	Ala
			340					345					350		
Tyr	Ala	Leu	Thr	Leu	Thr	Arg	Asp	Gln	Gly	Tyr	Pro	Ser	Val	Phe	Tyr
		355				360						365			
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Lys	Ser
	370					375					380				
Lys	Ile	Asp	Pro	Ile	Leu	Glu	Ala	Arg	Gln	Lys	Tyr	Ala	Tyr	Gly	Lys
385					390					395					400
Gln	Asn	Asp	Tyr	Leu	Asp	His	His	Asn	Met	Ile	Gly	Trp	Thr	Arg	Glu
				405					410					415	
Gly	Asn	Thr	Ala	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp
			420					425					430		
Gly	Pro	Gly	Gly	Asn	Lys	Trp	Met	Tyr	Val	Gly	Arg	Asn	Lys	Ala	Gly
		435					440					445			
Gln	Val	Trp	Arg	Asp	Ile	Thr	Gly	Asn	Arg	Ser	Gly	Thr	Val	Thr	Ile
	450					455					460				
Asn	Ala	Asp	Gly	Trp	Gly	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser
465					470					475					480
Ile	Trp	Val	Asn	Asn											
				485											

<210> SEQ ID NO 3

<211> LENGTH: 516

<212> TYPE: PRT

<213> ORGANISM: Bacillus sp.

-continued

<400> SEQUENCE: 3

Met Arg Lys Arg Lys Asn Gly Leu Ile Ser Ile Leu Leu Ala Phe Leu
 1 5 10 15
 Leu Val Leu Thr Ser Ile Pro Phe Thr Ser Ala Asn Val Glu Ala His
 20 25 30
 His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu
 35 40 45
 Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser Asn
 50 55 60
 Leu Lys Asp Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp Lys
 65 70 75 80
 Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp
 85 90 95
 Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr
 100 105 110
 Arg Asn Gln Leu Gln Ala Ala Val Thr Ala Leu Lys Ser Asn Gly Ile
 115 120 125
 Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp Ala
 130 135 140
 Thr Glu Trp Val Arg Ala Val Glu Val Asn Pro Ser Asn Arg Asn Gln
 145 150 155 160
 Glu Val Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp Phe
 165 170 175
 Pro Gly Arg Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr His
 180 185 190
 Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Arg Ile
 195 200 205
 Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val Asp Thr
 210 215 220
 Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met Asp
 225 230 235 240
 His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr Thr
 245 250 255
 Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His Ile
 260 265 270
 Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr Thr
 275 280 285
 Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Ile Gly
 290 295 300
 Ala Ile Glu Asn Tyr Leu Ser Lys Thr Asn Trp Asn His Ser Val Phe
 305 310 315 320
 Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Arg Ser Gly Gly
 325 330 335
 Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg His
 340 345 350
 Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro Glu
 355 360 365
 Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala Tyr
 370 375 380
 Ala Leu Thr Leu Thr Arg Asp Gln Gly Tyr Pro Ser Val Phe Tyr Gly
 385 390 395 400
 Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser Lys
 405 410 415

-continued

Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys Gln
420 425 430

Asn Asp Tyr Leu Asp His His Asn Met Ile Gly Trp Thr Arg Glu Gly
435 440 445

Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp Gly
450 455 460

Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Arg Asn Lys Ala Gly Gln
465 470 475 480

Val Trp Arg Asp Ile Thr Gly Asn Arg Ser Gly Thr Val Thr Ile Asn
485 490 495

Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser Ile
500 505 510

Trp Val Asn Asn
515

<210> SEQ ID NO 4

<211> LENGTH: 1554

<212> TYPE: DNA

<213> ORGANISM: Bacillus sp.

<400> SEQUENCE: 4

```

atgaaaatga gaacaggaaa aaagggtttt ttaagtattt tattagcgtt cttattggtg      60
attacttcaa taccgtttac tttagtagat gtagaagcac atcataacgg tacgaacggg      120
acaatgatgc aatactttga atgggtatcta cctaattgacg gaaatcattg gaatcgatta      180
aactctgatg cgagtaacct taaaagcaaa gggattacag cgggtgtggat tectccagca      240
tggaaggggcg cttctcaaaa tgacgtagga tacggagcct atgacctgta tgatctggga      300
gaatttaatc aaaaaggtag cgctccgtaca aaatatggaa cacgtagtca gttacaagct      360
gcggtaacct ccttaaaaaa taatggaatt caagtatatg gtgacgttgt tatgaatcac      420
aaaggtggcg cagacgctac tgaaatggta agggccgttg aagtgaatcc caataaccgt      480
aaccaagaag tgactgttga atataccatt gaagcttgga ctagatttga ttttccaggg      540
cgaggaaata ctcatcttag ctttaaatgg agatggatc attttgatgg tgtggattgg      600
gatcagtcac gtagactgaa caatcgcatc tataaattta gaggtcatgg caaagcttgg      660
gattgggaag ttgatacgga aaatggtaat tatgattatt taatgtacgc tgatattgat      720
atggatcacc cagaagtagt aaatgaatta agaaattggg gtgtttggta cacaaacaca      780
ttaggactcg atggatttag aatagatgcg gttaaacata taaagtatag ctttacgcgc      840
gattggatta atcacgttag aagtgcaca ggtaaaaata tgtttgcggg tgctgagttt      900
tggaagaatg atttaggtgc aattgaaaac tatctgcaga aaacaaactg gaaccattca      960
gtctttgatg tgccgttaca ttataatctt tataatgcat caaaaagcgg agggaaactat      1020
gatatgcgaa acatatattaa tggaacggtt gttcaacgac atccaagtca tgctgtaaca      1080
tttgttgata atcatgatc gcagcctgaa gaagcattag aatcttttgt tgaagaatgg      1140
tttaaaccat tagcgtatgc gcttacatta acgctgaac aaggataccc ttctgtattt      1200
tacggagatt attatgggat tccaacacat ggagtgccag caatgagatc aaaaatcgat      1260
cggatttttag aagcacgtca aaagtatgca tacggaaaac aaaatgatta cttagaccat      1320
cataatatca ttggttggac gcgtgaaggg aatacagcac accccaattc aggtctagct      1380
accatcatgt ctgatggagc ggggtgaagt aagtggatgt ttgttggcg taataaggct      1440

```

-continued

```

gggtcaagtat ggagtgatat tacaggaaac cgtacaggta cggttacaat caatgcagac 1500
ggttggggca atttctctgt gaatggaggg tcagtttcta tttgggtcaa caaa 1554

```

```

<210> SEQ ID NO 5
<211> LENGTH: 1452
<212> TYPE: DNA
<213> ORGANISM: Bacillus sp.

```

```

<400> SEQUENCE: 5

```

```

caccataatg gcacaaatgg aacaatgatg caatatattt aatggatttt gccaaatgac 60
ggtaatcatt ggaatagatt aagatcagat gcaagtaatc ttaaagataa agggattaca 120
gcggttttga taccacctgc ttggaaaggg gcttctcaaa atgatgtagg gtatggagcc 180
tatgatctgt atgatttagg agaattcaat caaaaaggaa ccgtacgtac aaagtacgga 240
acccgtaatc aattacaagc tgcagtaacc gccttaaaaa gtaatggat tcaagtatac 300
ggagatgtcg taatgaatca taagggttga gcggatgcca ctgagtgggt tcgagcgggt 360
gaagtgaacc caagtaatcg taatcaagaa gtctctggtg attatacgat tgaggcttgg 420
actaagtttg attttctctg tcgaggtaat acccactcta actttaaatg gagatgggat 480
catttcgatg gtgtagattg ggatcagtc cgtcaattgc agaatcgaat ctataaattc 540
agaggagatg gaaaagggtt ggactgggaa gttgatacag agaacggaaa ctatgactat 600
ctaattgtacg cggatattga tatggatcac cctgaagtag tgaatgaact cagaaactgg 660
gggtgtatgt ataccaatac actgggggta gacgggttca gaatagatgc ggtaaaaacat 720
ataaaatata gctttactcg tgattggctt actcacgtta gaaatacgac aggtaaaaat 780
atgtttgcag ttgcagagtt ctggaagaat gacataggtg caattgaaaa ttacttaagt 840
aaaacaaatt ggaatcattc agtttttgat gtgcccctgc attataacct ttataatgca 900
tcgagaagtg gtggcaatta tgatatgagg caaatattta atggaacagt tggtcagaga 960
catcctacac atgctgtaac atttgttgat aaccatgatt cacagccgga agaagcccta 1020
gagtcatttg ttgaagagtg gttcaaaccg ttagcgtatg ctctcacact aacacgtgat 1080
caaggataac cttccgtttt ttatggagat tattatggga ttccgacgca tgggtgtacca 1140
gcaatgaaat ctaagattga tccgatttta gaagcacgtc aaaagtatgc gtacggaaaa 1200
caaaatgatt atttggatca ccataatatg attggctgga cgcgtgaagg taatacagca 1260
catcccaact caggactagc aactattatg tcggatggcc caggaggaaa taaatggatg 1320
tatgttgggc gtaataaggc tggacaagtt tggagagata ttacaggaaa tcgctcaggt 1380
acggtgacga ttaacgcaga tgggtggggg aatttttctg taaatgggtg gtctgtatct 1440
atatgggtaa at 1452

```

```

<210> SEQ ID NO 6
<211> LENGTH: 1551
<212> TYPE: DNA
<213> ORGANISM: Bacillus sp.

```

```

<400> SEQUENCE: 6

```

```

atgacgatga gaaaacgtaa aaatggatta atcagtattc tattggcatt tttgttggt 60
cttacatcaa taccttttac ttcagcaaac gtagaagcac accataatgg cacaaatgga 120
acaatgatgc aatattttga atggattttg ccaaatgacg gtaatcattg gaatagatta 180
agatcagatg caagtaatct taaagataaa gggattacag cggtttggat accacctgct 240
tggaaagggg cttctcaaaa tgatgtaggg tatggagcct atgatctgta tgatttagga 300

```


-continued

```

gaattcaatc aaaaaggaac cgtacgtaca aagtacggaa cccgtaatca attacaagct 360
gcagtaaccg ccttaaaaag taatggtatt caagtatacg gagatgtcgt aatgaatcat 420
aagggtggag cggatgccac tgagtgggtt cgagcgggtg aagtgaaccc aagtaatcgt 480
aatcaagaag tctctggtga ttatacgatt gaggcttgga ctaagtttga ttttctggt 540
cgaggtaata cccactctaa ctttaaatgg agatgggtac atttcgtagg tgtagattgg 600
gatcagtcac gtcaattgca gaatcgaatc tataaattca gaggagatgg aaaaggttgg 660
gactgggaag ttgatacaga gaacggaaac tatgactatc taatgtacgc ggatattgat 720
atggatcacc ctgaagtagt gaatgaactc agaaactggg gtgtatggta taccaataca 780
ctggggctag acgggttcag aatagatgcg gtaaaacata taaaatatag ctttactcgt 840
gattggctta ctcacgttag aaatacgaca ggtaaaaata tgtttgcagt tgcagagttc 900
tggaagaatg acataggtgc aattgaaaat tacttaagta aaacaaattg gaatcattca 960
gtttttgatg tgcccctgca ttataacctt tataatgcat cgagaagtgg tggcaattat 1020
gatatgaggc aaatatttaa tggaacagtt gttcagagac atcctacaca tgctgtaaca 1080
tttgttgata accatgattc acagccggaa gaagccctag agtcatttgt tgaagagtgg 1140
ttcaaaccgt tagcgtatgc tctcacacta acacgtgacg aaggatatcc ttccgttttt 1200
tatggagatt attatgggat tccgacgcat ggtgtaccag caatgaaatc taagattgat 1260
ccgatttttag aagcacgtca aaagtatgcg tacggaaaac aaaatgatta ttgggatcac 1320
cataatatga ttggctggac gcgtgaaggt aatacagcac atcccaactc aggactagca 1380
actattatgt cggatggccc aggaggaaat aaatggatgt atgttgggcg taataaggct 1440
ggacaagttt ggagagatat tacaggaaat cgctcaggtg cggtgacgat taacgcagat 1500
gggtggggta atttttctgt aaatggtggg tctgtatcta tatgggtaaa t 1551

```

```

<210> SEQ ID NO 7
<211> LENGTH: 484
<212> TYPE: PRT
<213> ORGANISM: Bacillus sp.

```

```

<400> SEQUENCE: 7

```

```

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr
1          5          10          15
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser
20          25          30
Asn Leu Lys Asp Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp
35          40          45
Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50          55          60
Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
65          70          75          80
Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ala Leu Lys Ser Asn Gly
85          90          95
Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100         105         110
Ala Thr Glu Trp Val Arg Ala Val Glu Val Asn Pro Ser Asn Arg Asn
115         120         125
Gln Glu Val Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp
130         135         140
Phe Pro Gly Arg Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr
145         150         155         160

```

[illegible]

<400> SEQUENCE: 8

Met	Thr	Met	Arg	Lys	Arg	Lys	Asn	Gly	Leu	Ile	Ser	Ile	Leu	Leu	Ala
1				5					10					15	
Phe	Leu	Leu	Val	Leu	Thr	Ser	Ile	Pro	Phe	Thr	Ser	Ala	Asn	Val	Glu
			20					25					30		
Ala	His	His	Asn	Gly	Thr	Asn	Gly	Thr	Met	Met	Gln	Tyr	Phe	Glu	Trp
		35					40					45			

-continued

Tyr	Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Arg	Ser	Asp	Ala
50						55					60				
Ser	Asn	Leu	Lys	Asp	Lys	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala
65					70					75					80
Trp	Lys	Gly	Ala	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu
				85					90					95	
Tyr	Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr
		100						105					110		
Gly	Thr	Arg	Asn	Gln	Leu	Gln	Ala	Ala	Val	Thr	Ala	Leu	Lys	Ser	Asn
		115					120					125			
Gly	Ile	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala
	130					135					140				
Asp	Ala	Thr	Glu	Trp	Val	Arg	Ala	Val	Glu	Val	Asn	Pro	Ser	Asn	Arg
145					150					155					160
Asn	Gln	Glu	Val	Ser	Gly	Asp	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Lys	Phe
			165						170					175	
Asp	Phe	Pro	Gly	Arg	Gly	Asn	Thr	His	Ser	Asn	Phe	Lys	Trp	Arg	Trp
		180						185					190		
Tyr	His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Gln	Leu	Gln	Asn
		195					200					205			
Arg	Ile	Tyr	Lys	Phe	Arg	Gly	Asp	Gly	Lys	Gly	Trp	Asp	Trp	Glu	Val
	210					215					220				
Asp	Thr	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Ile	Asp
225					230					235					240
Met	Asp	His	Pro	Glu	Val	Val	Asn	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp
			245						250					255	
Tyr	Thr	Asn	Thr	Leu	Gly	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys
		260						265					270		
His	Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Leu	Thr	His	Val	Arg	Asn
		275					280					285			
Thr	Thr	Gly	Lys	Asn	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp
	290					295					300				
Ile	Gly	Ala	Ile	Glu	Asn	Tyr	Leu	Ser	Lys	Thr	Asn	Trp	Asn	His	Ser
305					310					315					320
Val	Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Arg	Ser
			325						330					335	
Gly	Gly	Asn	Tyr	Asp	Met	Arg	Gln	Ile	Phe	Asn	Gly	Thr	Val	Val	Gln
		340						345					350		
Arg	His	Pro	Thr	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln
		355					360					365			
Pro	Glu	Glu	Ala	Leu	Glu	Ser	Phe	Val	Glu	Glu	Trp	Phe	Lys	Pro	Leu
	370					375					380				
Ala	Tyr	Ala	Leu	Thr	Leu	Thr	Arg	Asp	Gln	Gly	Tyr	Pro	Ser	Val	Phe
385					390					395					400
Tyr	Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Lys
			405						410					415	
Ser	Lys	Ile	Asp	Pro	Ile	Leu	Glu	Ala	Arg	Gln	Lys	Tyr	Ala	Tyr	Gly
			420						425				430		
Lys	Gln	Asn	Asp	Tyr	Leu	Asp	His	His	Asn	Met	Ile	Gly	Trp	Thr	Arg
		435						440				445			
Glu	Gly	Asn	Thr	Ala	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser
	450						455					460			

-continued

Asp Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Arg Asn Lys Ala
 465 470 475 480

Gly Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Ser Gly Thr Val Thr
 485 490 495

Ile Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val
 500 505 510

Ser Ile Trp Val Asn
 515

<210> SEQ ID NO 9
 <211> LENGTH: 35
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 9

tggaatctcg aggtttttatc ctttaccttg tctcc 35

<210> SEQ ID NO 10
 <211> LENGTH: 103
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 10

ccccgcctcg aggtttttct tttggaagaa aatataggga aaatggtact tgttaaaaat 60

tcggaatatt tatacaatat catatgtttc acattgaaag ggg 103

<210> SEQ ID NO 11
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 11

accattggaa ccgcctgcgc agcgat 26

<210> SEQ ID NO 12
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 12

caggttgctc gcatcgctgc gcaggc 26

<210> SEQ ID NO 13
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 13

gatgcgagca acctgaaaga taaagg 26

<210> SEQ ID NO 14
 <211> LENGTH: 29
 <212> TYPE: DNA
 <213> ORGANISM: Artificial

-continued

<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 14

actgctgtga tgcctttatc ttccagggtt 29

<210> SEQ ID NO 15
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 15

gattgggatc aaagccgcca gctgaaca 28

<210> SEQ ID NO 16
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 16

agatgcgggtt gttcagctgg cgccttt 27

<210> SEQ ID NO 17
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 17

atctataaat ttcgcggcga tggcaaa 27

<210> SEQ ID NO 18
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 18

caatcccatg ctttgccatc gccgcga 27

<210> SEQ ID NO 19
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 19

tggatcaatc atgtcagaaa cgcgacg 27

<210> SEQ ID NO 20
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 20

catatttttg cccgtcgcgt ttctgac 27

-continued

<210> SEQ ID NO 21
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 21

caatcatgtc agaagcacga cgggcaaa 28

<210> SEQ ID NO 22
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 22

catatttttg cccgtcgtgc ttctgac 27

<210> SEQ ID NO 23
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 23

gcaagttcac catgcagtgt gtagc 25

<210> SEQ ID NO 24
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 24

tatcaagctt atcgataccg tcgac 25

<210> SEQ ID NO 25
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 25

cgattgtgag gagtggcttg tg 22

<210> SEQ ID NO 26
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 26

cttatcgata ccgtcgaccc tc 22

<210> SEQ ID NO 27
<211> LENGTH: 484
<212> TYPE: PRT
<213> ORGANISM: Bacillus sp.

-continued

<400> SEQUENCE: 27

His	His	Asn	Gly	Thr	Asn	Gly	Thr	Met	Met	Gln	Tyr	Phe	Glu	Trp	Tyr
1			5					10					15		
Leu	Pro	Asn	Asp	Gly	Asn	His	Trp	Asn	Arg	Leu	Asn	Ser	Asp	Ala	Ser
		20						25				30			
Asn	Leu	Lys	Ser	Lys	Gly	Ile	Thr	Ala	Val	Trp	Ile	Pro	Pro	Ala	Trp
		35					40					45			
Lys	Gly	Ala	Ser	Gln	Asn	Asp	Val	Gly	Tyr	Gly	Ala	Tyr	Asp	Leu	Tyr
	50				55						60				
Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg	Thr	Lys	Tyr	Gly
65					70				75						80
Thr	Arg	Ser	Gln	Leu	Gln	Ala	Ala	Val	Thr	Ser	Leu	Lys	Asn	Asn	Gly
			85					90							95
Ile	Gln	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys	Gly	Gly	Ala	Asp
		100						105						110	
Ala	Thr	Glu	Met	Val	Arg	Ala	Val	Glu	Val	Asn	Pro	Asn	Asn	Arg	Asn
		115					120					125			
Gln	Glu	Val	Thr	Gly	Glu	Tyr	Thr	Ile	Glu	Ala	Trp	Thr	Arg	Phe	Asp
	130					135					140				
Phe	Pro	Gly	Arg	Gly	Asn	Thr	His	Ser	Ser	Phe	Lys	Trp	Arg	Trp	Tyr
145					150					155					160
His	Phe	Asp	Gly	Val	Asp	Trp	Asp	Gln	Ser	Arg	Arg	Leu	Asn	Asn	Arg
			165					170							175
Ile	Tyr	Lys	Phe	Arg	Gly	His	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Asp
		180						185					190		
Thr	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Met	Tyr	Ala	Asp	Ile	Asp	Met
	195					200						205			
Asp	His	Pro	Glu	Val	Val	Asn	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp	Tyr
	210					215					220				
Thr	Asn	Thr	Leu	Gly	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys	His
225					230					235					240
Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Ile	Asn	His	Val	Arg	Ser	Ala
			245					250							255
Thr	Gly	Lys	Asn	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp	Leu
		260						265					270		
Gly	Ala	Ile	Glu	Asn	Tyr	Leu	Gln	Lys	Thr	Asn	Trp	Asn	His	Ser	Val
	275						280					285			
Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Lys	Ser	Gly
	290					295					300				
Gly	Asn	Tyr	Asp	Met	Arg	Asn	Ile	Phe	Asn	Gly	Thr	Val	Val	Gln	Arg
305					310					315					320
His	Pro	Ser	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln	Pro
			325					330							335
Glu	Glu	Ala	Leu	Glu	Ser	Phe	Val	Glu	Glu	Trp	Phe	Lys	Pro	Leu	Ala
		340						345					350		
Tyr	Ala	Leu	Thr	Leu	Thr	Arg	Glu	Gln	Gly	Tyr	Pro	Ser	Val	Phe	Tyr
	355					360						365			
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Arg	Ser
	370					375					380				
Lys	Ile	Asp	Pro	Ile	Leu	Glu	Ala	Arg	Gln	Lys	Tyr	Ala	Tyr	Gly	Lys
385					390					395					400
Gln	Asn	Asp	Tyr	Leu	Asp	His	His	Asn	Ile	Ile	Gly	Trp	Thr	Arg	Glu
			405					410							415

-continued

Gly	Asn	Thr	Ala	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp
			420					425					430		
Gly	Ala	Gly	Gly	Ser	Lys	Trp	Met	Phe	Val	Gly	Arg	Asn	Lys	Ala	Gly
		435					440					445			
Gln	Val	Trp	Ser	Asp	Ile	Thr	Gly	Asn	Arg	Thr	Gly	Thr	Val	Thr	Ile
	450					455					460				
Asn	Ala	Asp	Gly	Trp	Gly	Asn	Phe	Ser	Val	Asn	Gly	Gly	Ser	Val	Ser
465					470					475				480	
Ile	Trp	Val	Asn												

What is claimed is:

1. An isolated recombinant protein comprising an amino acid sequence having at least 97% amino acid sequence identity to SEQ ID NO: 1, and comprising a substitution corresponding to A186G, using SEQ ID NO: 1 for numbering, wherein the amino acid sequence has α -amylase activity.

2. A detergent additive comprising the α -amylase variant of claim 1.

3. The detergent additive of claim 2 in the form of a non-dusting granulate, microgranulate, stabilized liquid, or protected enzyme.

4. The detergent additive of claim 2, wherein the detergent additive further comprises an enzyme selected from the group consisting of a cellulase, protease, aminopeptidase, carboxypeptidase, catalase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, additional amylase, and any combination thereof.

5. The detergent additive of claim 4, wherein the additional amylase is another α -amylase, a β -amylase, an isoamylase, or a glucoamylase.

6. A detergent composition comprising the detergent additive of claim 2.

7. The detergent composition of claim 6, further comprising an enzyme from the group consisting of a cellulase, protease, aminopeptidase, carboxypeptidase, carboxypeptidase, catalase, chitinase, cutinase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, additional amylase, and any combination thereof.

8. A manual or automatic dishwashing composition comprising the α -amylase variant of claim 1.

9. The manual or automatic dishwashing composition of claim 8, further comprising one or more of a surfactant, detergent builder, complexing agent, polymer, bleaching system, stabilizer, foam booster, suds suppressor, anti-corrosion agent, soil-suspending agent, anti-soil redeposition agent, dye, bactericide, hydrotone, tarnish inhibitor, and perfume.

10. The manual or automatic dishwashing composition of claim 8, further comprising an enzyme selected from the group consisting of a cellulase, protease, aminopeptidase, carboxypeptidase, catalase, chitinase, cuti-

nase, cyclodextrin glucanotransferase, deoxyribonuclease, esterase, α -galactosidase, β -galactosidase, glucoamylase, α -glucosidase, β -glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, pullulanase, isoamylase, carrageenase, additional amylase, and any combination thereof.

11. A method of cleaning dishes, comprising administering to the dishes the manual or automatic dishwashing composition of claim 8.

12. A laundry detergent additive comprising the α -amylase variant of claim 1.

13. A laundry detergent composition comprising the laundry additive of claim 12, and further comprising one or more of a surfactant, detergent builder, complexing agent, polymer, bleaching system, stabilizer, foam booster, suds suppressor, anti-corrosion agent, soil-suspending agent, anti-soil redeposition agent, dye, bactericide, hydrotone, optical brightener, fabric conditioner, and perfume.

14. A method of laundering, comprising administering to laundry the laundry detergent additive of claim 12.

15. A biofilm hydrolyzing composition comprising the α -amylase variant of claim 1.

16. The biofilm hydrolyzing composition of claim 15, where the composition is in the form of a solution, powder, paste, gel, liquid, ointment, tablet or gel.

17. The biofilm hydrolyzing composition of claim 15 further comprising a cellulase, hemicellulase, xylanase, lipase, protease, pectinase, antimicrobial agent, or any combination thereof.

18. A method of hydrolyzing a biofilm, comprising administering to the biofilm the composition of claim 15 for a time sufficient to hydrolyze the biofilm.

19. A starch processing composition comprising the α -amylase variant of claim 1 in an aqueous solution.

20. The starch processing composition of claim 19 further comprising a glucoamylase, isoamylase, pullulanase, phytase or a combination thereof.

21. A method of processing a starch, comprising administering to the starch the composition of claim 19 for a time sufficient to process the starch.

22. A composition for saccharifying starch comprising the α -amylase variant of claim 1 in a solution.

23. A method of saccharifying starch, comprising administering to the starch the composition of claim 22 for a period sufficient to saccharify the starch.

24. A composition for liquefying starch comprising the α -amylase variant of claim 1 in a solution.

25. A method of liquefying starch, comprising administering to the starch the composition of claim 24 for a period sufficient to liquefy the starch.

85

26. A textile desizing composition comprising the α -amylase variant of claim **1** in a solution.

27. The textile desizing composition of claim **26** further comprising another enzyme.

28. A method of desizing a textile, comprising administering to the textile the textile desizing composition of claim **26** for a time sufficient to desize the textile. 5

29. A baking composition comprising the α -amylase variant of claim **1** in a solution or gel.

30. A method of baking, comprising administering to a bakery product the baking composition of claim **29**. 10

* * * * *

86